



1
2
3
4
5
6
7
8
9
10 **Revised Draft Technical Support Document for the Cumulative**
11 **Risk Analysis of Di(2-ethylhexyl) Phthalate (DEHP), Dibutyl**
12 **Phthalate (DBP), Butyl Benzyl Phthalate (BBP), Diisobutyl**
13 **Phthalate (DIBP), Dicyclohexyl Phthalate (DCHP), and**
14 **Diisononyl Phthalate (DINP) Under the Toxic Substances**
15 **Control Act (TSCA)**
16
17
18
19

20 **CASRN: 17-81-7 (DEHP), 84-74-2 (DBP), 85-68-7 (BBP), 84-69-5**
21 **(DIBP), 84-61-7 (DCHP), 28553-12-0 (DINP), 68515-48-0 (DINP)**
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41	TABLE OF CONTENTS	
42	TABLE OF CONTENTS	2
43	LIST OF TABLES	4
44	LIST OF FIGURES	4
45	LIST OF APPENDIX TABLES	5
46	KEY ABBREVIATIONS AND ACRONYMS	6
47	ACKNOWLEDGEMENTS	7
48	NOTE TO REVIEWERS	8
49	SUMMARY	8
50	1 INTRODUCTION AND SCOPE	10
51	1.1 Phthalate Syndrome Mode of Action	11
52	1.2 Phthalates Included in the Cumulative Chemical Group Based on Toxicologic Similarity.....	12
53	1.3 Endpoints and Options Considered for Relative Potency Factor Derivation	13
54	1.4 Relevant Populations	15
55	1.5 Relevant Durations	15
56	1.6 Exposure Evaluations	16
57	1.1 Risk Cup Concept in Cumulative Risk Assessment	17
58	2 RELATIVE POTENCY FACTORS	18
59	2.1 Relative Potency Factor Approach	18
60	2.2 Benchmark Dose Modeling of Fetal Testicular Testosterone to Determine Toxic Potency	19
61	2.2.1 Results: Benchmark Dose Estimation	22
62	2.3 Selection of the Index Chemical and the Index Chemical Point of Departure	22
63	2.4 Relative Potency Factors for the Cumulative Phthalate Assessment Based on Decreased Fetal	
64	Testicular Testosterone.....	24
65	2.5 Uncertainty Factors and the Benchmark Margin of Exposure	25
66	2.6 Applicability of Derived Relative Potency Factors (RPFs).....	26
67	2.7 Weight of Scientific Evidence: Relative Potency Factors and Index Chemical Point of	
68	Departure	27
69	3 SCENARIO-BASED PHTHALATE EXPOSURE AND RISK	29
70	3.1 Occupational Exposure for Workers	29
71	3.1.1 Industrial and Commercial Products Containing Multiple Phthalates	29
72	3.1.2 Multiple TSCA Phthalates at a Single Facility and/or Single Condition of Use.....	30
73	3.1.2.1 Parent Companies Reporting Use of Multiple Phthalates	30
74	3.1.2.2 Facilities Reporting Releases of Multiple Phthalates	30
75	3.1.2.3 Overlap in Industrial and Commercial COUs	31
76	3.1.3 Conclusions on Cumulative Occupational Phthalate Exposure.....	32
77	3.2 Consumer and Indoor Dust Exposure.....	32
78	3.2.1 Consumer Products Containing Multiple Phthalates.....	32
79	3.2.2 Consumer Use of Multiple Products and/or Articles in a Relevant Time Frame	33
80	3.2.3 Quantitative Cumulative Risk from Exposure to Indoor Dust	33
81	3.2.4 Conclusions on Cumulative Consumer and Indoor Dust Phthalate Exposure	37
82	3.3 General Population Exposure to Environmental Releases	37

83	3.3.1	Comparison of Fate Parameters Across Phthalates	37
84	3.3.2	Geographic Consideration of Reported Releases of Phthalates	40
85	3.3.3	Conclusions on Cumulative General Population Exposure to Environmental Releases of	
86		Phthalates.....	43
87	3.4	Non-TSCA Exposure to Diet.....	43
88	4	PHTHALATE EXPOSURE AND RISK FOR THE U.S. POPULATION USING NHANES	
89		URINARY BIOMONITORING DATA	45
90	4.1	Temporal Trends in Phthalate Exposure Based on NHANES Urinary Biomonitoring Data	47
91	4.1.1	Trends in National Aggregate Production Volume Data.....	49
92	4.2	Aggregate Phthalate Exposure Based on NHANES Urinary Biomonitoring Data and Reverse	
93		Dosimetry	49
94	4.3	Cumulative Phthalate Exposure Estimates Based on NHANES Urinary Biomonitoring	51
95	4.4	Cumulative Phthalate Risk Based on NHANES Urinary Biomonitoring	51
96	4.5	Conclusions from NHANES Analysis.....	52
97	5	CONCLUSION AND NEXT STEPS	62
98	5.1	Estimation of Cumulative Risk – Option 1.....	63
99	5.2	Estimation of Cumulative Risk – Option 2.....	66
100	5.3	Anticipated Impact of the Cumulative Analysis on Phthalates being Evaluated Under TSCA	
101		Under Option 1 and Option 2	70
102	5.3.1	Anticipated Impact of the Cumulative Analysis on Phthalates being Evaluated Under	
103		TSCA Using Option 1	70
104	5.3.1.1	Dibutyl Phthalate (DBP).....	70
105	5.3.1.2	Dicyclohexyl Phthalate (DCHP).....	70
106	5.3.1.3	Diisobutyl Phthalate (DIBP).....	71
107	5.3.1.4	Butyl Benzyl Phthalate (BBP).....	72
108	5.3.1.5	Diisononyl Phthalate (DINP).....	73
109	5.3.1.6	Diethylhexyl Phthalate (DEHP)	73
110	5.3.2	Anticipated Impact of the Cumulative Analysis on Phthalates being Evaluated Under	
111		TSCA Under Option 2	74
112	5.4	Comparison of Two Options for Estimating Cumulative Risk	74
113		REFERENCES.....	82
114		APPENDICES	92
115	Appendix A	FETAL TESTICULAR TESTOSTERONE DATA FOR DEHP AND DBP	92
116	Appendix B	CONSIDERATIONS FOR BENCHMARK RESPONSE (BMR) SELECTION	
117		FOR REDUCED FETAL TESTICULAR TESTOSTERONE	96
118	B.1	Purpose	96
119	B.2	Methods	96
120	B.3	Results.....	97
121	B.4	Weight of Scientific Evidence Conclusion.....	98
122	Appendix C	NHANES URINARY BIOMONITORING	101
123	C.1	Urinary Biomonitoring: Methods and Results.....	101
124	C.2	Urinary Biomonitoring: Temporal Trends Analysis.....	104
125	C.2.1	DEHP.....	104
126	C.2.2	DBP.....	105
127	C.2.3	BBP.....	106

128	C.2.4 DIBP	106
129	C.2.5 DINP	107
130	C.3 Reverse Dosimetry: Methods and Results	108
131	C.4 Statistical Analysis of Cumulative Phthalate Exposure.....	111
132	C.5 Limitations and Uncertainties of Reverse Dosimetry Approach.....	113
133	Appendix D Supporting Analyses for Occupational Exposure to Phthalates	114
134	D.1 Trends in National Aggregate Production Volume	114
135	D.2 Industrial and Commercial Products Containing Multiple Phthalates	116
136	D.3 Parent Company Overlap in Phthalate Manufacture and Processing	117
137	D.4 Conditions of Use Listed in Final Scopes for Individual Phthalate Risk Evaluations	122
138	Appendix E Calculation of Occupational Exposure Values Based on Cumulative Exposures	
139	and Relative Potency Assumptions.....	125
140	E.1 Occupational Exposure Value for the Index Chemical (DBP).....	125
141	E.2 Estimating Inhalation Risk to Air Mixtures using Cumulative and Individual OEVs	126
142	Appendix F Supporting Analyses for Consumer Exposure to Phthalates.....	128

143

144 LIST OF TABLES

145	Table 2-1. Summary of Studies Included in EPA’s Updated Meta-Analysis and BMD Modeling	
146	Analysis.....	20
147	Table 2-2. BMD Modeling Results of Fetal Testicular Testosterone for DEHP, DBP, DIBP, BBP,	
148	DCHP, and DINP	22
149	Table 2-3. Comparison of the Number of Studies Supporting Key Outcomes Associated with Phthalate	
150	Syndrome ^a	23
151	Table 2-4. Comparison of Candidate Relative Potency Factors Based on BMD ₅ , BMD ₁₀ , and BMD ₄₀	
152	Estimates	25
153	Table 3-1. Confidence in Phthalate Settled Dust Monitoring Studies	35
154	Table 3-2. Cumulative Phthalate Daily Intake (µg/kg-day) Estimates from Indoor Dust Monitoring Data	
155	36
156	Table 3-3. Summary of Physical Chemical Properties and Fate Parameters of DCHP, DBP, DIBP, BBP,	
157	DEHP, and DINP	39
158	Table 4-1. Urinary Phthalate Metabolites Included in NHANES.....	46
159	Table 4-2. Cumulative Phthalate Daily Intake (µg/kg-day) Estimates for Women of Reproductive Age	
160	and Male Children from the 2017–2018 NHANES Cycle	54
161	Table 4-3. Cumulative Phthalate Daily Intake (µg/kg-day) Estimates for Women of Reproductive Age	
162	(16 to 49 years old) by Race and Socioeconomic Status from the 2017–2018 NHANES	
163	Cycle	56
164	Table 5-1. DCHP Risk Calculation Example for Female Workers of Reproductive Age.....	76
165	Table 5-2. DEHP Risk Calculation Example for Female Workers of Reproductive Age.....	78
166	Table 5-3. Summary of Impact of Cumulative Assessment on Phthalates Being Evaluated Under TSCA	
167	80
168	Table 5-4. Summary of Non-Attributable Cumulative Exposure From NHANES Being Combined for	
169	Each Assessed Population.....	81

170

171 LIST OF FIGURES

172	Figure 1-1. Phthalate Syndrome Mode of Action Following Gestational Exposure	12
-----	------------------------------------------------------------------------------------	----

173 Figure 3-1. Mapping of Facilities with One of Multiple Phthalates 42
174 Figure 4-1. Median Phthalate Metabolite Concentrations Over Time for All NHANES Participants From
175 1999 Through 2018..... 49
176 Figure 4-2. Percent Contribution to Cumulative Exposure for DEHP, DBP, BBP, DIBP, and DINP for
177 Women of Reproductive Age (16 to 49 years) in 2017–2018 NHANES, Stratified by
178 Race..... 59
179 Figure 4-3. Percent Contribution to Cumulative Exposure for DEHP, DBP, BBP, DIBP, and DINP for
180 Women of Reproductive Age (16 to 49 years) in 2017–2018 NHANES, Stratified by
181 Socioeconomic Status 60
182 Figure 4-4. Percent Contribution to Cumulative Exposure for DEHP, DBP, BBP, DIBP, and DINP for
183 Male Children Ages 3 to 5, 6 to 11, and 12 to 15 years in 2017–2018 NHANES 61
184 Figure 5-1. DCHP Risk Calculation Generic Example (Not to Scale) for Female Workers of
185 Reproductive Age 77
186 Figure 5-2. DEHP Risk Calculation Generic Example (Not to Scale) for Female Workers of
187 Reproductive Age 79
188
189

190 LIST OF APPENDIX TABLES

191 Table_Apx A-1. Summary of Fetal Testicular Testosterone Data for DEHP^a 92
192 Table_Apx A-2. Summary of Fetal Testicular Testosterone Data for DBP 94
193 Table_Apx B-1. Comparison of BMD/BMDL Values Across BMRs of 5%, 10%, and 40% with PODs
194 and LOAELs for Apical Outcomes for DEHP, DBP, DIBP, BBP, DCHP, and DINP .. 100
195 Table_Apx C-1. Limit of Detection (ng/mL) of Urinary Phthalate Metabolites by NHANES Survey Year
196 103
197 Table_Apx C-2. Summary of Phthalate Metabolite Detection Frequencies in NHANES^a 103
198 Table_Apx C-3. Fug Values Used for the Calculation of Daily Intake Values of DEHP, BBP, DBP,
199 DIBP, and DINP 109
200 Table_Apx C-4. Statistical Analysis (t-test) of Cumulative Phthalate Exposure for Women of
201 Reproductive Age by Race^a 111
202 Table_Apx C-5. Statistical Analysis (ANOVA with Tukey Post-Hoc Test) of Cumulative Phthalate
203 Exposure for Women of Reproductive Age by Race^a 112
204 Table_Apx C-6. Statistical Analysis (ANOVA with Tukey Post-Hoc Test) of Cumulative Phthalate
205 Exposure for Women of Reproductive Age by Socioeconomic Status^a..... 112
206 Table_Apx C-7. Statistical Analysis (ANOVA with Tukey Post-Hoc Test) of Cumulative Phthalate
207 Exposure for Women of Reproductive Age and Male Children by Age^a..... 112
208 Table_Apx D-1. Trends in Nationally Aggregated Production Volume (lbs) Data for DEHP, DBP, BBP,
209 DIBP, DCHP, and DINP..... 115
210 Table_Apx D-2. Summary of Industrial and Commercial Products that Contain Multiple Phthalates.. 116
211 Table_Apx D-3. Parent Companies Reporting Use of Multiple Phthalates (DEHP, DBP, BBP, DIBP,
212 DINP, DCHP) to 2016 and 2020 CDR and 2017 through 2022 TRI 118
213 Table_Apx D-4. Categories of Conditions of Use for High-Priority Phthalates and a Manufacturer-
214 Requested Phthalate 122
215 Table_Apx F-1. Sample of Consumer Products Containing Phthalates^f 128
216

217 **KEY ABBREVIATIONS AND ACRONYMS**

218	AIC	Akaike information criterion
219	AGD	Anogenital distance
220	BBP	Butyl benzyl phthalate
221	BMD	Benchmark dose
222	BMDL	Benchmark dose (lower confidence limit)
223	BMR	Benchmark response
224	CASRN	Chemical Abstracts Service registry number
225	CDR	Chemical Data Reporting
226	COU	Condition of use
227	CPSC	Consumer Product Safety Commission (U.S.)
228	CRA	Cumulative risk assessment
229	DBP	Dibutyl phthalate
230	DCHP	Dicyclohexyl phthalate
231	DEHP	Di(2-ethylhexyl) phthalate
232	DIBP	Diisobutyl phthalate
233	DIDP	Diisodecyl phthalate
234	DINP	Diisononyl phthalate
235	DMR	Discharge Monitoring Report
236	EPA	Environmental Protection Agency (U.S.)
237	GD	Gestation day
238	MNG	Multinucleated gonocyte
239	MOA	Mode of action
240	MOE	Margin of exposure
241	NASEM	National Academies of Sciences, Engineering, and Medicine
242	NEI	National Emissions Inventory
243	NR	Nipple/areolae retention
244	OCSP	Office of Chemical Safety and Pollution Prevention
245	OES	Occupational exposure scenario
246	OEV	Occupational exposure value
247	OPPT	Office of Pollution Prevention and Toxics
248	POD	Point of departure
249	PESS	Potentially Exposed or Susceptible Subpopulations(s)
250	PV	Production volume
251	RPF	Relative potency factor
252	SACC	Science Advisory Committee on Chemicals
253	SD	Sprague-Dawley (rat)
254	TRI	Toxics Release Inventory
255	TSCA	Toxic Substances Control Act
256	UF	Uncertainty factor
257	U.S.	United States

ACKNOWLEDGEMENTS

The Assessment Team gratefully acknowledges the participation, input, and review comments from the U.S. Environmental Protection Agency (EPA or the Agency) Office of Pollution Prevention and Toxics (OPPT) and Office of Chemical Safety and Pollution Prevention (OCSPP) senior managers and science advisors, as well as intra-agency reviewers including the Office of Research and Development (ORD). Special acknowledgement is given for the contributions of technical experts from ORD, including Justin Conley and Earl Gray. The Agency is also grateful for assistance from EPA contractors ERG (Contract No. 68HERD20A0002 and GS-00F-079CA); ICF (Contract No. 68HERC23D0007); and SRC, Inc. (Contract No. 68HERH19D0022).

Docket

Supporting information can be found in the public docket Docket IDs ([EPA-HQ-OPPT-2018-0504](#), [EPA-HQ-OPPT-2018-0434](#), [EPA-HQ-OPPT-2018-0503](#), [EPA-HQ-OPPT-2018-0433](#), and [EPA-HQ-OPPT-2018-0501](#)).

Disclaimer

Reference herein to any specific commercial products, process or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement, recommendation, or favoring by the United States Government.

Authors: Anthony Luz, Maiko Arashiro, S. Xiah Kragie, Keith Jacobs, Yousuf Ahmad, Ryan Sullivan, Aaron Murray, Collin Beachum (Branch Supervisor)

Contributors: Bryan Groza, Robert Landolfi, Daniel DePasquale , Maggie Clark

Technical Support: Hillary Hollinger and Mark Gibson

284 NOTE TO REVIEWERS

285 This document provides a revision to Section 5 of the *Draft Technical Support Document for the*
286 *Cumulative Risk Analysis of Di(2-ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), Butyl Benzyl*
287 *Phthalate (BBP), Diisobutyl Phthalate (DIBP), Dicyclohexyl Phthalate (DCHP), and Diisononyl*
288 *Phthalate (DINP) Under the Toxic Substances Control Act (TSCA)* ([U.S. EPA, 2024q](#)) that was released
289 to the public in January 2025. In Section 5 of the draft cumulative risk analysis technical support
290 document (TSD) release to the public in January 2025 ([U.S. EPA, 2024q](#)), EPA outlines one option for
291 characterizing cumulative risk from exposure to phthalates under TSCA. This revision provides
292 clarification for the option already presented and also outlines a second option for characterizing
293 cumulative risk of phthalates under TSCA, as well as compares the two risk characterization options.
294 **This revision is intended to replace Section 5 (Conclusions and Next Steps) in the draft cumulative**
295 **risk analysis TSD released in January 2025 (U.S. EPA, 2024q).** This revision to Section 5 of the draft
296 cumulative risk analysis TSD is being released for public comment and peer-review by the SACC
297 during the summer of 2025, when EPA will be soliciting feedback on the proposed options for
298 implementation of its cumulative risk analysis approach.
299
300

301 SUMMARY

302 The U.S. Environmental Protection Agency (EPA) has developed this draft technical support document
303 (TSD) for the cumulative risk assessment (CRA) of six toxicologically similar phthalates being
304 evaluated under Section 6 of the Toxic Substances Control Act (TSCA): di(2-ethylhexyl) phthalate
305 (DEHP), butyl benzyl phthalate (BBP), dibutyl phthalate (DBP), dicyclohexyl phthalate (DCHP),
306 diisobutyl phthalate (DIBP), and diisononyl phthalate (DINP). EPA previously issued a *Draft Proposed*
307 *Approach for Cumulative Risk Assessment of High-Priority Phthalates and a Manufacturer-Requested*
308 *Phthalate under the Toxic Substances Control Act* ([U.S. EPA, 2023b](#)) which was subsequently peer-
309 reviewed by the Science Advisory Committee on Chemicals (SACC) ([U.S. EPA, 2023c](#)). In the 2023
310 proposed approach, EPA identified a cumulative chemical group and potentially exposed or susceptible
311 subpopulations (PESS) [15 U.S.C. § 2605(b)(4)]. These conclusions were supported by the SACC in
312 their final peer-review report to EPA ([U.S. EPA, 2023c](#)) and carried forward in this draft cumulative risk
313 assessment TSD.
314

315 As each chemical substance was prioritized or requested individually, EPA is required to evaluate the
316 health and environmental risks of each individual phthalate and determine for each chemical substance
317 whether it presents unreasonable risk or injury to health or the environment. Analytical pieces from this
318 TSD are elaborated to inform EPA's individual phthalate risk determinations, pending completion of the
319 individual phthalate risk evaluations. Specifically, this TSD provides the following for reference in the
320 individual chemical substance risk evaluations and for consideration in any subsequent risk
321 management:

- 322 • **Common Hazard Assessment via RPFs.** Section 1.1 calculates draft relative potency factors
323 (RPFs) for phthalate syndrome based on the shared endpoint and pooled dataset for assessing
324 fetal testicular testosterone health endpoint for each of the six chemical substances using DBP as
325 an index chemical. This provides a more robust basis for assessing the dose-response to the
326 shared hazard endpoint across all assessed phthalates. For all the assessed phthalates, RPFs have
327 been applied to convert exposures into equivalent units for summation across phthalates.
- 328 • **Scenario-Based Phthalate Exposure.** Section 3 frames the relevant frequency and duration of
329 exposures and provides qualitative analysis of where co-exposures are expected with exposures

330 assessed within the individual TSCA risk evaluations under specific conditions of use (COUs)
331 for workers and consumers. Section 3 also provides a quantitative analysis of cumulative risk
332 from indoor dust using monitoring data and a general update to the literature regarding non-
333 TSCA exposures from diet.

- 334
- 335 • **National Cumulative Exposure and Risk.** Average aggregate exposures to the assessed
336 phthalates for the U.S. population are presented in Section 4 using reverse dosimetry from
337 urinary biomonitoring in the National Health and Nutrition Examination Survey (NHANES).
338 This NHANES reverse dosimetry, combined with the RPFs, provides a common understanding
339 of non-attributable exposures and risks to the U.S. population, including the susceptible
340 subpopulations of women of reproductive age or male children, which can augment specific
acute scenarios described further in individual risk evaluations.
 - 341 • **Examples for Calculating Cumulative Risk.** This TSD also elaborates an example of
342 cumulative risk calculations for combining exposures from individual chemical substance risk
343 evaluations, from monitoring data, or in support of decision making using the RPFs. Most
344 notably, an option is elaborated for considering a cumulative occupational exposure value
345 (OEV). The calculated draft value is provided for public comment and transparency and may be
346 considered during risk management efforts for some or all of the six toxicologically similar
347 phthalates under TSCA section 6(a), 15 U.S.C. §2605.

348 This TSD concludes with an overview of how the RPFs can supplement the hazard values for each
349 individual phthalate and then be used in combination with the NHANES data for risk characterization
350 within the individual risk evaluations.

351 1 INTRODUCTION AND SCOPE

352 The U.S. Environmental Protection Agency (EPA or the Agency) is individually evaluating the health
353 and environmental risks of several phthalates under section 6 of the Toxic Substances Control Act
354 (TSCA) as separate chemical substances. Phthalates are a group of chemicals used in many industrial
355 and consumer products, including building and construction materials, and polyvinyl chloride products,
356 to make plastics more flexible and durable. Some phthalates are used in cosmetic, as well as food
357 contact materials and have been measured in food. Studies investigating human exposure to phthalates
358 have demonstrated widespread exposure to some phthalates and that humans may become co-exposed to
359 multiple phthalates at the same time. Further, some phthalates have been shown to cause common
360 adverse effects on the developing male reproductive system, sometimes referred to as “phthalate
361 syndrome.” TSCA requires EPA, in conducting risk evaluations pursuant to section 6 to consider the
362 reasonably available information, consistent with the best available science, and make decisions based
363 on the weight of scientific evidence [15 U.S.C. § 2625(h), (i), (k)]. EPA recognizes that for some
364 chemical substances undergoing risk evaluation, the best available science may require analysis of
365 cumulative risk to ensure that any risks to human health are adequately characterized in support of
366 TSCA risk evaluations.

367
368 In 2023, EPA issued a *Draft Proposed Approach for Cumulative Risk Assessment of High-Priority*
369 *Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act* (draft
370 2023 approach) which outlined an approach for cumulative risk assessment (CRA) of six toxicologically
371 similar phthalates being evaluated under TSCA ([U.S. EPA, 2023b](#)). EPA’s proposal was subsequently
372 peer-reviewed by the Science Advisory Committee on Chemicals (SACC) in May 2023 ([U.S. EPA,](#)
373 [2023c](#)). In this approach, EPA identified a cumulative chemical group and potentially exposed or
374 susceptible subpopulations (PESS) [15 U.S.C. § 2605(b)(4)]. Based on toxicological similarity and
375 induced effects on the developing male reproductive system consistent with a disruption of androgen
376 action and phthalate syndrome, EPA proposed a cumulative chemical group of di(2-ethylhexyl)
377 phthalate (DEHP), butyl benzyl phthalate (BBP), dibutyl phthalate (DBP), dicyclohexyl phthalate
378 (DCHP), diisobutyl phthalate (DIBP), and diisononyl phthalate (DINP), but not diisodecyl phthalate
379 (DIDP). DIDP was not included in the cumulative chemical group because it does not induce effects
380 consistent with phthalate syndrome. This approach emphasizes a uniform measure of hazard for
381 sensitive subpopulations, namely women of reproductive age and/or male infants and children; however
382 additional health endpoints are known for broader populations and described in the individual non-
383 cancer human health hazard assessments for DEHP ([U.S. EPA, 2024h](#)), DBP ([U.S. EPA, 2024f](#)), DIBP
384 ([U.S. EPA, 2024i](#)), BBP ([U.S. EPA, 2024e](#)), DCHP ([U.S. EPA, 2024g](#)), and DINP ([U.S. EPA, 2025p](#)),
385 including hepatic, kidney, and other developmental and reproductive toxicity.

386
387 While additional groups and subpopulations may be susceptible to health effects from phthalate
388 exposure, EPA identified groups with higher susceptibility to phthalate syndrome due to lifestyle as (1)
389 pregnant women/women of reproductive age, and (2) male infants, male toddlers, and male children.
390 These conclusions were supported by the SACC in their final peer-review report to EPA ([U.S. EPA,](#)
391 [2023c](#)) and carried forward in this draft cumulative risk assessment technical support document.

392
393 Sections 1.1 through 1.1 further outline the scope of this draft cumulative risk assessment technical
394 support document.

395
396 This draft cumulative risk assessment technical support document is being released for public comment
397 and peer-review by the SACC during the summer of 2025, when EPA will be soliciting feedback on the

398 implementation of its cumulative risk analysis approach. EPA will not solicit specific feedback on
399 options previously considered by the SACC during its May 2023 peer-review meeting ([U.S. EPA,
400 2023c](#)).

401 **1.1 Phthalate Syndrome Mode of Action**

402 EPA has previously described the mode of action (MOA) for phthalate syndrome in the *Draft Proposed*
403 *Approach for Cumulative Risk Assessment of High-Priority Phthalates and a Manufacturer-Requested*
404 *Phthalate under the Toxic Substances Control Act* (draft 2023 approach) ([U.S. EPA, 2023b](#)), as well as
405 in its non-cancer hazard assessments for DEHP ([U.S. EPA, 2024h](#)), DBP ([U.S. EPA, 2024f](#)), DIBP
406 ([U.S. EPA, 2024i](#)), BBP ([U.S. EPA, 2024e](#)), DCHP ([U.S. EPA, 2024g](#)), and DINP ([U.S. EPA, 2025p](#)).
407 A brief description of the MOA for phthalate syndrome is provided in this section. Readers are directed
408 to EPA's draft 2023 approach and the non-cancer hazard assessments cited above for more detailed
409 MOA information.

410
411 Although the MOA underlying phthalate syndrome has not been fully established, key cellular-, organ-,
412 and organism-level effects are generally understood (Figure 1-1). Studies have demonstrated that
413 gestational exposure to certain phthalate diesters, and their subsequent hydrolysis to monoester
414 metabolites, which occur during a critical window of development (*i.e.*, the masculinization
415 programming window) can lead to antiandrogenic effects on the developing male reproductive system
416 ([NRC, 2008](#)). In rats, the masculinization programming window in which androgen action drives
417 development of the male reproductive system occurs between days 15.5 to 18.5 of gestation, while the
418 mouse critical window corresponds to gestational days 14 to 16, and the human masculinization
419 programming window is between gestational weeks 8 to 14 ([MacLeod et al., 2010](#); [Welsh et al., 2008](#);
420 [Carruthers and Foster, 2005](#)).


421
422 *In vivo* pharmacokinetic studies with rats have demonstrated that the monoester metabolites of DEHP,
423 DBP, BBP, and DINP can cross the placenta and be delivered to the target tissue, the fetal testes
424 ([Clewell et al., 2013](#); [Clewell et al., 2010](#)). *In utero* phthalate exposure can affect both Leydig and
425 Sertoli cell function in the fetal testes. Histologic effects observed following phthalate exposure include
426 Leydig cell aggregation and/or altered tissue distribution, as well as reductions in Leydig cell numbers.
427 Functional effects on Leydig cells have also been reported. Leydig cells are responsible for producing
428 hormones required for proper development of the male reproductive system, including insulin-like
429 growth factor 3 (INSL3), testosterone, and dihydrotestosterone (DHT) ([Scott et al., 2009](#)). Phthalate
430 exposure during the critical window reduces mRNA and/or protein levels of INSL3, as well as genes
431 involved in steroidogenesis, sterol synthesis, and steroid and sterol transport (Figure 1-1) ([Gray et al.,
432 2021](#); [Hannas et al., 2012](#)). Decreased steroidogenic mRNA expression leads to decreased fetal testicular
433 testosterone production, as well as reductions in DHT levels, which is produced from testosterone by 5 α -
434 reductase in the peripheral tissues. Because DHT is required for growth and differentiation of the
435 perineum and for normal regression of nipple development in male rats, reduced DHT levels can lead to
436 phenotypic changes (*i.e.*, nipple/areolae retention [NR] and reduced anogenital distance [AGD] in
437 males) indicative of reduced Leydig cell function and androgen action.

438
439 Gestational exposure to certain phthalate diesters can also affect Sertoli cell function, development, and
440 interactions with germ cells contributing to seminiferous tubule degeneration ([Boekelheide et al., 2009](#)).
441 Immature Sertoli cells secrete Anti-Müllerian hormone and play an essential role in gonadal
442 development ([Lucas-Herald and Mitchell, 2022](#)). Reported Sertoli cell effects include decreased cell
443 numbers, changes in mRNA and/or protein levels of genes involved in Sertoli cell function, their
444 development and altered Sertoli-germ cell interactions. Because proper Sertoli cell function is necessary

445 for germ cell proliferation and development, altered Sertoli cell function can contribute to increased
446 germ cell death, decreased germ cell numbers, and increased formation of multinucleated gonocytes
447 (MNGs) ([Arzuaga et al., 2020](#)).

448
449 At the organ level, a disruption of androgen action can lead to reduced testes and accessory sex gland
450 (e.g., epididymis, seminal vesicle [SV], prostate, etc.) weight; agenesis of accessory organs; delayed
451 preputial separation (PPS); testicular pathology (e.g., interstitial cell hyperplasia); and severe
452 reproductive tract malformations such as hypospadias. INSL3 is crucial for gubernacular cord
453 development and the initial transabdominal descent of the testes to the inguinal region ([Adham et al.,
454 2000](#)), while androgen action is required for the inguinoscrotal phase of testicular descent. Thus,
455 reduced INSL3 and testosterone levels following gestational phthalate exposure can prevent
456 gubernaculum development and testicular descent into the scrotum. Collectively, these effects can lead
457 to reduced spermatogenesis, increased sperm abnormalities, and reduced fertility and reproductive
458 function ([Gray et al., 2021](#); [Arzuaga et al., 2020](#); [Howdeshell et al., 2017](#); [NASEM, 2017](#); [NRC, 2008](#)).

459
460



461
462
463
464
465
466

Figure 1-1. Phthalate Syndrome Mode of Action Following Gestational Exposure

Figure adapted from ([Conley et al., 2021](#); [Gray et al., 2021](#); [Schwartz et al., 2021](#); [Howdeshell et al., 2017](#)). AR = androgen receptor; INSL3 = insulin-like growth factor 3; MNG = multinucleated gonocyte; PPAR α = peroxisome proliferator-activated receptor alpha.

467
468

1.2 Phthalates Included in the Cumulative Chemical Group Based on Toxicologic Similarity

469 In the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA evaluated the MOA for phthalate syndrome
470 consistent with modified Bradford Hill criteria (i.e., temporal and dose-response concordance; strength,
471 consistency and specificity; biological plausibility) outlined in EPA and other international guidance
472 documents ([IPCS, 2007](#); [U.S. EPA, 2005](#)). Additional phthalates could be included based on this

473 toxicological similarity but were not evaluated during this phase of risk evaluation under TSCA. For
474 example, Health Canada ([ECCC/HC, 2020](#)) recently conducted a CRA of phthalates, which included the
475 six high-priority and manufacturer-requested phthalates (DIBP, DCHP, DINP, BBP, DBP, DEHP) as
476 well as 10 phthalates not undergoing risk evaluation at EPA, including: butyl cyclohexyl phthalate
477 (BCHP, CASRN 84-64-0), dibenzyl phthalate (DBzP, CASRN 523-31-9), cyclohexyl isobutyl phthalate
478 (CHIBP, CASRN 5334-09-8), benzyl 3-isobutyryloxy-1-isopropyl-2,2-dimethylpropyl phthalate (B84P,
479 CASRN 16883-83-3), benzyl isooctyl phthalate (BIOP, CASRN 27215-22-1),
480 bis(methylcyclohexyl)phthalate (DMCHP, CASRN 27987-25-3), benzyl octyl phthalate (B79P, CASRN
481 68515-40-2), diisooctyl phthalate (DIHepP, CASRN 71888-89-6), diisooctyl phthalate (DIOP, CASRN
482 27554-26-3), and dihexyl ester phthalate (DnHP, CASRN 84-75-3).

483
484 Overall, EPA concluded that DEHP, BBP, DBP, DCHP, DIBP, and DINP, but not DIDP, are
485 toxicologically similar and can induce effects on the developing male reproductive system consistent
486 with a disruption of androgen action and phthalate syndrome. This conclusion was supported by the
487 SACC in its the final peer-review report to EPA ([U.S. EPA, 2023c](#)). **Therefore, EPA is including**
488 **DEHP, BBP, DBP, DCHP, DIBP, and DINP in its draft CRA.** DIDP was not included in the
489 cumulative chemical group because it does not induce effects on the developing male reproductive
490 system consistent with phthalate syndrome.

491 **1.3 Endpoints and Options Considered for Relative Potency Factor** 492 **Derivation**

493 To conduct its cumulative risk assessment of phthalates, EPA is using a relative potency factor (RPF)
494 approach. In the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA outlined six potential options for deriving
495 RPFs that considered use of data from two gestational outcomes (*i.e.*, altered expression of steroidogenic
496 genes in the fetal testis and decreased fetal rat testicular testosterone) and four postnatal outcomes (*i.e.*,
497 reduced anogenital distance (AGD), increased nipple retention, seminiferous tubule atrophy, and
498 hypospadias). Options 1 through 4 involve benchmark dose (BMD) modeling of fetal outcomes
499 associated with the MOA underlying phthalate syndrome (*i.e.*, reduced fetal testicular testosterone
500 content and/or reduced testicular steroidogenic gene expression), and involve BMD modeling of data
501 from individual studies (Options 1 and 3) or combining data from studies of similar design prior to
502 BMD modeling (Options 2 and 4). Similarly, Options 5 and 6 involve BMD modeling of postnatal
503 outcomes (*i.e.*, reduced AGD, increased nipple/areolae retention, seminiferous tubule atrophy,
504 hypospadias), and involve BMD modeling of data from individual studies (Option 5) or combining data
505 from studies of similar design prior to BMD modeling (Option 6). Section 4.4 of the draft 2023
506 approach ([U.S. EPA, 2023b](#)) provides further details regarding the six options considered by EPA for
507 deriving RPFs.

508
509 In its final peer-review report to EPA ([U.S. EPA, 2023c](#)), SACC did not endorse any single option to
510 derive RPFs, but instead concluded:

511
512 *“In terms of options to calculate RPFs, the committee was in consensus that it prefers any*
513 *approach which uses as much of the data as possible assuming the dose-response aspects are*
514 *considered in the process for selecting endpoints. Option 2 and 4 that incorporate dose-*
515 *response data are preferable to not using some of the data. Option 6 is similar except it uses*
516 *postnatal outcomes instead of fetal ones. In an attempt to use the greatest amount of data, the*
517 *committee suggests a combination of prenatal and postnatal outcomes would provide the best of*
518 *both approaches.”*
519

520 Strengths, limitations, and uncertainties of the available datasets for each of the six key outcomes
521 considered for RPF derivation are discussed in detail in Section 4.4 of the draft 2023 approach ([U.S.](#)
522 [EPA, 2023b](#)) and discussed briefly below. Overall, EPA noted several factors that increased its
523 confidence in using the fetal testicular testosterone dataset to derive RPFs, including:

- 524 • Reduced testosterone production in the fetal testis plays an early role in the phthalate syndrome
525 MOA.
- 526 • Androgen action has a conserved role in the development of the male reproductive system across
527 mammalian species, including humans.
- 528 • There are dose-response data available for all six of the toxicologically similar phthalates from
529 multiple studies that are similar in design to support RPF derivation (*i.e.*, utilize the same
530 species/strain of rat, same route/method of exposure, similar exposure durations, similar timing
531 and method (*ex vivo* testosterone production via radioimmunoassay) of measurement.

532 In contrast, EPA noted several factors that decreased its confidence in using postnatal outcomes to
533 derive RPFs, including:

- 534 • ***Anogenital distance (AGD)***. AGD is the measured distance between the anus to the base of the
535 penis, and decreased AGD is considered a biomarker of a disruption of androgen action and male
536 reproductive health. There is variability in how studies report decreased male AGD. Changes in
537 AGD are sometimes but not always normalized to body weight. Per OECD guidance ([OECD,](#)
538 [2013](#)), AGD should be normalized to body weight (preferably the cubic root of body weight)
539 since animal size can influence AGD. Further, in the case of DIBP only one dose-response study
540 is available, and this study only reports absolute AGD. Another source of uncertainty stems from
541 the DINP dataset. In contrast to DEHP, BBP, DBP, DCHP, and DIBP where consistent effects
542 on AGD are reported, statistically significant effects on AGD are less consistently reported for
543 DINP across studies that test comparable doses (*i.e.*, DINP reduced AGD in two of six studies).
544 Inconsistency in the DINP dataset reduces EPA's confidence in deriving RPFs based on this
545 outcome.
- 546 • ***Nipple/Areolae Retention***. Across available studies, there is variability in how nipple/areolae
547 retention is reported. For example, sometimes this outcome is reported as mean number of
548 nipples/areolas per male, incidence of males with nipples, or mean percent of litters including
549 males with nipples. Variability in data reporting makes comparisons across studies difficult.
550 Additionally, although male pup nipple/areolae retention is a biomarker of disrupted androgen
551 action in rodents, it is not directly a human relevant effect. This uncertainty reduces EPA's
552 confidence in deriving RPFs based on nipple/areolae retention in male pups
- 553 • ***Seminiferous Tubule Atrophy***. Seminiferous tubule atrophy, associated with infertility, testicular
554 atrophy, and pain, has been reported consistently for DEHP, DBP, DIBP, BBP, and DCHP;
555 however, available studies reporting seminiferous tubule atrophy are of varying design and
556 durations. For example, seminiferous tubule atrophy has been reported in two-generation studies
557 of DCHP and BBP, while for DIBP seminiferous tubule atrophy has only been reported in one
558 study in which rats were exposed throughout gestation. Additionally, effects on seminiferous
559 tubular atrophy are less consistently reported in studies of DINP that test comparable doses.
560 Differences in study design and exposure duration across available studies and inconsistency in
561 the DINP dataset reduces EPA's confidence in deriving RPFs based on this outcome.
- 562 • ***Hypospadias***. Hypospadias, birth defects of abnormal urethral opening on the penis, have been
563 reported consistently in studies of DEHP, DBP, DIBP, BBP, and DCHP; however, significant

564 increases in hypospadias have not been reported in studies of DINP. Further, available studies
565 reporting hypospadias are of varying design and duration. For example, hypospadias have been
566 reported in a single study of BBP (a two-generation reproductive study) and a single study of
567 DIBP (a gestational exposure study). Differences in study design and exposure duration and
568 inconsistency in the DINP dataset reduces EPA's confidence in deriving RPFs based on this
569 outcome.

570 Given the strengths, limitations, and uncertainties of each key outcome discussed above and in Section
571 4.4. of ([U.S. EPA, 2023b](#)), **EPA has selected reduced fetal testicular testosterone as the basis for**
572 **deriving draft RPFs.**

573
574 Consistent with the SACC's recommendation that it prefers any option for deriving RPFs that makes use
575 of as much of the available data as possible ([U.S. EPA, 2023c](#)), **EPA selected Option 2 for deriving**
576 **RPFs. This option involves combining fetal testicular testosterone data from studies of similar design**
577 **prior to conducting BMD modeling.** EPA's BMD modeling approach of fetal testicular testosterone data to
578 derive RPFs is discussed further in Section 1.1.

579 **1.4 Relevant Populations**

580 Gestational exposure to DEHP, BBP, DBP, DIBP, DCHP and DINP can disrupt testicular
581 steroidogenesis and cause adverse effects on the developing male reproductive system consistent with
582 phthalate syndrome. Postnatal phthalate exposure can also cause male reproductive toxicity; however,
583 the perinatal and peripubertal lifestages are believed to be the most sensitive to phthalate exposure
584 ([NRC, 2008](#)). In the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA proposed to focus its CRA for
585 phthalates on two groups that may be more susceptible to phthalate syndrome due to lifestage:

- 586 • pregnant women/women of reproductive age, and
- 587 • male infants, male toddlers, and male children.

588 While additional populations may experience health effects, these populations are considered the most
589 susceptible for phthalate syndrome. Overall, SACC agreed with EPA that these lifestages "should
590 certainly be considered susceptible populations given the abundant data from hazard assessment studies"
591 ([U.S. EPA, 2023c](#)). **Therefore, EPA is focusing its CRA on pregnant women/women of**
592 **reproductive age, and male infants, male toddlers, and male children.**

593 **1.5 Relevant Durations**

594 As described in the non-cancer human health hazard assessment for DINP ([U.S. EPA, 2025p](#)) and draft
595 non-cancer human health hazard assessments for DEHP ([U.S. EPA, 2024h](#)), DBP ([U.S. EPA, 2024f](#)),
596 BBP ([U.S. EPA, 2024e](#)), DIBP ([U.S. EPA, 2024i](#)), and DCHP ([U.S. EPA, 2024g](#)), there is evidence that
597 effects on the developing male reproductive system consistent with a disruption of androgen action can
598 result from a single exposure during the critical window of development (*i.e.*, gestation day (GD) 14 to
599 18). Therefore, EPA considers effects on fetal testicular testosterone relevant as an acute effect
600 associated with higher, acute exposures. Notably, SACC agreed with EPA's decision to consider effects
601 on the developing male reproductive system consistent with a disruption of androgen action to be
602 relevant for setting a point of departure (POD) for acute durations during the July 2024 peer-review
603 meeting of the DINP human health hazard assessment ([U.S. EPA, 2024r](#)). In addition, phthalates have
604 relatively rapid elimination kinetics with half-lives on the order of several hours before being quickly
605 excreted from the body ([ATSDR, 2022](#); [EC/HC, 2015](#)). Thus, unlike chemical substances with more
606 bioaccumulative potential, historical exposures are not as relevant as concurrent or recent exposures
607 particularly in relation to critical windows of development. Taken together, **EPA is focusing the**

608 **application of its phthalate CRA on acute exposure durations** which are expected to represent the
609 highest relevant exposures for the common health effect for susceptible populations. Notably, protecting
610 for acute exposure durations will be protective of longer duration exposures, since acute exposures are
611 higher than longer duration exposures.

612 **1.6 Exposure Evaluations**

613 In the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA proposed both a reverse-dosimetry method for
614 estimating cumulative non-attributable phthalate exposure from NHANES urinary biomonitoring and
615 the development of scenarios for combining exposures from multiple sources in conjunction with the
616 individual phthalate risk evaluations ([U.S. EPA, 2023b](#)). The proposed scenario-based approach
617 included estimating and combining reasonable combinations of exposure attributable to TSCA COUs, to
618 non-TSCA sources (*e.g.*, diet, food packaging cosmetics, etc.), and any other non-attributable exposures
619 to determine cumulative risk.

620
621 Overall, the SACC endorsed the use of reverse dosimetry for estimating exposure using biomonitoring,
622 over the use of modeling, where monitoring represents exposed sub-populations. However, the SACC
623 noted that highly exposed subpopulations, including workers with occupational exposures, would not
624 likely be represented by a national survey. Nonetheless, NHANES data do provide total exposure,
625 including non-attributable and non-TSCA exposures, which could be aggregated with any scenario-
626 specific estimates.

627
628 Exposures and risks for each individual phthalate under its conditions of use (COUs) continue to be
629 evaluated in individual risk evaluations in accordance with TSCA.¹ EPA assesses exposure for
630 consumers, workers, and general population exposed to environmental releases for each individual
631 phthalate. Within these exposed populations, there are PESS with increased susceptibility to the
632 developmental and reproductive effects associated with phthalate syndrome, including pregnant
633 women/women of reproductive age, male infants, male toddlers, and male children. The 2023 proposal
634 laid out a multi-step approach and conceptual model which suggested the results of the individual
635 phthalate risk evaluations could be combined into a single cumulative risk assessment.

636
637 These individual assessments represent a mix of deterministic and probabilistic methods as well as
638 differing tiers of analyses (*i.e.* screening through more refined approaches). In its review, the SACC
639 specifically expressed “concern” about mixing these estimates in an approach that combines estimates
640 from these individual assessments ([U.S. EPA, 2023c](#)). In addition, credible exposure scenario-based
641 approaches would need to be informed by site specific data and “laborious” to construct (if even
642 possible) with reasonably available data.

643
644 Therefore, **EPA is using NHANES data to supplement, not substitute, evaluations for exposure**
645 **scenarios for TSCA COUs to provide non-attributable, total exposure for addition to the relevant**
646 **scenarios presented in the individual risk evaluations.** Section 5.1 provides this quantitative approach
647 to be tabulated in each individual relevant risk evaluation for evaluating cumulative risk resulting from
648 aggregate exposure to a single phthalate from an exposure scenario or COU plus non-attributable
649 cumulative risk from NHANES.

650

¹ Conditions of use (COUs) are defined as “the circumstances, as determined by the Administrator, under which a chemical substance is intended, known, or reasonably foreseen to be manufactured, processed, distributed in commerce, used, or disposed of.” (15 U.S.C. 2602(4))

651 Finally, the SACC recommended more discussion and analyses related to exposure, specifically related
652 to emphasis on the importance of indoor dust exposures, updates to estimates of phthalates in diet given
653 the highly diverse U.S. population, and specific emphasis on potential risk to arctic communities from
654 exposures to environmental releases ([U.S. EPA, 2023c](#)). The SACC also recommended that EPA
655 provide the physical-chemical and fate parameters for consideration across the group. These
656 recommendations are addressed in Section 3 in a qualitative or semi-quantitative manner.

657 **1.1 Risk Cup Concept in Cumulative Risk Assessment**

658 The analogy of a “risk cup” is used throughout this document to describe cumulative exposure estimates.
659 The “risk cup” term is used to help conceptualize the contribution of various phthalate exposure routes
660 and pathways to overall cumulative risk estimates and serves primarily as a communication tool. The
661 "risk cup" concept describes exposure estimates where the full cup represents the total exposure that
662 leads to risk (cumulative margin of exposure (MOE)) and each chemical substance contributes a specific
663 amount of exposure that adds a finite amount of risk to the cup.
664

665 To estimate non-cancer cumulative risks from exposure to phthalates, EPA is using a cumulative MOE
666 approach. As discussed further in Section 5.1, the cumulative MOE is a ratio of the index chemical POD
667 to the cumulative exposure estimate expressed in index chemical equivalent units. The MOE is then
668 compared to the benchmark MOE (*i.e.*, the total uncertainty factor associated with the assessment) to
669 characterize risk. The MOE estimate is interpreted as a human health risk of concern if the MOE
670 estimate is less than the benchmark MOE (*i.e.*, the total UF). On the other hand, if the MOE estimate is
671 equal to or exceeds the benchmark MOE, the risk is not considered to be of concern and mitigation is
672 not needed. Typically, the larger the MOE, the more unlikely it is that a non-cancer adverse effect
673 occurs relative to the benchmark. When determining whether a chemical substance presents
674 unreasonable risk to human health or the environment, calculated risk estimates are not “bright-line”
675 indicators of unreasonable risk, and EPA has the discretion to consider other risk-related factors in
676 addition to risks identified in the risk characterization.
677

678 A full risk cup indicates that the cumulative MOE has dropped below the benchmark MOE of 30,
679 whereas cumulative MOEs above the benchmark indicate that only a percentage of the risk cup is full.
680 For example, a cumulative MOE of 120 would indicate that the risk cup is 25 percent full, since the
681 benchmark MOE is 30 (empirical examples of the risk cup approach are provided in Section 5).

682 2 RELATIVE POTENCY FACTORS

683 This section describes the approach used by EPA to derive draft relative potency factors (RPFs) for the
684 six phthalates (*i.e.*, DEHP, DBP, BBP, DIBP, DCHP, DINP) that EPA is including in its draft CRA.
685 These RPFs are used to scale each phthalate exposure by potency and to calculate risk in common units
686 of index chemical (DBP) equivalents for cumulative assessment.

687
688 The remainder of this hazard chapter is organized as follows:

- 689 • Section 2.1 – Describes the general principles of the RPF approach.
- 690 • Section 2.2 – Describes the benchmark dose (BMD) modeling approach used by EPA for
691 deriving draft RPFs.
- 692 • Section 2.3 – Describes selection of the index chemical used as a point of reference to
693 standardize the potency of each phthalate,
- 694 • Section 2.4 – Describes the draft RPFs derived by EPA for each phthalate included in the CRA.
- 695 • Section 2.5 – Describes the uncertainty factors selected by EPA for use as the benchmark margin
696 of exposure (benchmark MOE).
- 697 • Section 2.6 – Describes the applicability of the draft RPFs.
- 698 • Section 2.7 – Describes EPA’s weight of scientific evidence conclusions.

699 2.1 Relative Potency Factor Approach

700 As described in the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA proposed to use a RPF approach to
701 characterize risk from cumulative exposure to phthalates under TSCA. Overall, SACC was “generally
702 supportive of the approach,” but noted several uncertainties ([U.S. EPA, 2023c](#)), which are addressed by
703 EPA in Section 2.4. Consistent with its initial proposal ([U.S. EPA, 2023b](#)), **EPA is using a RPF**
704 **approach for its draft CRA of phthalates under TSCA.**

705
706 For the RPF approach, chemical substances being evaluated require data that support toxicologic
707 similarity (*e.g.*, components of a mixture share a known or suspected common mode of action or share a
708 common apical endpoint/effect) and have dose-response data for the effect of concern over similar
709 exposure ranges ([U.S. EPA, 2023a](#), [2000](#), [1986](#)). RPF values account for potency differences among
710 chemicals in a mixture and scale the dose of one chemical to an equitoxic dose of another chemical (*i.e.*,
711 the index chemical). The chemical selected as the index chemical is often among the best characterized
712 toxicologically and considered to be representative of the type of toxicity elicited by other components
713 of the mixture. Implementing an RPF approach requires a quantitative dose response assessment for the
714 index chemical and pertinent data that allow the potency of the mixture components to be meaningfully
715 compared to that of the index chemical. In the RPF approach, RPFs are calculated as the ratio of the
716 potency of the individual component to that of the index chemical using either (1) the response at a fixed
717 dose; or (2) the dose at a fixed response (Equation 2-1).

718 719 Equation 2-1. Calculating RPFs

$$720 RPF_i = \frac{BMD_{R-IC}}{BMD_{R-i}}$$

721 where:

- 722 • *BMD* = benchmark dose (mg/kg/day)
- 723 • *R* = magnitude of response (*i.e.*, benchmark response)

- 724 • $i = i^{th}$ chemical
725 • IC = index chemical

726 After scaling the chemical component doses to the potency of the index chemical, the scaled doses are
727 summed and expressed as index chemical equivalents for the mixture (Equation 2-2).

728
729 **Equation 2-2. Calculating index chemical equivalents**

730 $Index\ Chemical\ Equivalents_{MIX} = \sum_{i=1}^n d_i \times RPF_i$

731 where:

- 732 • Index chemical equivalents = dose of the mixture in index chemical equivalents (mg/kg-day)
733 • d_i = dose of the i^{th} chemical in the mixture (mg/kg-day)
734 • RPF_i = relative potency factor of the i^{th} chemical in the mixture (unitless)

735 Non-cancer risk associated with exposure to the mixture can then be assessed by calculating a MOE,
736 which in this case is the ratio of the index chemical's non-cancer benchmark dose lower confidence limit
737 (BMDL) to an estimate of mixture exposure expressed in terms of index chemical equivalents. The
738 MOE is then compared to the benchmark MOE (*i.e.*, the total uncertainty factor associated with the
739 assessment) to characterize risk.

740 **2.2 Benchmark Dose Modeling of Fetal Testicular Testosterone to** 741 **Determine Toxic Potency**

742 In 2017, the National Academies of Sciences, Engineering, and Medicine (NASEM) demonstrated the
743 utility of a meta-analysis and meta-regression approach to combine fetal rat testicular testosterone data
744 from multiple studies of similar design prior to conducting BMD modeling (NASEM, 2017). Meta-
745 analysis is a statistical procedure that can be used to summarize outcomes from a number of studies and
746 can be used to explore sources of heterogeneity in the data through use of random effects models.
747 Therefore, meta-analysis can help overcome limitations associated with results from individual studies
748 and provide a more robust dataset across the chemicals for modeling dose-response of a common
749 endpoint.

750
751 To derive RPFs for DEHP, DBP, BBP, DIBP, DCHP, and DINP based on reduced fetal testicular
752 testosterone, EPA used the same meta-analysis and BMD modeling approach used by NASEM (2017),
753 with several notable updates. First, EPA identified new fetal testicular testosterone data that was not
754 included in the 2017 NASEM analysis. This new data was included in EPA's updated meta-analysis and
755 BMD analysis. Table 2-1 provides a summary of studies included in the updated analysis. EPA's
756 updated analysis also utilized the most up-to-date version of the Metafor meta-analysis package for R
757 (<https://wviechthb.github.io/metafor/index.html>) available at the time of the updated analysis (*i.e.*,
758 Version 4.6.0). However, EPA also conducted the updated analysis using the same version of Metafor
759 originally used by NASEM (2017) (*i.e.*, Version 2.0.0) so that results could be compared. As part of its
760 updated analysis, EPA also evaluated benchmark responses (BMRs) of 5, 10, and 40 percent based on
761 biological and statistical considerations (comparatively, NASEM evaluated BMRs of 5 and 40%).

762
763 Results of EPA's updated meta-analysis and BMD analysis are provided in Section 2.2.1. Readers are
764 directed to EPA's *Draft Meta-Analysis and Benchmark Dose Modeling of Fetal Testicular Testosterone*
765 *for Di(2-ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), Butyl Benzyl Phthalate (BBP),*
766 *Diisobutyl Phthalate (DIBP), and Dicyclohexyl Phthalate (DCHP)* (U.S. EPA, 2024d) and *Non-Cancer*
767 *Human Health Hazard Assessment for Diisononyl Phthalate* (U.S. EPA, 2025p) for a more thorough
768 discussion of the methodology and results of EPA's updated analysis.

Table 2-1. Summary of Studies Included in EPA's Updated Meta-Analysis and BMD Modeling Analysis

Reference	Study Details					Phthalate					
	Strain/ Species	Exposure Route (Method)	Exposure Window	Measured Outcome (Timing of Measure)	TSCA Study Quality Rating	DEHP	DBP	DIBP	BBP	DCHP	DINP
(Martino-Andrade et al., 2008)	Wistar rat	Oral (gavage)	GD 13-21	Fetal testis testosterone content (GD 21)	Medium confidence	X ^a	X ^a				
(Furr et al., 2014)	SD rat	Oral (gavage)	GD 14-18	<i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) (GD 18)	High confidence	X ^a	X ^a		X ^a	X ^b	X ^b
(Howdeshell et al., 2008)	SD rat	Oral (gavage)	GD 8-18	<i>Ex vivo</i> fetal testicular testosterone production (2-hour incubation) (GD 18)	High confidence	X ^a	X ^a	X ^a	X ^a		
(Gray et al., 2021)	SD rat	Oral (gavage)	GD 14-18	<i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) (GD 18)	High (DEHP, DBP, BBP, DCHP) or Medium (DIBP) confidence	X ^b					
(Hannas et al., 2011)	SD rat	Oral (gavage)	GD 14-18	<i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) (GD 18)	Medium confidence	X ^a		X ^a			X ^a
	Wistar rat	Oral (gavage)	GD 14-18	<i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) (GD 18)	Medium confidence	X ^a					
(Kuhl et al., 2007)	SD rat	Oral (gavage)	GD 18	Fetal testis testosterone content (GD 19)	Low confidence		X ^a				
(Struve et al., 2009)	SD rat	Oral (gavage)	GD 12-19	Fetal testis testosterone content (GD 19; 4 or 24 hours post-exposure)	Medium confidence		X ^a				
(Johnson et al., 2011)	SD rat	Oral (gavage)	GD 12-20	Fetal testis testosterone content (GD 20)	Medium confidence		X ^a				

Reference	Study Details					Phthalate					
	Strain/ Species	Exposure Route (Method)	Exposure Window	Measured Outcome (Timing of Measure)	TSCA Study Quality Rating	DEHP	DBP	DIBP	BBP	DCHP	DINP
(Johnson et al., 2007)	SD rat	Oral (gavage)	GD 19	Fetal testis testosterone content (GD 19)	Medium confidence		X ^a				
(Lin et al., 2008)	Long- Evans rat	Oral (gavage)	GD 2-20	Fetal testis testosterone content (GD 21)	Medium confidence	X ^a					
(Culty et al., 2008)	SD rat	Oral (gavage)	GD 14-20	<i>Ex vivo</i> fetal testicular testosterone production (24-hour incubation) (GD 21)	Medium confidence	X ^a					
(Saillenfait et al., 2013)	SD rat	Oral (gavage)	GD 12-19	<i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) (GD 19)	High confidence	X ^a					
(Boberg et al., 2011)	Wistar rat	Oral (gavage)	GD 7-21	<i>Ex vivo</i> fetal testicular testosterone production (GD 21) & fetal testis testosterone content (GD 21)	Medium confidence						X ^a
(Gray et al., 2024)	SD rat	Oral (gavage)	GD 14-18	<i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) (GD 18)	Medium confidence						X ^b

^a Data included in NASEM ([2017](#)) analysis.

^b Cells highlighted in gray indicate data not included in the 2017 NASEM analysis. However, this data was included in EPA's updated analysis.

771
772
773
774
775
776
777
778
779
780
781
782

2.2.1 Results: Benchmark Dose Estimation

Table 2-2 summarizes BMD modeling results of fetal testicular testosterone for DEHP, DBP, DIBP, BBP, DCHP, and DINP from EPA’s updated meta-analysis using Metafor Version 4.6.0. Readers are directed to EPA’s *Draft Meta-Analysis and Benchmark Dose Modeling of Fetal Testicular Testosterone for Di(2-ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), Butyl Benzyl Phthalate (BBP), Diisobutyl Phthalate (DIBP), and Dicyclohexyl Phthalate (DCHP)* ([U.S. EPA, 2024d](#)) and *Non-Cancer Human Health Hazard Assessment for Diisononyl Phthalate* ([U.S. EPA, 2025p](#)) for more detailed reporting and discussion of results.

Table 2-2. BMD Modeling Results of Fetal Testicular Testosterone for DEHP, DBP, DIBP, BBP, DCHP, and DINP

Phthalate	Model Providing Best Fit ^a	BMD ₅ Estimates (mg/kg-day) [95% Confidence Interval]	BMD ₁₀ Estimates (mg/kg-day) [95% Confidence Interval]	BMD ₄₀ Estimates (mg/kg-day) [95% Confidence Interval]
DBP	Linear Quadratic	14 [9, 27]	29 [20, 54]	149 [101, 247]
DEHP	Linear Quadratic	17 [11, 31]	35 [24, 63]	178 [122, 284]
DIBP	Linear Quadratic	-- ^b	55 [NA, 266] ^b	279 [136, 517]
BBP	Linear Quadratic	-- ^b	-- ^b	284 [150, 481]
DCHP	Linear Quadratic	8.4 [6.0, 14]	17 [12, 29]	90 [63, 151]
DINP	Linear Quadratic	74 [47, 158]	152 [97, 278]	699 [539, 858]

^a Based on lowest Akaike information criterion (AIC) and visual inspection.
^b BMD and/or BMDL estimate could not be derived.

783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800

2.3 Selection of the Index Chemical and the Index Chemical Point of Departure

As described in EPA mixture and cumulative risk assessment guidance documents ([2023a](#), [2016](#), [2002a](#), [2000](#), [1986](#)), for the RPF approach to be applied one chemical must be selected as the index chemical. The index chemical is used as the point of reference for standardizing the common toxicity of the other chemicals being evaluated as part of the cumulative chemical group. Once the index chemical is selected, RPFs are calculated (*i.e.*, the ratio of the toxic potency of one chemical to that of the index chemical). RPFs are used to convert exposures of all chemicals in the cumulative chemical group into exposure equivalents of the index chemical. Given that the RPF method portrays risk as exposure in terms of index chemical equivalents, it is preferred that the index chemical: 1) have the highest quality toxicological database of chemicals in the cumulative chemical group; 2) have high quality dose-response data; 3) be considered the most representative of the type of toxicity caused by other chemicals in the cumulative chemical group; and 4) be well characterized for the proposed mode of action ([2023a](#), [2016](#), [2002a](#), [2000](#), [1986](#)).

Table 2-3 provides a high-level comparison of the number of studies available for each phthalate that examined each outcome considered for RPF derivation. Of the six phthalates included in the cumulative chemical group (*i.e.*, DEHP, DBP, BBP, DIBP, DCHP, and DINP), **EPA considered DEHP and DBP**

801 **as candidates for the index chemical** because both phthalates have high quality toxicological databases
802 demonstrating effects on the developing male reproductive system consistent with a disruption of
803 androgen action and phthalate syndrome, demonstrate toxicity representative of all phthalates in the
804 cumulative chemical group, and are well characterized for the MOA associated with phthalate
805 syndrome. Compared to DEHP and DBP, other phthalates included in the cumulative chemical group
806 (*i.e.*, BBP, DIBP, DCHP, DINP) have considerably smaller databases and fewer dose-response data
807 (Table 2-3), and were not considered candidates for the index chemical.

808
809
810 **Table 2-3. Comparison of the Number of Studies Supporting Key Outcomes Associated with**
811 **Phthalate Syndrome^a**

Key Outcome	# of Studies Per Phthalate by Species					
	DEHP	DBP	BBP	DIBP	DCHP	DINP
↓ Steroidogenic gene and <i>Ins13</i> expression in fetal testis	7 (all rat)	9 (rat [8]; mouse [1])	2 (all rat)	6 (rat [5]; mouse [1])	2 (all rat)	5 (all rat)
↓ Fetal testicular testosterone	15 (rat [13]; mouse [2])	17 (rat [16]; mouse [1])	5 (all rat)	6 (rat [5]; mouse [1])	3 (all rat)	9 (all rat)
↓ Anogenital distance (AGD)	19 (rat [16]; mouse [3])	18 (all rat)	5 (all rat)	4 (rat [3]; mouse [1])	5 (all rat)	6 (all rat)
↑ Nipple retention (NR)	12 (all rat)	8 (all rat)	2 (all rat)	1 (all rat)	2 (all rat)	3 (all rat)
↑ Hypospadias	10 (rat [9]; mouse [1])	11 (rat [9]; rabbit [1]; marmoset [1])	3 (all rat)	1 (all rat)	1 (all rat)	3 (all rat)
↑ Seminiferous tubule atrophy	3 (all rat)	8 (all rat)	3 (all rat)	1 (all rat)	2 (all rat)	5 (all rat)
↑ Multinucleated gonocytes (MNGs)	7 (all rat)	11 (rat [9]; mouse [1]; marmoset [1])	1 (all rat)	1 (all rat)	2 (all rat)	4 (all rat)

^a Data from Section 3.1.3.1 through Section 3.1.3.7 of EPA’s draft proposed approach for CRA of phthalates under TSCA ([U.S. EPA, 2023b](#)).

812
813
814 The toxicological databases for DEHP and DBP are characterized elsewhere in EPA’s draft non-cancer
815 human health hazard assessments of DEHP ([U.S. EPA, 2024h](#)) and DBP ([U.S. EPA, 2024f](#)), as well as
816 in the 2023 draft approach ([U.S. EPA, 2023b](#)), and are briefly summarized herein. Briefly, numerous
817 studies of experimental rodent models are available that demonstrate that gestational exposure to DEHP
818 and DBP during the critical window of development (*i.e.*, GD 15.5 to 18.5 in rats) can reduce
819 steroidogenic gene and *Ins13* mRNA expression in the fetal testis and reduced fetal testis testosterone
820 content and/or *ex vivo* fetal testis testosterone production. Consistent with a disruption of androgen
821 action, studies have demonstrated that DEHP and DBP can reduce male offspring anogenital distance,
822 increase nipple/areolae retention, and cause severe reproductive tract malformations such as hypospadias
823 and cryptorchidism, as well as cause numerous other effects consistent with phthalate syndrome (*e.g.*,
824 reduce weight of androgen sensitive tissues such as the prostate and testis; increase incidence of

825 testicular pathology such as seminiferous tubule atrophy; increase incidence of multinucleated
826 gonocytes; cause various sperm effects; and decrease male fertility).

827
828 Because RPFs are being derived using fetal testicular testosterone data, EPA next compared the quantity
829 and quality of available dose-response data for this outcome for DBP and DEHP. As can be seen from
830 Table 2-1, EPA included fetal testicular testosterone data from 8 studies of DBP and 8 studies of DEHP
831 in its updated meta-analysis and BMD analysis. As can be seen from Table_Apx A-1, most of the
832 available fetal testicular testosterone data for DEHP are from studies of rats dosed with 100 mg/kg-day
833 DEHP or higher. One study of DEHP provides testosterone data at a dose of 50 mg/kg-day ([Saillenfait et
834 al., 2013](#)), while one other study of DEHP provides testosterone data at a dose of 10 mg/kg-day ([Lin et
835 al., 2008](#)). Comparatively, more dose-response data is available for the low-end range of the dose-
836 response curve for DBP. As can be seen from Table_Apx A-2, this includes two studies of DBP that
837 provide testosterone data at 1 mg/kg-day DBP ([Furr et al., 2014](#); [Johnson et al., 2007](#)), two studies that
838 provide testosterone data at 10 mg/kg-day DBP ([Furr et al., 2014](#); [Johnson et al., 2007](#)), two studies that
839 provide testosterone data at 33 mg/kg-day DBP ([Furr et al., 2014](#); [Howdeshell et al., 2008](#)), and two
840 studies that provide testosterone data at 50 mg/kg-day DBP ([Furr et al., 2014](#); [Howdeshell et al., 2008](#)).

841
842 As can be seen from Table 2-2, the BMD₅/BMDL₅ estimates for DEHP and DBP based on decreased
843 fetal testicular testosterone are 17/11 mg/kg-day and 14/9 mg/kg-day, respectively, while the
844 BMD₁₀/BMDL₁₀ estimates for DEHP and DBP are 35/24 mg/kg-day and 29/20 mg/kg-day, respectively
845 (Table 2-2).

846
847 Overall, DBP has more dose-response data than DEHP in the low-end range of the dose-response curve
848 where the BMD and BMDL estimates at the 5 and 10 percent response level are derived. **Therefore,**
849 **EPA has preliminarily selected DBP as the index chemical.**

850
851 As with any risk assessment that relies on BMD analysis, the point of departure (POD) is the lower
852 confidence limit used to mark the beginning of extrapolation to determine risk associated with human
853 exposures. For the index chemical, DBP, EPA calculated BMDL₅, BMDL₁₀ and BMDL₄₀ values of 9,
854 20, and 101 mg/kg-day for reduced fetal testicular testosterone (Table 2-2). EPA selected the 95 percent
855 lower confidence limit for the BMD₅ (*i.e.*, 14 mg/kg-day), the BMDL₅ (*i.e.*, 9 mg/kg-day DBP). EPA
856 selected the BMDL₅ as the POD because as discussed further in Appendix B, EPA does not consider
857 BMRs of 10 or 40 percent health protective for all phthalates included in the cumulative chemical group.
858 Using allometric body weight scaling to the three-quarters power ([U.S. EPA, 2011b](#)), **EPA**
859 **extrapolated an HED of 2.1 mg/kg-day from the BMDL₅ of 9 mg/kg-day to use as the index**
860 **chemical POD for the draft CRA of phthalates.**

861

862 **2.4 Relative Potency Factors for the Cumulative Phthalate Assessment** 863 **Based on Decreased Fetal Testicular Testosterone**

864 As described in EPA mixture and cumulative risk assessment guidance documents ([2023a](#), [2016](#), [2002a](#),
865 [2000](#), [1986](#)), RPFs are calculated using Equation 2-1 by taking the ratio of the toxic potency of one
866 chemical to that of the index chemical. As described in Section 2.3, EPA has preliminarily selected DBP
867 as the index chemical and is using BMD₅, BMD₁₀, and BMD₄₀ estimates from the best-fitting linear
868 quadratic model derived using Metafor Version 4.6.0 (Table 2-2) to calculate RPFs based on decreased
869 fetal testicular testosterone.

870

871 Table 2-4 shows calculated RPFs using BMD₅, BMD₁₀, and BMD₄₀ estimates. As can be seen from
872 Table 2-4, RPFs calculated using BMD₅, BMD₁₀, and BMD₄₀ estimates for DEHP, DCHP, and DINP
873 were nearly identical for each phthalate. RPFs ranged from 0.82 to 0.84 for DEHP, 1.66 to 1.71 for
874 DCHP, and 0.19 to 0.21 for DINP. For DIBP, an RPF of 0.53 was calculated using both BMD₁₀ and
875 BMD₄₀ estimates; however, no RPF could be calculated using a BMD₅ because a BMD could not be
876 estimated for DIBP at the 5 percent response level. For BBP, an RPF of 0.52 was calculated using the
877 BMD₄₀ estimate. RPFs could not be estimated for BBP at the 5 or 10 percent response levels because
878 BMD₅ and BMD₁₀ values could not be estimated for BBP.
879

880 As discussed by the National Resource Council in 2008 ([NRC, 2008](#)), there may be challenges
881 associated with the RPF approach because phthalates may have differing shape and slope dose-response
882 curves leading to variability in RPFs across different BMRs. This concern was echoed by the SACC
883 during their peer-review of EPA’s *Draft Proposed Approach for Cumulative Risk Assessment (CRA) of*
884 *High-Priority Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control*
885 *Act* ([U.S. EPA, 2023c](#)). However, EPA’s current analysis demonstrates that for reduced fetal testicular
886 testosterone, RPFs do not vary across a range of BMRs (*i.e.*, BMRs of 5, 10, and 40%), which provides
887 confidence in the overall approach.
888

889 **For input into the draft CRA of phthalates under TSCA, EPA is using RPFs calculated using**
890 **BMD₄₀ estimates shown in Table 2-4.** There is some uncertainty in the applicability of the selected
891 RPFs for DIBP and BBP at the low response levels (*i.e.*, 5% to 10% changes), since RPFs could not be
892 estimated for BBP at the 5 or 10 percent response levels or for DIBP at the 5 percent response level.
893 However, the lack of variability in calculated RPFs for DEHP, DCHP, and DINP across response levels,
894 and the fact that the RPF for DIBP was identical at the 10 and 40 percent response levels, increases
895 EPA’s confidence in the selected RPFs for BBP and DIBP.
896
897

898 **Table 2-4. Comparison of Candidate Relative Potency Factors Based on BMD₅, BMD₁₀, and**
899 **BMD₄₀ Estimates**

Phthalate	RPF (Based on BMD ₅)	RPF (Based on BMD ₁₀)	RPF (Based on BMD ₄₀) (Selected RPFs)
DBP (Index Chemical)	1	1	1
DEHP	0.82	0.83	0.84
DIBP	-- ^a	0.53	0.53
BBP	-- ^a	-- ^a	0.52
DCHP	1.67	1.71	1.66
DINP	0.19	0.19	0.21

^aRPF could not be estimated because BMD₅ or BMD₁₀ could not be estimated.

900 **2.5 Uncertainty Factors and the Benchmark Margin of Exposure**

901 Consistent with Agency guidance ([U.S. EPA, 2022, 2002b](#)), EPA selected an intraspecies uncertainty
902 factor (UF_H) of 10, which accounts for variation in susceptibility across the human population and the

903 possibility that the available data might not be representative of individuals who are most susceptible to
904 the effect.

905
906 As described in Section 2.3, EPA used allometric body weight scaling to the three-quarters power to
907 derive an HED of 2.1 mg/kg-day DBP from the BMDL₅ of 9 mg/kg-day for reduced fetal testicular
908 testosterone, which accounts for species differences in toxicokinetics. Consistent with EPA Guidance
909 ([U.S. EPA, 2011b](#)), the interspecies uncertainty factor (UF_A), was reduced from 10 to 3 to account for
910 remaining uncertainty associated with interspecies differences in toxicodynamics.

911
912 EPA considered reducing the UF_A further to a value of 1 based on apparent differences in
913 toxicodynamics between rats and humans. As discussed in Section 3.1.4 of the 2023 draft approach
914 ([U.S. EPA, 2023b](#)), several explant ([Lambrot et al., 2009](#); [Hallmark et al., 2007](#)) and xenograft studies
915 ([van Den Driesche et al., 2015](#); [Spade et al., 2014](#); [Heger et al., 2012](#); [Mitchell et al., 2012](#)) using human
916 donor fetal testis tissue have been conducted to investigate the antiandrogenicity of mono-2-ethylhexyl
917 phthalate (MEHP; a monoester metabolite of DEHP), DBP, and monobutyl phthalate (MBP; a
918 monoester metabolite of DBP) in a human model. Generally, results from human explant and xenograft
919 studies suggest that human fetal testes are less sensitive to the antiandrogenic effects of phthalates,
920 although effects on Sertoli cells and increased MNGs have been observed in available studies of donor
921 fetal testis tissue. As discussed in EPA's 2023 draft approach ([U.S. EPA, 2023b](#)), the available human
922 explant and xenograft studies have limitations and uncertainties, which preclude definitive conclusions
923 related to species differences in sensitivity. For example, key limitations and uncertainties of the human
924 explant and xenograft studies include: small sample size; human testis tissue was collected from donors
925 of variable age and by variable non-standardized methods; and most of the testis tissue was taken from
926 fetuses older than 14 weeks, which is outside of the critical window of development (*i.e.*, gestational
927 weeks 8 to 14 in humans). Therefore, EPA did not reduce the UF_A from a value of 3 to 1.

928
929 **Overall, a total uncertainty factor of 30 was selected for use as the benchmark margin of exposure**
930 **for the cumulative risk analysis (based on an interspecies uncertainty factor [UF_A] of 3 and an**
931 **intraspecies uncertainty factor [UF_H] of 10).**

932

933 **2.6 Applicability of Derived Relative Potency Factors (RPFs)**

934 *Exposure Route*

935 EPA derived RPFs using data from gestational exposure studies in which pregnant rats were orally
936 dosed with DEHP, DBP, BBP, DIBP, DCHP, or DINP. Because RPFs were derived from oral exposure
937 studies, they are most directly applicable for the oral exposure route. As described in the non-cancer
938 human health hazard assessment for DINP ([U.S. EPA, 2025p](#)) and draft non-cancer human health hazard
939 assessments for DEHP ([U.S. EPA, 2024h](#)), DBP ([U.S. EPA, 2024f](#)), BBP ([U.S. EPA, 2024e](#)), DIBP
940 ([U.S. EPA, 2024i](#)), and DCHP ([U.S. EPA, 2024g](#)), there are no dermal or inhalation exposure studies
941 available that have evaluated fetal testicular testosterone in rats following gestational exposure during
942 the critical window of development. Therefore, EPA could not derive route-specific RPFs. For the draft
943 phthalate CRA, EPA is using the oral RPFs to scale inhalation and dermal phthalate exposures. This
944 requires an inherent assumption of similar potency across exposure routes, which is a source of
945 uncertainty. However, EPA cannot predict whether use of oral RPFs for the inhalation and dermal
946 exposure routes will lead to an under- or overestimation of risk.

947

948

949

950 *Population*

951 Because the draft RPFs are based on reduced fetal testicular testosterone, EPA considers the draft RPFs
952 most directly applicable to pregnant women, women of reproductive age, and male infants. Use of the
953 draft RPFs for other lifestages (e.g., adult males) may be conservative.

954 **2.7 Weight of Scientific Evidence: Relative Potency Factors and Index**
955 **Chemical Point of Departure**

956 EPA has preliminary selected an HED of 2.1 mg/kg-day (BMDL₅ of 9 mg/kg-day) as the index chemical
957 (i.e., DBP) POD. This POD is based on a meta-analysis and BMD modeling of decreased fetal testicular
958 testosterone from eight studies of rats exposed to DBP during gestation. EPA has also derived draft
959 RPFs of 1 for DBP (index chemical), 0.84 for DEHP, 0.53 for DIBP, 0.52 for BBP, 1.66 for DCHP, and
960 0.21 for DINP, respectively, based on a uniform measure (i.e., reduced fetal testicular testosterone).
961 Overall, EPA has **robust overall confidence in the proposed index chemical (DBP) POD and the**
962 **draft RPFs** based on the following weight of the scientific evidence considerations:

- 963
- 964 • EPA has previously considered the weight of scientific evidence and concluded that oral
965 exposure to DEHP, DBP, BBP, DIBP, DCHP, and DINP can induce effects on the developing
966 male reproductive system consistent with a disruption of androgen action (see EPA's 2023 draft
967 approach ([U.S. EPA, 2023b](#))). Notably, EPA's conclusion was supported by the SACC ([U.S.
EPA, 2023c](#)).
 - 968 • EPA selected DBP as the index chemical because it has a high quality toxicological database
969 demonstrating effects on the developing male reproductive system consistent with a disruption of
970 androgen action and phthalate syndrome; demonstrates toxicity representative of all phthalates in
971 the cumulative chemical group; is well characterized for the MOA associated with phthalate
972 syndrome; and has the most fetal testicular testosterone dose-response data in the low-end range
973 of the dose-response curve where the BMD and BMDL estimates at the 5 and 10 percent
974 response level are derived.
 - 975 • As discussed in the *Draft Non-cancer Human Health Hazard Assessment for Dibutyl Phthalate*
976 (*DBP*) ([U.S. EPA, 2024f](#)), EPA has also preliminarily selected the HED of 2.1 mg/kg-day
977 (BMDL₅ of 9 mg/kg-day) for calculation of risk from exposures to DBP in the individual
978 chemical risk evaluation. EPA has robust overall confidence in the proposed POD selected for
979 DBP. Overall, the same weight of evidence considerations apply to the POD selected for the
980 individual DBP risk evaluation and the draft CRA. Readers are directed to the *Draft Non-cancer*
981 *Human Health Hazard Assessment for Dibutyl Phthalate (DBP)* ([U.S. EPA, 2024f](#)) for a
982 complete discussion of the weight of evidence supporting the selected POD.
 - 983 • In the MOA for phthalate syndrome, which has been described by EPA elsewhere ([U.S. EPA,](#)
984 [2023b](#)), decreased fetal testicular testosterone is an early, upstream event in the MOA that
985 precedes downstream apical outcomes such as male nipple retention, decreased anogenital
986 distance, and male reproductive tract malformations (e.g., hypospadias and cryptorchidism).
987 Decreased fetal testicular testosterone should occur at doses that are lower than or equal to doses
988 that cause downstream apical outcomes associated with a disruption of androgen action.
 - 989 • EPA derived draft RPFs using a meta-analysis and BMD modeling approach, which integrates
990 fetal testicular testosterone data from 14 medium- and high-quality studies for DEHP, DBP,
991 BBP, DIBP, DCHP, and DINP (Table 2-1). Notably, the statistical significance of the meta-
992 analysis results were robust to leaving out individual studies as part of a sensitivity analysis (see
993 updated meta-analysis technical support document ([U.S. EPA, 2024d](#))).

- EPA derived candidate RPFs using BMD₅, BMD₁₀, and BMD₄₀ estimates (Table 2-2) to allow for a comparison of RPFs at the three evaluated BMR levels of 5, 10, and 40 percent. RPFs calculated using BMD₅, BMD₁₀, and BMD₄₀ estimates for DEHP, DCHP, and DINP were nearly identical for each phthalate (Table 2-4). RPFs ranged from 0.82 to 0.84 for DEHP, 1.66 to 1.71 for DCHP, and 0.19 to 0.21 for DINP. For DIBP, an RPF of 0.53 was calculated using both BMD₁₀ and BMD₄₀ estimates; however, no RPF could be calculated using a BMD₅ because a BMD could not be estimated for DIBP at the 5 percent response level. For BBP, an RPF of 0.52 was calculated using the BMD₄₀ estimate. RPFs could not be estimated for BBP at the 5 or 10 percent response levels because BMD₅ and BMD₁₀ values could not be estimated for BBP. There is some uncertainty in the applicability of the selected RPFs based on BMD₄₀ estimates for DIBP and BBP at the low response levels (*i.e.*, 5% to 10% changes), since RPFs could not be estimated for BBP at the 5 or 10 percent response levels or for DIBP at the 5 percent response level. However, the lack of variability in calculated RPFs for DEHP, DCHP, and DINP across response levels, and the fact that the RPF for DIBP was identical at the 10 and 40 percent response levels, increases EPA's confidence in the selected RPFs for BBP and DIBP.

3 SCENARIO-BASED PHTHALATE EXPOSURE AND RISK

This section provides a qualitative analysis of co-exposures expected for workers (Section 3.1), consumers (Section 3.2), and general population (Section 3.3) exposed to environmental releases for each individual phthalate under their COUs. However, as discussed further in this section, EPA did not quantify cumulative phthalate exposures for these populations resulting from multiple COUs. Per TSCA, each evaluation must assess risks to human health and the environment under the chemical substance's COUs and determine whether the chemical substance presents unreasonable risk.²

3.1 Occupational Exposure for Workers

Occupational exposures to a combination of phthalates may occur in a variety of industrial and commercial settings. For instance, businesses may manufacture, import, process, or dispose of multiple phthalates within the same facility, which may lead to worker exposure to multiple phthalates. Also, some products used by workers may contain more than one phthalate, or workers may use multiple phthalate-containing products throughout a workday. Due to the workplace and task-specific nature of cumulative exposure scenarios that may exist in phthalate-containing workplaces, it was not possible to provide a full quantitative assessment of cumulative risk for workers who may be exposed to multiple phthalates. However, EPA was able to characterize the various businesses that use multiple phthalates and the products that contain multiple phthalates, and has developed one option for deriving an occupational exposure value (OEV) based on relative potency considerations. In addition to individual chemical OEVs, this cumulative option is intended to summarize the occupational exposure scenario and sensitive health endpoint into a single value. Similar to the individual OEVs, the calculated draft cumulative OEV may be used to support risk management efforts for these evaluated phthalates under TSCA section 6(a), 15 U.S.C. 6155 §2605.

This section provides an overview of the industrial and commercial products identified by EPA that contain multiple phthalates (Section 3.1.1), and the parent companies that report use of multiple phthalates and facilities that report release of multiple phthalates (Section 3.1.2). Section 3.1.3 provides a summary of EPA's preliminary conclusions, while Appendix E summarizes one option being considered by EPA for deriving an OEV based on relative potency considerations.

3.1.1 Industrial and Commercial Products Containing Multiple Phthalates

One way workers may be occupationally exposed to multiple phthalates being evaluated under TSCA (*i.e.*, DEHP, DBP, BBP, DIBP, DCHP, DINP) is through use of an industrial or commercial product that contains multiple phthalates. To assess the potential for co-exposure to multiple phthalates through the use of industrial and commercial products containing multiple phthalates, EPA reviewed product safety data sheets (SDSs) for products included in the occupational exposure assessments for DEHP ([U.S. EPA, 2025l](#)), DBP ([U.S. EPA, 2025k](#)), BBP ([U.S. EPA, 2025j](#)), DIBP ([U.S. EPA, 2025m](#)), DCHP ([U.S. EPA, 2024c](#)), and DINP ([U.S. EPA, 2025o](#)).

Overall, only 15 industrial and commercial products were identified that contained multiple phthalates (Table_Apx D-2). The majority of products identified that contain multiple phthalates are laboratory chemicals (13 out of 15 identified products with multiple phthalates are laboratory chemicals), with the exception of one clay polymer product and one adhesive. Further, the laboratory chemical formulations shown in Table_Apx D-2 have low phthalate concentrations (generally less than 1% by weight fraction).

² Conditions of use (COUs) are defined as "the circumstances, as determined by the Administrator, under which a chemical substance is intended, known, or reasonably foreseen to be manufactured, processed, distributed in commerce, used, or disposed of." (15 U.S.C. 2602(4))

1051 The clay polymer product also has low phthalate concentrations (less than 2.5% by weight fraction) and
1052 solid physical form, and the material is commonly used in fashioning commercial pens, while the
1053 adhesive product also has low concentrations of two phthalates (*i.e.*, 1–5% DBP and 1–5% DCHP).
1054

1055 Given the small number of industrial and commercial products identified that contain multiple
1056 phthalates and given the low concentrations of phthalates in the identified products (Table_Apx D-2),
1057 **EPA does not expect these products to be a significant source of phthalate exposures contributing**
1058 **to cumulative risk under most occupational and commercial exposure scenarios.**

1059 **3.1.2 Multiple TSCA Phthalates at a Single Facility and/or Single Condition of Use**

1060 EPA acknowledges that there is potential for workers to be exposed to multiple phthalates being
1061 evaluated under TSCA at a single facility. This may occur if a single facility works with multiple
1062 phthalates. To provide an overview of potential phthalate co-exposures that may occur in the workplace,
1063 EPA relied on programmatic data from the Chemical Data Reporting (CDR) rule, Toxics Release
1064 Inventory (TRI), Discharge Monitoring Report (DMR), and the National Emissions Inventory (NEI).
1065 These databases provide manufacture, processing, and release data reported by businesses across the
1066 U.S.

1067 **3.1.2.1 Parent Companies Reporting Use of Multiple Phthalates**

1068 To better understand the landscape of parent companies that work with multiple phthalates, EPA first
1069 reviewed 2016 and 2020 CDR data and 2017 through 2022 TRI data to identify parent companies that
1070 report use of multiple phthalates. One limitation of this initial analysis is that only DEHP and DBP are
1071 reportable under TRI (DINP is reportable to TRI as of January 2024). Data from CDR provides
1072 manufacture and processing information from parent companies, including overall production volume
1073 and number of facilities, and all phthalates considered in this cumulative assessment are reported to
1074 CDR.
1075

1076 Table_Apx D-3 characterizes the various parent companies from CDR and TRI that report use of
1077 multiple phthalates. As can be seen from Table_Apx D-3, EPA identified 56 domestic parent companies
1078 that report use of multiple phthalates being evaluated under TSCA. Though these data provide a broad
1079 overview of the various businesses involved in the phthalate industry, the CDR data provide information
1080 about the parent company only and are not granular enough to determine if multiple phthalates are being
1081 processed within a singular facility. Therefore, there is uncertainty associated with assigning co-
1082 exposures based on parent company reporting data from CDR.

1083 **3.1.2.2 Facilities Reporting Releases of Multiple Phthalates**

1084 Data from TRI, DMR, and NEI provide release information for businesses that meet reporting
1085 thresholds. TRI provides data for releases to air, water, and land, while DMR provides data for releases
1086 to water, and NEI provides data for releases to air. However, since release reporting for some phthalates
1087 is not currently required by programmatic reporting standards (*i.e.*, for DIBP, DINP, and DCHP), TRI
1088 and NEI data are limited to businesses that release DEHP and DBP, while DMR data are limited to
1089 businesses that release DEHP, DBP, and BBP. Identified facilities from TRI (2017 to 2022), DMR
1090 (2017 to 2023), and NEI (2017 and 2020) that reported use of multiple phthalates considered in this
1091 cumulative assessment are provided in the *Draft Summary of Facility Release Data for Di(2-ethylhexyl)*
1092 *Phthalate (DEHP), Dibutyl Phthalate (DBP), and Butyl Benzyl Phthalate (BBP)* ([U.S. EPA, 2024p](#)).
1093

1094 Overall, EPA identified 1,922 unique facilities that report releases of DEHP, DBP, or BBP to TRI,
1095 DMR, and NEI ([U.S. EPA, 2024p](#)). Of the identified facilities, 1,461 report environmental releases of a

1096 single phthalate, including 973, 483, and 5 facilities that report releases of DEHP, DBP, and BBP,
1097 respectively. Overall, 461 facilities were identified that reported releases of multiple phthalates,
1098 including the following combinations:

- 1099 • 419 facilities report releases of DBP and DEHP;
- 1100 • 15 facilities report releases of DEHP and BBP;
- 1101 • 4 facilities report releases of DBP and BBP; and
- 1102 • 23 facilities report releases of DBP, DEHP, and BBP.

1103 **This analysis indicates that there are approximately 461 facilities where workers may become co-**
1104 **exposed to multiple phthalates while working.** It is important to note that TRI, DMR, and NEI often
1105 provide information from the release facility rather than the parent company, and this reduces
1106 uncertainty when assigning potential co-exposure for a particular chemical in a facility.

1107
1108 There are some limitations and uncertainties associated with the current analysis. First, it is important to
1109 re-iterate that because DIBP, DINP, and DCHP are not reportable to TRI, DMR, or NEI, specific
1110 facilities working with these phthalates were not identified by EPA and therefore the number of facilities
1111 identified by EPA as working with one or multiple phthalates is an underestimate. Another uncertainty
1112 with the current analysis is that facilities that work with multiple phthalates may run campaigns in which
1113 each phthalate is only used for part of the year. Further, these campaigns may not overlap and therefore
1114 workers may not actually be co-exposed to multiple phthalates at all of the facilities identified by EPA.
1115 For example, Exxon runs continuous half-year operations dedicated to the manufacture of DINP and
1116 DIDP, which are staggered campaigns ([ExxonMobil, 2022](#)). This makes it difficult to determine if
1117 workers are actually co-exposed to multiple phthalates in the workplace, without conducting a facility-
1118 by-facility analysis, which is outside the scope of this cumulative assessment.

1119 **3.1.2.3 Overlap in Industrial and Commercial COUs**

1120 EPA acknowledges that there is overlap in industrial and commercial COUs, and that overlap in COUs
1121 may lead to worker co-exposure to multiple phthalates at facilities where multiple phthalates are
1122 handled. As part of the 2023 draft proposal ([U.S. EPA, 2023b](#)), COU tables from final scope documents
1123 were compared for DEHP, DBP, BBP, DCHP, DIBP, and DINP, demonstrating COU overlap
1124 (Table_Apx D-4).

1125
1126 As part of its cumulative approach, EPA considered combining phthalate exposures for COUs with
1127 overlap for multiple phthalates. For example, exposures for phthalates with the industrial use of
1128 adhesives and sealants COU could be combined to estimate occupational cumulative exposure and risk.
1129 However, this approach would require several assumptions that would likely lead to unrealistic
1130 cumulative exposure estimates that are not reflective of the complexity and wide range of cumulative
1131 exposure scenarios that may exist in phthalate-containing workplaces. For example, this approach would
1132 require the assumption that most facilities with industrial use of adhesives and sealants are working with
1133 multiple phthalates and that these facilities are working with multiple phthalates concurrently and not
1134 running staggered campaigns with each individual phthalate. As discussed in Section 3.1.2.2, not all
1135 facilities work with multiple phthalates. In fact, the majority of facilities may work with only one
1136 phthalate (*e.g.*, 1,461 of the 1,922 facilities identified in Section 3.1.2.2 report use of a single phthalate).

1137
1138 Given the complexity and wide range of cumulative exposure scenarios that may exist in phthalate-
1139 containing workplaces, EPA considers there to be too much uncertainty associated with combining
1140 phthalate exposures across COUs that apply to multiple phthalates.

1141 **3.1.3 Conclusions on Cumulative Occupational Phthalate Exposure**

1142 As discussed above in Sections 3.1.1 and 3.1.2, workers may be occupationally exposed to multiple
1143 phthalates through use of an industrial or commercial product containing multiple phthalates or through
1144 working at a facility that handles multiple phthalates. However, EPA identified a limited number of
1145 industrial and commercial products that contained multiple phthalates, and the products that were
1146 identified contained low concentrations of phthalates (Section 3.1.1). This indicates that industrial and
1147 commercial products containing multiple phthalates are not anticipated to be a major source of
1148 cumulative phthalate exposure for most workers.

1149
1150 As discussed in Section 3.1.2, EPA identified approximately 461 facilities that report working with
1151 multiple phthalates. However, these facilities report working with varying combinations of phthalates
1152 (e.g., DEHP and DBP, DEHP and BBP, DBP and BBP, or DEHP, DBP, and BBP), and may run
1153 campaigns in which each phthalate is only used for part of the year. These campaigns may not overlap
1154 and therefore there is uncertainty as to whether workers are actually co-exposed to multiple phthalates at
1155 all of the facilities identified by EPA. For example, Exxon runs continuous half-year operations
1156 dedicated to the manufacture of DINP and DIDP, which are staggered campaigns ([ExxonMobil, 2022](#)).

1157
1158 Due to the wide range of cumulative exposure scenarios that may exist in phthalate-containing
1159 workplaces, it was not possible to provide a robust quantitative assessment of cumulative risk for
1160 workers who may be exposed to multiple phthalates. Instead, EPA has developed an option for deriving
1161 an OEV that accounts for cumulative exposure and differences in relative potency based on air
1162 monitoring methods (Appendix E.1).

1163 **3.2 Consumer and Indoor Dust Exposure**

1164 Consumers may become co-exposed to multiple TSCA phthalates through a variety of potential
1165 exposure scenarios. Relevant consumer exposure scenarios that may lead to co-exposure to multiple
1166 TSCA phthalates include:

- 1167 • Consumer use of a product that contains multiple phthalates, thus the consumer is directly
1168 exposed simultaneously;
- 1169 • Consumer use of multiple products and/or articles with multiple phthalates in a relevant time
1170 frame (e.g., same day); or
- 1171 • Products and/or articles containing multiple phthalates contaminate indoor dust which is then
1172 inhaled or ingested.

1173 This section provides a qualitative overview of consumer use scenarios could plausibly lead to co-
1174 exposure to multiple phthalates (Sections 3.2.1 and 3.2.2) and a quantitative assessment of cumulative
1175 exposure to indoor dust using available monitoring data (Section 3.2.3).

1176 **3.2.1 Consumer Products Containing Multiple Phthalates.**

1177 Most products previously identified by EPA only contain a single phthalate (See Table_Apx F-1 from
1178 2023 CRA proposal ([U.S. EPA, 2023b](#))). EPA identified a product (PSI PolyClay Canes and PSI
1179 PolyClay Bricks) that contains multiple phthalates (DEHP, BBP, DBP, and DINP), with each phthalate
1180 below 2.5 percent. EPA compared the source and manufacturer information for the consumer products
1181 and articles included in the consumer exposure assessments for DEHP ([U.S. EPA, 2025e](#)), DBP ([U.S.
1182 EPA, 2025c](#)), BBP ([U.S. EPA, 2025b](#)), DIBP ([U.S. EPA, 2025d](#)), DCHP ([U.S. EPA, 2024a](#)), and DINP
1183 ([U.S. EPA, 2025a](#)). This comparison identified one additional trade name, 3M™ Economy Vinyl
1184 Electrical Tape 1400, 1400C, as containing DEHP and DINP. A few other generic product and article

1185 categories contained multiple phthalates (e.g., Car Mats (BBP, DBP, DEHP, DIBP, DINP); synthetic
1186 leather (DBP, DEHP, DIBP, DINP); adult toy (BBP, DBP, DEHP, DINP); garden hose and cutting
1187 board (DBP, DEHP, DIBP, DINP); footwear (BBP, DBP, DIBP); shower curtain, children toys
1188 compliant, football, wallpaper (DBP, DEHP, DIBP); children’s toys (BBP, DBP, DINP); packaging
1189 (BBP, DBP, DEHP); work gloves, pet chew toys, 3M electrical vinyl tape (DEHP, DINP)); however,
1190 EPA is unable to confirm whether multiple phthalates are used concurrently in each of these items, or if
1191 the phthalates are used interchangeably.

1192 **3.2.2 Consumer Use of Multiple Products and/or Articles in a Relevant Time Frame**

1193 Co-exposures to multiple phthalates across products and/or articles are dependent on evidence of co-use
1194 and/or co-location. In the context of TSCA, co-uses typically refer to scenarios from which an individual
1195 (e.g., consumer) may be exposed to two or more COUs such as when a spray and powdered cleaner are
1196 used concurrently to clean a bathtub. Due to the numerous consumer products and articles found in the
1197 domestic environment that contain phthalates, it is likely that a consumer may be simultaneously
1198 exposed to phthalates from two or more different consumer products or articles. However, for co-
1199 exposure to occur, exposure would need to occur in a narrow timeframe (i.e., same day) due to the fast
1200 elimination kinetics of phthalates.

1201
1202 As described in EPA’s 2023 draft approach ([U.S. EPA, 2023b](#)), there is limited information on the co-
1203 use and/or co-location of consumer products to serve as evidence for co-exposure to different chemicals
1204 present in multiple consumer products. Some studies have investigated co-use patterns for personal care
1205 products ([Safford et al., 2015](#); [Biesterbos et al., 2013](#)). Thus far, only one co-use study by Han et al. has
1206 been identified, which considered multiple TSCA-relevant consumer products in its analysis, including
1207 laundry detergents, fabric softeners, air fresheners, dishwashing detergents, and all-purpose cleaners.
1208 However, the authors found no strong correlation of co-use between any pair of household and personal
1209 care products ([Han et al., 2020](#)).

1210
1211 Another approach to determine co-use of products has been to use purchase data or presence of certain
1212 consumer products in the home to extrapolate combined exposure and risk ([Stanfield et al., 2021](#);
1213 [Tornero-Velez et al., 2021](#)). However, the presence of consumer products in the home is insufficient to
1214 conclude resultant daily exposure for consumers. This further emphasizes the importance of co-use data
1215 that help to describe consumer use patterns (e.g., which combinations of products are used, how often,
1216 how much, etc.) for products currently on the market. Currently, available co-use studies indicate that
1217 there is lack of evidence of co-use specifically for the TSCA COUs shown in Table_Apx D-4. This may
1218 in part be because many of the TSCA COUs associated with the phthalates are not necessarily common
1219 household products regularly studied for concurrent use.

1220
1221 At this time, EPA did not estimate co-exposure of phthalates from multiple consumer products and
1222 articles, as there is limited quantitative information on the co-occurrence of exposures to phthalate-
1223 containing consumer products and articles within the same day.

1224 **3.2.3 Quantitative Cumulative Risk from Exposure to Indoor Dust**

1225 As emphasized by the SACC in their review of the draft 2023 approach document, indoor dust is a key
1226 pathway for phthalate exposure and represents a sink for mixtures of phthalates from multiple sources,
1227 summarized succinctly from their report as follows ([U.S. EPA, 2023c](#)):

1228 *“Dust is a very relevant exposure pathway that may vary by community and can reflect*
1229 *many sources – for example outdoor dust and soil can be tracked inside, take home*

1230 *occupation exposures, building materials, furniture and products in the home can all*
1231 *contribute to household dust levels and human exposures to mixtures with phthalates.*
1232 *Household dust exposures will also vary by age, as younger children have faster*
1233 *metabolisms, greater relative surface area, more exposure to the floor, and increased*
1234 *hand to mouth behavior, making them likely to ingest more.”*

1235 To estimate cumulative risk from phthalate exposure from indoor dust, EPA relied on monitoring data of
1236 settled dust for six phthalates (*i.e.*, BBP, DBP, DCHP, DEHP, DIBP and DINP). Using the monitoring
1237 studies on settled dust gathered via systematic review, EPA estimated average daily doses for:

- 1238 • Geometric mean dust ingestion and mean phthalate concentration;
- 1239 • Geometric mean dust ingestion and 95th percentile phthalate concentration;
- 1240 • High end dust ingestion and mean phthalate concentration; and
- 1241 • High end dust ingestion and 95th percentile phthalate concentration.

1242 Settled dust monitoring concentrations were estimated from various monitoring studies across the US
1243 (Table 3-1) ([Hammel et al., 2019](#); [Bi et al., 2018](#); [Bi et al., 2015](#); [Dodson et al., 2015](#); [Shin et al., 2014](#);
1244 [Guo and Kannan, 2011](#); [Wilson et al., 2003](#); [Rudel et al., 2001](#); [Wilson et al., 2001](#)). These studies were
1245 selected as they contained original settled dust data, were conducted in the U.S., and reported high
1246 quality sampling and analytical methods and measured dust in homes, offices, or other indoor
1247 environments representative of the U.S. general population. Studies with unclear sampling descriptions
1248 (*e.g.*, unclear number of samples collected, unclear whether suspended dust or settled dust), were
1249 excluded from the analysis.

1250
1251 Using monitoring studies listed in Table 3-1, EPA calculated cumulative risk for various age groups (0–
1252 1 month, 1–3 months, 3–6 months, 6–12 months, 1–2 years, 2–3 years, 3–6 years, 6–11 years, 11–16
1253 years, 16–21 years, 21–30 years, 30–40 years, 40–50 years, 50–60 years, 60–70 years and over 80 years)
1254 using the RPF approach described above in Section 1.1.

1255
1256 Table 3-2 provides the cumulative phthalate intake estimate for ages 3 to 6 years, and 16 to 50 years
1257 from the indoor dust monitoring data. When comparing these dust intake estimates to cumulative risk
1258 estimates for NHANES in Table 4-3, the percent contribution of NHANES to the risk cup is always
1259 greater than ingestion of settled dust. This is anticipated as NHANES urinary biomonitoring provides an
1260 estimate of aggregate exposure (*i.e.*, exposure via all routes and pathways, including dust ingestion) to
1261 each phthalate rather than just through ingestion of phthalates in settled dust.

1262 **Table 3-1. Confidence in Phthalate Settled Dust Monitoring Studies**

Phthalate	Statistic	N ^a	Ingestion (µg/g)	Studies	Study Confidence
BBP	Mean	388	46	(Hammel et al., 2019 ; Bi et al., 2018 ; Bi et al., 2015 ; Guo and Kannan, 2011 ; Wilson et al., 2001)	Robust
	95th	234	151	(Hammel et al., 2019 ; Dodson et al., 2015)	
DBP	Mean	329	38.8	(Hammel et al., 2019 ; Bi et al., 2018 ; Bi et al., 2015 ; Dodson et al., 2015 ; Guo and Kannan, 2011 ; Rudel et al., 2001 ; Wilson et al., 2001)	Robust
	95th	234	64.8	(Hammel et al., 2019 ; Dodson et al., 2015)	
DCHP	Mean	3	1.9	(Rudel et al., 2001)	Slight
	95th	49	7.4	(Dodson et al., 2015)	
DEHP	Mean	346	174	(Hammel et al., 2019 ; Bi et al., 2018 ; Bi et al., 2015 ; Rudel et al., 2001)	Robust
	95th	234	479	(Hammel et al., 2019 ; Dodson et al., 2015)	
DIBP	Mean	43	16	(Bi et al., 2015)	Moderate
	95th	188	33.9	(Hammel et al., 2019)	
DINP	Mean	188	78.8	(Hammel et al., 2019)	Moderate
	95th	188	787.6	(Hammel et al., 2019)	

^a EPA did not calculate central tendencies or 95th percentiles for individual studies, rather gathered the central tendencies and 95th percentiles that were reported in the individual studies. This is why the 'n' and number of studies vary between means and 95th percentile estimates as some studies only reported central tendencies while others only reported 95th percentile values.

1263

PUBLIC RELEASE DRAFT
May 2025

1264

Table 3-2. Cumulative Phthalate Daily Intake (µg/kg-day) Estimates from Indoor Dust Monitoring Data

Age	Percentile	Phthalate	Aggregate Daily Intake (µg/kg-day) Mean ^b	Aggregate Daily Intake (µg/kg-day) High-End ^b	RPF	Aggregate Daily Intake in DBP Equivalents (µg/kg-day) Mean	Cumulative Daily Intake in DBP Equivalents (µg/kg-day)	Cumulative MOE (POD = 2,100 µg/kg-day)	% Contribution to Risk Cup (Benchmark = 30) ^a
3 – 6 years age	50	BBP	0.10	0.66	0.52	0.05	0.34	6,095	0.5%
		DBP	0.08	0.47	1	0.08			
		DCHP	0.00	0.00	1.66	0.00			
		DEHP	0.23	1.45	0.84	0.19			
		DIBP	0.01	0.07	0.53	0.01			
		DINP	0.06	0.40	0.21	0.01			
	95	BBP	0.07	0.43	0.52	0.23	2.39	880	3.4%
		DBP	0.03	0.17	1	0.17			
		DCHP	0.00	0.01	1.66	0.01			
		DEHP	0.20	1.26	0.84	1.06			
		DIBP	0.03	0.16	0.53	0.09			
		DINP	0.64	3.98	0.21	0.84			
16 – 50 years age ^a	50	BBP	0.01	0.08	0.52	0.00	0.02	97,684	0.0%
		DBP	0.00	0.06	1	0.00			
		DCHP	0.00	0.00	1.66	0.00			
		DEHP	0.01	0.18	0.84	0.01			
		DIBP	0.00	0.01	0.53	0.00			
		DINP	0.00	0.05	0.21	0.00			
	95	BBP	0.00	0.06	0.52	0.03	0.31	6,830	0.4%
		DBP	0.00	0.02	1	0.02			
		DCHP	0.00	0.00	1.66	0.00			
		DEHP	0.01	0.16	0.84	0.13			
		DIBP	0.00	0.02	0.53	0.01			
		DINP	0.04	0.51	0.21	0.11			

^a Cumulative estimates from the 16–21 years age range were used to represent 16–50 years of age as all of these age groups (16–21 years, 21–30 years, 30–40 years and 40–50 years) had the same % contribution to the risk cup (0.0% and 0.4% for the 50th and 95th percentiles). 16–21 years of age had the lowest MOEs of these age groups (16-21 years, 21–30 years, 30–40 years and 40–50 years).

^b Bolded values are carried forward to calculate cumulative Daily Intake (DBP Equivalents, µg/kg-day).

1265

1266 **3.2.4 Conclusions on Cumulative Consumer and Indoor Dust Phthalate Exposure**

1267 For co-exposure to occur, exposure would need to occur in a narrow timeframe (*i.e.*, same day) due to
1268 the fast elimination kinetics of phthalates. This could occur from use of a single product containing
1269 multiple phthalates but, as discussed above in Sections 3.2.1, EPA has not identified much evidence of
1270 multiple phthalates being used in a single consumer product to suggest that this is a substantial pathway
1271 of co-exposure to multiple phthalates for consumers.

1272
1273 Due to the numerous consumer products and articles found in the domestic environment that contain
1274 phthalates, it is highly plausible that a consumer may be simultaneously exposed to phthalates from two
1275 or more different consumer products or articles. EPA identified limited quantitative information on the
1276 co-occurrence or co-use of phthalate-containing consumer products and articles within the same day to
1277 facilitate a robust and specific cumulative scenario based on specific COUs.

1278
1279 However, as discussed in Section 3.2.3, occurrence of TSCA phthalates in house dust is widespread.
1280 EPA has estimated cumulative exposure and risk from exposure to phthalates from ingestion of house
1281 dust. The highest cumulative phthalate exposure from ingestion of house dust was for children (3–5
1282 years of age) using high-end dust ingestion assumptions and 95th percentile phthalate concentrations in
1283 house dust. When comparing these dust intake estimates to cumulative risk estimates for NHANES in
1284 Table 4-3, the percent contribution of NHANES to the risk cup is always much greater than ingestion of
1285 settled dust. This is anticipated as NHANES urinary biomonitoring provides an estimate of aggregate
1286 exposure (*i.e.*, exposure via all routes and pathways, including dust ingestion) to each phthalate rather
1287 than just through ingestion of phthalates in settled dust.

1288
1289 Therefore, at this time, EPA did not estimate co-exposure of phthalates from the direct use of multiple
1290 consumer products (Section 3.2.2) beyond the estimation of non-attributable exposure described further
1291 in Section 4.

1292 **3.3 General Population Exposure to Environmental Releases**

1293 General population exposures to environmental releases occur when phthalates are released into the
1294 environment and the environmental media is then a pathway for exposure. As described in the draft
1295 approach, the general population may be exposed to multiple phthalates either from single facilities
1296 releasing more than one phthalate or from being in close proximity to co-located facilities. This section
1297 provides a brief overview of the chemical properties across the phthalates of interest in Section 3.3.1 and
1298 considers the geographic distribution of facilities with phthalate releases in Section 3.3.2.

1299 **3.3.1 Comparison of Fate Parameters Across Phthalates**

1300 Phthalate releases from facilities are expected to occur to air, water, and land. Based on the fate
1301 parameters of the various phthalates, once released into the environment, phthalates are expected to
1302 primarily partition to sediment and biosolids. However, despite phthalates being expected primarily in
1303 sediments and biosolid, exposure to the general population would be mostly likely to occur primarily
1304 through drinking water and fish ingestion based on the individual phthalate risk evaluation exposure
1305 assessments. The physical chemical properties and fate parameters govern environmental fate and
1306 transport and are detailed in the draft technical support documents for each chemical substance: DEHP
1307 ([U.S. EPA, 2024m](#)), BBP ([U.S. EPA, 2024j](#)), DBP ([U.S. EPA, 2024k](#)), DIBP ([U.S. EPA, 2024n](#)), DCHP
1308 ([U.S. EPA, 2024l](#)), DINP ([U.S. EPA, 2025q](#)). These properties and parameters for the cumulative
1309 chemical group are summarized below in Table 3-3 and in this section.

1311 The magnitude of the partitioning coefficients identified for these phthalates suggest that they may exist
1312 in surface water in both aqueous form and in suspension, and sorbed to organic carbon fractions in soil,
1313 sediment, and air in the environment. The lower Henry's Law constants of these phthalates indicate that
1314 they are not expected to volatilize from surface water. DEHP, BBP, DBP, DIBP, DCHP, and DINP have
1315 very low to slight solubility in water. DEHP and DIDP have very low water solubility (0.003 mg/L for
1316 DEHP; 0.00061 mg/L for DINP; 0.00017 mg/L for DIDP), while BBP, DBP, DIBP, and DCHP are
1317 slightly soluble in water (2.3 mg/L for BBP; 11.2 mg/L for DBP; 6.2 mg/L for DIBP; 0.03–1.48 mg/L
1318 for DCHP). Sorption to organics present in sediment and suspended and dissolved solids present in
1319 water is expected to be a dominant process given the range of identified log K_{oc} values across DEHP,
1320 DBP, BBP, DIBP, DCHP, and DINP (Table 3-3). BBP's solubility and range of log K_{oc} values for
1321 phthalates in the cumulative chemical group (Table 3-3) suggests that they are unlikely to exhibit
1322 mobility in soils, which is also supported by fugacity modeling results. In general, amongst phthalates in
1323 the cumulative chemical group, as molecular weight decreases, water solubility and vapor pressure
1324 increase, while tendency to partition to organic carbon (sorption to soils and sediments) and
1325 environmental half-lives also decrease.

1326
1327 Phthalates in the cumulative chemical group in surface water are subject to two primary competing
1328 processes: biodegradation and adsorption to organic matter in suspended solids and sediments.
1329 Phthalates in the cumulative chemical group in the freely dissolved phase are expected to show low
1330 persistence, with rapid biodegradation under aerobic conditions. The fraction of phthalates in the
1331 cumulative chemical group adsorbed to particulates increases with water salinity due to a salting out
1332 effect, as indicated by greater log K_{oc} values measured in saltwater as compared to those measured with
1333 freshwater. Monitoring data in the U.S. generally show low detection frequencies in surface water.
1334 Sampling of U.S. surface water sediments yielded a wide range of concentrations; however all of these
1335 phthalates were generally found in low concentrations where they were detected and often with low
1336 detection frequencies. Phthalates in the cumulative chemical group are expected to be removed in
1337 conventional drinking water treatment processes by means of aggregation to floccules and subsequent
1338 settling and filtration processes, as well as by oxidation by chlorination byproducts in post-treatment and
1339 transmission of finished drinking water.

1340
1341 The vapor pressures of the phthalates in the cumulative chemical group indicate that they will
1342 preferentially adsorb to particulates in the atmosphere, with adsorbed fractions being resistant to
1343 photolysis. This is consistent with measured and estimated octanol:air partition coefficients (Table
1344 3-3). Phthalates in the cumulative chemical group that do occur in the atmosphere will likely degrade via
1345 ·OH-mediated indirect photolysis with a half-life of hours to days based on an estimated ·OH reaction
1346 rate constants, and assuming a 12-hour day with 1.5×10^6 ·OH/cm³ (U.S. EPA, 2017). Phthalates in the
1347 cumulative chemical group are generally consistently detected at low concentrations in ambient air;
1348 however, given their atmospheric half-lives, they are not expected to be persistent in air or undergo long
1349 range transport.

1350
1351 Phthalates in the cumulative chemical group present low bioconcentration potential in fish, are unlikely
1352 to biomagnify, and will exhibit trophic dilution in aquatic species. Biomagnification or bioaccumulation
1353 of terrestrial and avian species is also not likely.

1354

Table 3-3. Summary of Physical Chemical Properties and Fate Parameters of DCHP, DBP, DIBP, BBP, DEHP, and DINP

Property	DEHP (U.S. EPA, 2024m)	BBP (U.S. EPA, 2024j)	DBP (U.S. EPA, 2024k)	DIBP (U.S. EPA, 2024n)	DCHP (U.S. EPA, 2024l)	DINP (U.S. EPA, 2025q)
Molecular formula	C ₂₄ H ₃₈ O ₄	C ₁₉ H ₂₀ O ₄	C ₁₆ H ₂₂ O ₄	C ₁₆ H ₂₂ O ₄	C ₂₀ H ₂₆ O ₄	C ₂₆ H ₄₂ O ₄
Molecular Weight (g/mol)	390.56	312.37	278.35	278.35	330.43	418.62
Physical state of the chemical	Colorless, oily liquid	Clear oil, liquid	Colorless to faint yellow, oily liquid	Colorless, clear, viscous liquid	White, granular solid	Clear Liquid
Melting Point (°C)	-55	-35	-35	-64	66	-48
Boiling Point (°C)	384	370	340	296.5	225	>400
Density (g/cm ³)	0.981	1.119	1.0459 to 1.0465	1.049	1.383	0.97578
Vapor Pressure (mmHg)	1.42×10 ⁻⁷	8.25×10 ⁻⁶	2.01×10 ⁻⁵	4.76×10 ⁻⁵	8.69×10 ⁻⁷	5.40×10 ⁻⁷
Water Solubility (ng/L)	3,000	2,690,000	11,200,000	6,200,000	30000 - 1,480,000	610
Log K _{ow}	7.6	4.73	4.5	4.34	4.82	8.8
Log K _{oa} (estimated using EPI Suite™)	10.76	9.2	8.63	9.47	10.23	11.9
Log K _{oc}	3.75-5.48	2.09-2.91	3.16-4.19	2.5-3.14	3.46-4.12	5.5-5.7
Henry's Law Constant (atm·m ³ /mol)	1.71×10 ⁻⁵	7.61×10 ⁻⁷	1.81×10 ⁻⁶	1.83×10 ⁻⁷	9.446×10 ⁻⁸	9.14×10 ⁻⁵
Flash Point (°C)	206	199	157.22	185	207	213
Autoflammability (°C)	390	-	402.778	432	No data	400
Viscosity (cP)	57.94	55	20.3	41	Not applicable (solid)	77.6
Overall Environmental Persistence	Low	Low	Low	Low	Low	Low
Bioaccumulation Factor (Log BAF A-G)	3.02	1.60	2.20	1.41	2.14	1.14
Bioconcentration Factor (Log BCF A-G)	2.09	2.88	2.20	1.41	2.13	0.39

1355

3.3.2 Geographic Consideration of Reported Releases of Phthalates

In the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA recognized that the general population, those impacted by facility release of phthalates, could be exposed to multiple phthalates from single facilities that release more than one phthalate or be exposed to multiple phthalates due to living in close proximity to co-located facilities. Given the chemical properties described in Section 3.3.1 and the chemical-specific Fate TSDs, the major pathway for any environmental exposure would be sediments and biosolids from continuous or recent concurrent releases. Therefore, EPA analyzed the co-location of all the known phthalate-releasing facilities within common watersheds.

As described above in Section 3.1.2.2, EPA identified DMR, NEI, and TRI data for DEHP, DBP, and BBP, but not for DCHP, DINP, and DIBP. These EPA databases provide information on facilities releasing phthalates to various environmental media and provide latitude and longitude data for releasing facilities. Using the release information, EPA identified 1,461 facilities that report use of a single phthalate, while 461 report use of multiple phthalates (*i.e.*, any combination of DEHP, DBP, or BBP). Using the available location data, EPA mapped the reporting facilities in Figure 3-1 to look for geographic patterns or hotspots. Individual facilities are broadly dispersed around the United States. Of note, no releasing facilities are reported in Alaska, an area of note in the SACC review of the draft 2023 approach ([U.S. EPA, 2023c](#)).

EPA also analyzed the locations of the identified facilities by watershed or hydrologic units. A hydrologic unit represents the area of the landscape that drains to a portion of the stream network and is identified by a unique Hydrologic Unit Code (HUC). EPA searched for the HUC12 watershed level, which represents an average size of 36 square miles ([The RPS Methodology: Comparing Watersheds, Evaluating Options | US EPA](#)), for each the identified facilities. These are listed in in the *Draft Summary of Facility Release Data for Di(2-ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), and Butyl Benzyl Phthalate (BBP)* ([U.S. EPA, 2024p](#)). In the following HUC12 watersheds, four or more releasing facilities are identified:

- 120401040703 in Harris County, TX (11 facilities)
- 180300090701 in Fresno County, CA (9 facilities)
- 120401040706 in Harris County, TX (8 facilities)
- 120402040100 in Harris County and Brazoria County, TX (8 facilities)
- 101900030304 in Denver County, CO (6 facilities)
- 040601020303 in Wexford County, MI (6 facilities)
- 180701050401 in Los Angeles County, CA (5 facilities)
- 180701060701 in Los Angeles County, CA (5 facilities)
- 170900120202 in Multnomah County, OR (5 facilities)
- 180701030202 in Ventura County, CA (5 facilities)
- 030501010804 in Burke and Catawba Counties, NC (5 facilities)
- 030501010701 in Caldwell County, NC (5 facilities)
- 180702030804 in San Bernardino and Riverside Counties, CA (4 facilities)
- 180701060502 in Los Angeles County, CA (4 facilities)
- 180400030205 in San Joaquin County, CA (4 facilities)
- 180701060102 in Los Angeles County, CA (4 facilities)
- 180703041202 in San Diego County, CA (4 facilities)
- 071401010403 in St. Clair County, IL and St. Louis County, MO (4 facilities)

PUBLIC RELEASE DRAFT
May 2025


- 020301040205 in Hudson County, NJ and Kings County, NY (4 facilities)
- 020402010407 in Burlington County, NJ and Bucks County, PA (4 facilities)
- 020200041108 in Schenectady County, NY (4 facilities)

Even where co-located facilities within watersheds have been identified, there is difficulty in estimating the cumulative exposures in those locations. First, the programmatic data from DMR, NEI, and TRI are reported per facility for a single reporting year. Although information such as the highest release is reported, there is no information on the timing of release of phthalates into the environment, making it difficult to identify any areas that are impacted by multiple phthalates concurrently.

Additionally, although EPA identified 461 facilities reporting the use of multiple phthalates, the reporting data does not state whether the multiple phthalates are used concurrently within the facility and released simultaneously to the environment. Often, use or production of multiple chemicals such as the phthalates occur in campaigns, where a single phthalate is used for a determined period of time before the facility uses another phthalate for another period of time. In these instances, phthalates would not be released from the facility concurrently and, therefore, may not pose a cumulative exposure to surrounding communities based on the fate parameters of the phthalates. EPA recognizes that the lack of data on the timing of the releases makes it difficult to quantify cumulative exposure from facilities reporting use of multiple phthalates.

In general, EPA recognizes that there may be discrete locations impacted by the release of multiple phthalates either through single facilities releasing multiple phthalates or multiple facilities within the same watershed or releasing to the same wastewater facility. Releases would need to be continuous to lead to ongoing exposure given the relatively low persistence in the environment. In the risk evaluations for the individual phthalates, the general population exposures from pathways such as drinking water, recreational swimming, ambient air, incidental soil ingestion, and fish ingestion for each phthalate are estimated and found to be much lower than exposures for consumer and occupational populations, even when quantified using a screening-level assessment using conservative (*e.g.*, low tier, high risk) assumptions.

1430



1431
1432

Figure 3-1. Mapping of Facilities with One of Multiple Phthalates

3.3.3 Conclusions on Cumulative General Population Exposure to Environmental Releases of Phthalates

The general population may be exposed to the environmental releases of multiple phthalates from a facility that releases multiple phthalates or from facilities in proximity releasing into the same watershed. As discussed above in Section 3.3.1 and in the individual chemical technical support documents, phthalates are expected to partition primarily to sediments and biosolids with human exposure most likely to occur through drinking water and fish ingestion. However, the phthalates have relatively low persistence, low bioaccumulation potential, and low long-range transport so they are unlikely to build up in the environment, including arctic environments. Localized, site specific co-exposures are possible but overall exposures are expected to be marginal compared to total exposure.

Therefore, at this time, EPA did not estimate co-exposure of phthalates from multiple releasing facilities or facilities releasing multiple phthalates. Given the reliance on screening methods for estimating general population exposure to environmental releases, EPA discourages the aggregation of modelled screening estimates without more refined exposure models or monitoring data.

3.4 Non-TSCA Exposure to Diet

Non-TSCA exposures to a combination of phthalates may occur through diet which includes the consumption of phthalates from food packaging. Using a scenario-based approach, U.S. Consumer Product Safety Commission (CPSC) found the majority of women's exposure to DEHP, DINP, and DIBP was from diet (DCHP was not included in their analysis). Their estimates were in general agreement (within an order of magnitude) with two other studies estimating phthalate exposure using scenario-based exposure assessment methods with differences attributable to differing approaches for dietary exposure estimation ([Clark et al., 2011](#); [Wormuth et al., 2006](#)). U.S. CPSC (2014) estimated dietary exposure using two datasets of phthalate residues in food items ([Bradley et al., 2013](#); [Page and Lacroix, 1995](#)). Additional studies were used for food categorization and consumption estimates, including the U.S. EPA National Center for Environmental Assessment's analysis of food intake and diet composition ([Clark et al., 2011](#); [U.S. EPA, 2007](#); [Wormuth et al., 2006](#)).

Health Canada concluded that the main sources of exposure to the general Canadian population for medium-chain phthalates were food, indoor air, dust, and breast milk ([ECCC/HC, 2020](#)). For their estimation of dietary intake of DIBP, BBP, DBP, and DEHP, Health Canada used the 2013 Canadian Total Diet Study ([ECCC/HC, 2020](#)). For other phthalates, they used the 2013 through 2014 and 2014 through 2015 Food Safety Action Plan (Canadian Food Inspection Agency) and/or a dietary exposure study from the United States ([Schechter et al., 2013](#)). A United Kingdom total diet study ([Bradley et al., 2013](#)) was used to fill in data gaps. The phthalate concentrations were matched to 2004 Canadian Community Health Survey on nutrition ([Statistics Canada, 2004](#)) consumption values for each individual food.

In the draft 2023 approach ([U.S. EPA, 2023b](#)), EPA proposed using a scenario-based exposure assessment to determine non-attributable and non-TSCA source exposure levels to all phthalates and to reconstruct an aggregated daily exposure profile for receptors varied by age (women of reproductive age, male infants, toddlers, and children). The approach proposed was to use similar methods to Health Canada ([ECCC/HC, 2020](#)) and U.S. CPSC (2014), which determined that diet comprised a large portion of total daily intake for populations of interest. In its review of the approach, SACC recommended reviewing literature related to estimates of exposure from diet given the highly diverse U.S. population ([U.S. EPA, 2023c](#)). EPA conducted a literature search to investigate if there were any large-scale

1479 phthalate dietary assessments that would influence a national scale dietary assessment or warrant an
1480 update to the previously conducted analyses. However, EPA has concluded that there is limited updated
1481 information to substantially change the daily intake estimates previously constructed by the other
1482 agencies using scenario-based methods, including for sensitive subpopulations.

1483
1484 Health Canada ([ECCC/HC, 2020](#)) and U.S. CPSC ([2014](#)) had both estimated total phthalate daily intake
1485 values using reverse dosimetry with human urinary biomonitoring data and scenario-based exposure
1486 assessment approaches. Health Canada and U.S. CPSC found that both the reverse dosimetry and
1487 scenario-based approaches resulted in daily intake values that were generally similar in magnitude.
1488 However, this depended on the recency and quality of data available for use, particularly for data on
1489 major exposure pathways like diet. Rather than construct new national estimates of dietary intake, EPA
1490 is similarly using reverse dosimetry with national human urinary biomonitoring data, described further
1491 in Section 4, which provides total intake for total population and subpopulations by demographic
1492 category.

4 PHTHALATE EXPOSURE AND RISK FOR THE U.S. POPULATION USING NHANES URINARY BIOMONITORING DATA

The U.S. Center for Disease Control’s (CDC) National Health and Nutrition Examination Survey (NHANES) is an ongoing exposure assessment of the U.S. population’s exposure to environmental chemicals using biomonitoring. The NHANES biomonitoring dataset is a national, statistical representation of the general, non-institutionalized, civilian U.S. population. As described in the *Draft Proposed Approach for Cumulative Risk Assessment of High-Priority Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act* (draft 2023 approach) ([U.S. EPA, 2023b](#)), a reverse dosimetry approach for exposure and risk analysis relies on CDC’s NHANES urinary biomonitoring dataset and a single compartment toxicokinetic model to estimate total exposure to individual phthalates for the U.S. civilian population. However, exposures measured via NHANES cannot be attributed to specific sources. Given the short half-lives of phthalates, neither can NHANES capture acute, low frequency exposures. Instead, as concluded by the SACC review of the draft 2023 approach, NHANES provides a “snapshot” or estimate of total, non-attributable phthalate exposure for the U.S. population and relevant subpopulations ([U.S. EPA, 2023c](#)). These estimates of total non-attributable exposure can supplement assessments of scenario-specific acute risk in individual risk evaluations.

As can be seen from Table 4-1, monoester metabolites of BBP, DBP, DEHP, DIBP, and DINP in human urine are regularly measured as part of the NHANES biomonitoring program and are generally detectable in human urine at a high frequency, including during the most recent NHANES survey period (*i.e.*, 2017 to 2018). For DEHP, four urinary metabolites are regularly monitored as part of NHANES, including mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP). For DBP and DIBP, two urinary metabolites of each phthalate are regularly monitored, including mono-n-butyl phthalate (MnBP) and mono-3-hydroxybutyl phthalate (MHBP) for DBP and mono-2-methyl-2-hydroxypropyl phthalate (MHiBP) and mono-isobutyl phthalate (MIBP) for DIBP. For DINP, three urinary metabolites are regularly monitored (*i.e.*, mono-isononyl phthalate [MINP], mono-oxoisononyl phthalate [MONP], and mono-(carboxyoctyl) phthalate [MCOP]), while one metabolite is regularly monitored for BBP (*i.e.*, mono-benzyl phthalate [MBzP]). One urinary metabolite of DCHP (*i.e.*, monocyclohexyl phthalate [MCHP]) was included in NHANES from 1999 through 2010, but was excluded from NHANES after 2010 due to low detection levels and a low frequency of detection in human urine (detected in less than 10% of samples in 2009 to 2010 NHANES survey) ([CDC, 2013a](#)). Further details regarding the limit of detection, frequency of detection, additional methodological and results for each phthalate can be found in Appendix C, as well as in the environmental media and general population exposure assessments for DEHP ([U.S. EPA, 2025h](#)), DBP ([U.S. EPA, 2025g](#)), BBP ([U.S. EPA, 2025f](#)), DIBP ([U.S. EPA, 2025i](#)), DINP ([U.S. EPA, 2025n](#)), and DCHP ([U.S. EPA, 2024b](#)).

1535 **Table 4-1. Urinary Phthalate Metabolites Included in NHANES**

Phthalate	NHANES Urinary Metabolite ^a	Associated Parent Compound	NHANES Reporting Years ^b	% Samples Below the LOD in 2017-2018 ^b NHANES (All Participants, N=2,762)
DEHP	Mono-2-ethylhexyl phthalate (MEHP)	DEHP	1999–2018	43.77%
	Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP)	DEHP	2001–2018	0.98%
	Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP)	DEHP	2001–2018	0.83%
	Mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP)	DEHP	2003–2018	0.18%
DBP	Mono-3-hydroxybutyl phthalate (MHBP)	DBP	2013–2018 ^d	24.91%
	Mono-n-butyl phthalate (MnBP)	DBP, BBP	1999–2018	0.69%
BBP	Mono-benzyl phthalate (MBzP)	BBP	1999–2018	3.8%
DIBP	Mono-isobutyl phthalate (MIBP)	DIBP	2001–2018	4.89%
	Mono-2-methyl-2-hydroxypropyl Phthalate (MHiBP)	DIBP	2013–2018 ^d	2.17%
DCHP	Mono-cyclohexyl phthalate (MCHP)	DCHP	1999–2010	- ^c
DINP	Mono-isononyl phthalate (MiNP)	DINP	1999–2018	12.57%
	Mono-oxoisononyl phthalate (MONP)	DINP	2015–2018	12.85%
	Mono-(carboxyoctyl) phthalate (MCOP)	DINP	2005–2018	0.51%

LOD = limit of detection
^a NHANES reports uncorrected and creatinine corrected urine concentrations for each metabolite.
^b 2017–2018 is the most recently available NHANES dataset.
^c In the 2009 to 2010 survey year (last survey in which MCHP was monitored), MCHP was above the LOD in 4.3% of samples for all adults 16 years and older, and 7.9% of samples for all children 3 to less than 16 years of age (see Appendix C for further details).
^d MHBP and MHiBP were measured in the 2013 to 2018 NHANES cycles; however, the data for the 2013 to 2014 NHANES cycle was determined to be inaccurate due to procedural error and only released as surplus data, which is not readily publicly available (https://www.cdc.gov/Nchs/Nhanes/2013-2014/SSPHTE_H.htm). As a result, the present analysis only includes urinary MHBP data from the 2015 to 2018 NHANES cycles.

1536
1537 EPA analyzed NHANES urinary biomonitoring data from 1999 through 2018 for metabolites of DEHP,
1538 DBP, BBP, DIBP, DINP, and DCHP for several subpopulations reported within NHANES to determine
1539 median and 95th percentile exposure estimates for each urinary metabolite measured in NHANES. EPA
1540 also analyzed the available urinary biomonitoring data to understand temporal trends in phthalate
1541 exposure for the civilian U.S. population (discussed further in Section 4.1). These analyses were
1542 performed for the following populations reported within NHANES, including:

- 1543
- Male and female children aged 3 to less than 6 years, 6 to 11 years, and 11 to less than 16 years;
 - Male and female adults 16 years of age and older; and
 - Women of reproductive age (16 to 49 years of age).
- 1544
1545

1546 Using reverse dosimetry, EPA also estimated non-attributable daily intake values for DEHP, DBP, BBP,
1547 DIBP, and DINP using the most recent NHANES urinary biomonitoring data from 2017 to 2018.
1548 Reverse dosimetry involves estimating aggregate exposure (expressed as a daily intake value) for each
1549 individual phthalate from human urinary biomonitoring data for metabolites unique to each parent
1550 phthalate (discussed further in Section 4.2). Reverse dosimetry approaches that incorporate basic
1551 pharmacokinetic information are available for phthalates ([Koch et al., 2007](#); [Koch et al., 2003](#); [David,](#)

1552 [2000](#)) and have been used in previous human health cumulative risk assessments conducted by U.S.
1553 CPSC ([2014](#)) and Health Canada ([ECCC/HC, 2020](#)). Consistent with EPA's decision to focus its draft
1554 phthalate CRA on women of reproductive age (16 to 49 years) and male infants, male toddlers, and male
1555 children as susceptible subpopulations (Section 1.4) ([U.S. EPA, 2023b](#)) EPA used NHANES urinary
1556 biomonitoring and reverse dosimetry to estimate daily intake values for:

- 1557 • Women of reproductive age (16 to 49 years of age);
- 1558 • Male children 3 to less than 6 years of age (used as a proxy for male infants and toddlers);
- 1559 • Male children 6 to 11 years of age; and
- 1560 • Male children 12 to less than 16 years of age.

1561 Daily intake values were calculated for women of reproductive age, because this population most
1562 closely aligns with the selected hazard (*i.e.*, reduced fetal testicular testosterone content) and generally
1563 too few pregnant women are sampled as part of NHANES to support a statistical analysis in survey
1564 years after 2005 to 2006 ([CDC, 2013b](#); [NCHS, 2012](#)), and other national datasets are not available.
1565 Daily intake values were calculated for male children because testosterone plays an important role in
1566 male sexual development during fetal and postnatal lifestages. Since NHANES does not include urinary
1567 biomonitoring for infants or toddlers, and other national datasets are not available, EPA used
1568 biomonitoring data from male children 3 to less than 6 years of age as a proxy for male infants (<1 year)
1569 and toddlers (1–2 years).

1570
1571 For women of reproductive age, daily intake values were also calculated based on race as reported in
1572 NHANES (*i.e.*, white non-Hispanic, black non-Hispanic, Mexican-American, other) and socioeconomic
1573 status (*i.e.*, above or below the poverty line, unknown income) to better understand if these factors
1574 influence phthalate exposure and cumulative risk for the U.S. population. A similar analysis by race was
1575 not done for male children because the NHANES sample size is smaller for this population.

1576
1577 EPA provides a summary of temporal trends observed for each phthalate metabolite in Section 4.1.
1578 Sections 4.2 and 4.3 provide estimates of aggregate and cumulative phthalate daily intake values,
1579 respectively, for women of reproductive age and male children reported within NHANES. Section 4.4.
1580 provides cumulative risk estimates for women of reproductive age and male children within the U.S.
1581 population based on daily intake estimates from NHANES. Section 4.5 summarizes EPA weight of
1582 scientific evidence conclusions.

1583 **4.1 Temporal Trends in Phthalate Exposure Based on NHANES Urinary** 1584 **Biomonitoring Data**


1585 EPA evaluated NHANES urinary biomonitoring data from 1999 to 2018 for DEHP, DBP, BBP, DIBP,
1586 and DINP to determine any trends in phthalate exposure within the U.S. civilian population over the past
1587 two decades. This temporal trends analysis was conducted for the following populations:

- 1588 • All NHANES participants;
- 1589 • All adults (16 years and older);
- 1590 • Female adults (16 years and older);
- 1591 • Male adults (16 years and older);
- 1592 • Children 3 to less than 6 years, 6 to less than 11 years, and 11 to less than 16 years (not stratified
1593 by sex);
- 1594 • Male children less than 16 years of age; and
- 1595 • Female children less than 16 years of age.

1596 Results for this temporal trends analysis are summarized below and in more detail in Appendix C.2. For
1597 convenience, median phthalate urinary metabolite concentrations for the NHANES ‘All Participants’
1598 group from 1999 through 2018 are provided in Figure 4-1. Overall, several notable trends in phthalate
1599 exposure for the U.S. population were observed, including:

- 1600 • Overall 50th and 95th percentile urinary metabolites of DEHP (MEHP, MEHPP, MEOHP,
1601 MEOCP), DBP (MnBP), and BBP (MBzP) have statistically significantly decreased over time
1602 (1999–2018) for all populations, indicating declining exposure for these phthalates in the U.S.
1603 population (see Appendices C.2.1 – C.2.3 for further details).
- 1604 • For DIBP, 50th and 95th percentile urinary MIBP concentrations statistically significantly
1605 increased over time (1999–2018) for all lifestages, while 50th and 95th percentile MHiBP
1606 urinary concentrations statistically significantly decreased over time (2015–2018) for most life
1607 stages (see Appendix C.2.4 for further details). However, urinary MHiBP data is only available
1608 from two NHANES survey periods and it is unclear if this trend in declining exposure will
1609 persist as additional NHANES data becomes available.
- 1610 • For DINP, urinary concentrations of MCOP and MINP statistically significantly increased from
1611 2005 through 2014 for all NHANES participants. After 2014, urinary concentrations of MCOP
1612 and MINP statistically significantly decreased for all NHANES participants (see Appendix C.2.5
1613 for further details).

1614 EPA did not conduct a temporal trends analysis for DCHP. The DCHP urinary metabolite, MCHP, was
1615 monitored as part of NHANES from 1999 through 2010, but was not included in subsequent survey
1616 years because of the low detection levels and low frequency of detection of MCHP in urine. For
1617 example, in the 2009 to 2010 NHANES survey, MCHP was detectable in only 4.3 percent of samples
1618 for all adults 16 years and older, and 7.9 percent of samples for all children 3 to less than 16 years of
1619 age. These results indicate low exposure to DCHP for the U.S. civilian population (Appendix C.1).
1620



1621
1622 **Figure 4-1. Median Phthalate Metabolite Concentrations Over Time for All NHANES**
1623 **Participants From 1999 Through 2018**

1624 **4.1.1 Trends in National Aggregate Production Volume Data**

1625 EPA also considered whether temporal trends in national aggregate production volume data mirror those
1626 observed in NHANES urinary biomonitoring data. To do this, EPA extracted national aggregate
1627 production volume (PV) data for DEHP, DBP, DIBP, BBP, DCHP, and DINP from the 2016 and 2020
1628 Chemical Data Reporting (CDR) (Appendix D.1). In CDR, national aggregate PV data is reported as a
1629 range to protect PV data claimed as confidential business information (CBI). Given the large ranges in
1630 reported PV data for each phthalate, EPA was unable to conclude whether or not there are any trends in
1631 PV for any phthalate over this time period.

1632 **4.2 Aggregate Phthalate Exposure Based on NHANES Urinary**
1633 **Biomonitoring Data and Reverse Dosimetry**

1634 Using DEHP, DBP, BBP, DIBP, and DINP urinary metabolite concentrations measured in the most
1635 recently available NHANES survey from 2017 to 2018, EPA estimated the daily intake of each phthalate
1636 through reverse dosimetry. NHANES provides an estimate of aggregate exposure for each individual
1637 phthalate. EPA defines *aggregate exposure* as the “combined exposures to an individual from a single
1638 chemical substance across multiple routes and across multiple pathways” (40 CFR § 702.33). Reverse
1639 dosimetry approaches that incorporate basic pharmacokinetic information are available for phthalates
1640 (Koch et al., 2007; Koch et al., 2003; David, 2000) and have been used in previous phthalate risk
1641 assessments conducted by U.S. CPSC (2014) and Health Canada (ECCC/HC, 2020) to estimate daily

1642 intake values for exposure assessment. For phthalates, reverse dosimetry can be used to estimate a daily
1643 intake value for a parent phthalate diester based on phthalate monoester metabolites measured in human
1644 urine. Further details regarding the reverse dosimetry method used by EPA to estimate daily intake
1645 values, as well as a discussion of limitations and uncertainties associated with the reverse dosimetry
1646 method, are provided in Appendices C.3 and C.5, respectively.

1647
1648 Table 4-2 shows the 50th and 95th percentile aggregate daily intake values for DBP, DEHP, BBP,
1649 DIBP, and DINP for women of reproductive age (16 to 49 years) and male children (ages 3 to 5, 6 to 11,
1650 and 12 to 15 years), while Table 4-3 shows the aggregate 50th and 95th percentile daily intake values for
1651 women of reproductive age stratified by race and socioeconomic status. For women of reproductive age
1652 (Table 4-2), aggregate daily intake values were highest for DEHP and DINP, with 50th and 95th
1653 percentile aggregate daily intake values of 0.53 and 1.48 $\mu\text{g}/\text{kg}\text{-day}$, respectively, for DEHP and 0.7 and
1654 5.6 $\mu\text{g}/\text{kg}\text{-day}$, respectively, for DINP. Comparatively, aggregate daily intake values for women of
1655 reproductive age were lower for DBP (50th and 95th percentile daily intake values: 0.21 and 0.61 $\mu\text{g}/\text{kg}\text{-}$
1656 day, respectively), BBP (50th and 95th percentile daily intake values: 0.08 and 0.42 $\mu\text{g}/\text{kg}\text{-day}$,
1657 respectively), and DIBP (50th and 95th percentile daily intake values: 0.2 and 0.57 $\mu\text{g}/\text{kg}\text{-day}$,
1658 respectively) (Table 4-2).

1659
1660 As can be seen from Table 4-2, for male children, aggregate exposure to each individual phthalate was
1661 generally the highest for male children 3 to 5 years old, and declined with age such that male children 11
1662 to 15 years old generally had the lowest aggregate exposure estimates. Similar to women of reproductive
1663 age, aggregate daily intake values were highest for DEHP and DINP for all age groups for male
1664 children, followed by DBP, DIBP, and BBP (Table 4-2). Aggregate daily intake values ranged from 0.66
1665 to 2.11 $\mu\text{g}/\text{kg}\text{-day}$ and 2.51 to 6.44 $\mu\text{g}/\text{kg}\text{-day}$ at the 50th and 95th percentiles, respectively, for DEHP
1666 (depending on age group), and ranged from 0.6 to 1.4 $\mu\text{g}/\text{kg}\text{-day}$ and 3.4 to 4.8 $\mu\text{g}/\text{kg}\text{-day}$ at the 50th
1667 and 95th percentiles, respectively, for DINP (depending on age group) (Table 4-2). Comparatively,
1668 aggregate daily intake values for male children were lower for DBP (ranging from 0.33 to 0.56 $\mu\text{g}/\text{kg}\text{-}$
1669 day and 0.62 to 2.02 $\mu\text{g}/\text{kg}\text{-day}$ day at the 50th and 95th percentiles, respectively, depending on age
1670 group); BBP (ranging from 0.14 to 0.22 $\mu\text{g}/\text{kg}\text{-day}$ and 0.64 to 2.46 $\mu\text{g}/\text{kg}\text{-day}$ day at the 50th and 95th
1671 percentiles, respectively, depending on age group); and DIBP (ranging from 0.21 to 0.57 $\mu\text{g}/\text{kg}\text{-day}$ and
1672 0.59 to 2.12 $\mu\text{g}/\text{kg}\text{-day}$ day at the 50th and 95th percentiles, respectively, depending on age group)
1673 (Table 4-2).

1674
1675 A public commentor on the draft risk evaluations for DIDP and DINP ([EPA-HQ-OPPT-2024-0073-](#)
1676 [0081](#)) indicated that EPA may be overestimating phthalate daily intake values using reverse dosimetry
1677 compared to a more recent Bayesian approach developed by scientists in EPA's Office of Research and
1678 Development ([Stanfield et al., 2024](#)). EPA considered the Bayesian approach for estimating phthalate
1679 daily intake values reported by Stanfield et al. However, an important limitation of the Bayesian
1680 approach published by Stanfield et al. is that it does not incorporate phthalate-specific information, such
1681 as fractional urinary excretion values, which will lead to an underestimation of daily intake values for
1682 phthalates. For example, Stanfield et al. report a median daily intake value of 0.41 $\mu\text{g}/\text{kg}\text{-day}$ DEHP for
1683 all NHANES participants in the 2015 to 2016 NHANES cycle using the Bayesian approach (see Table
1684 S8 of Stanfield et al.), while EPA estimated a daily intake of 1.07 $\mu\text{g}/\text{kg}\text{-day}$ for the same population in
1685 the 2017 to 2018 NHANES cycle (*Note: an exact comparison was not possible because Stanfield et al.*
1686 *did not evaluate 2017-2018 NHANES data, while EPA only estimated daily intake values for 2017-2018*
1687 *data*). For DEHP, the sum fractional urinary excretion of urinary metabolites (MEHP, MEHHP,
1688 MEOHP, MECPP) is 0.453, and normalizing the Bayesian daily intake estimates for fractional urinary
1689 excretion provides a very similar daily intake estimate as that obtained using the reverse dosimetry

1690 approach (*i.e.*, $0.41 \mu\text{g}/\text{kg}\text{-day} \div 0.453 = 0.91 \mu\text{g}/\text{kg}\text{-day}$). Therefore, EPA expects that if the Bayesian
1691 approach were to account for fractional urinary excretion values, daily intake estimates using the
1692 Bayesian approach would be similar to the reverse dosimetry daily intake estimates.

1693 **4.3 Cumulative Phthalate Exposure Estimates Based on NHANES Urinary** 1694 **Biomonitoring**

1695 In contrast to aggregate exposure, which refers to exposure to a single chemical substance, cumulative
1696 exposure refers to aggregate exposure to multiple chemical substances. To estimate cumulative phthalate
1697 exposure, EPA scaled the individual aggregate phthalate daily intake estimates for each population by
1698 relative potency using the RPFs shown in Table 2-4. Phthalate daily intake values, expressed in terms of
1699 index chemical equivalents (*i.e.*, DBP equivalents in $\mu\text{g}/\text{kg}\text{-day}$), were then summed to estimate
1700 cumulative phthalate daily intake values for each population. Table 4-2 shows the 50th and 95th
1701 percentile cumulative daily intake values for DBP, DEHP, BBP, DIBP, and DINP for women of
1702 reproductive age (16 to 49 years old) and male children (ages 3 to 5, 6 to 11, and 12 to 15), while Table
1703 4-3 shows 50th and 95th percentile cumulative daily intake values for women of reproductive age
1704 stratified by race and socioeconomic status.

1705
1706 For women of reproductive age, 50th and 95th percentile cumulative daily intake estimates were 0.95
1707 and $3.55 \mu\text{g}$ DBP-equivalents/kg-day (Table 4-2). When stratified by race and socioeconomic status,
1708 there was some evidence for higher cumulative exposure for black non-Hispanic women of reproductive
1709 age at the 95th percentile. For this population 50th and 95th percentile cumulative daily intake estimates
1710 were 0.67 and $5.16 \mu\text{g}$ DBP-equivalents/kg-day (Table 4-3). However, differences in cumulative
1711 exposure between races and socioeconomic status for women of reproductive age at the 50th or 95th
1712 percentiles were statistically non-significant (Appendix C.4). As can be seen from Figure 4-2 and Figure
1713 4-3, DEHP was the largest contributor to 50th percentile cumulative exposure estimates (contributing 36
1714 to 52%, depending on race and socioeconomic status), followed by DBP (15 to 28%), DINP (12 to
1715 22%), DIBP (7 to 12%), and BBP (3 to 5%). For 95th percentile cumulative exposure estimates, DEHP
1716 (contributing 28 to 70%, depending on race and socioeconomic status) and DINP (14 to 47%) were the
1717 largest contributors to cumulative exposure, followed by DBP (9 to 25%), DIBP (4 to 12%), and BBP (3
1718 to 8%).

1719
1720 For male children ages 3 to 5 year, 6 to 11 years, and 12 to 15 years, 50th and 95th percentile cumulative
1721 daily intake estimates decreased with age, with the highest cumulative exposure being estimated for
1722 male children ages 3 to 5 years (50th and 95th percentile: 3.04 and $10.8 \mu\text{g}$ DBP-equivalents/kg-day),
1723 followed by 6 to 11 year olds (50th and 95th percentile: 1.89 and $7.35 \mu\text{g}$ DBP-equivalents/kg-day), and
1724 then 12 to 15 year olds (50th and 95th percentile: 1.19 and $4.36 \mu\text{g}$ DBP-equivalents/kg-day) (Table
1725 4-2). However, the differences between age groups were not statistically significantly different at either
1726 the 50th or 95th percentiles (Appendix C.4). As can be seen from Figure 4-4, DEHP was the largest
1727 contributor to both 50th and 95th percentile cumulative exposure for all age groups (contributing 48 to
1728 58% depending on age group), followed by DBP (14 to 23%), DINP (9 to 23%), DIBP (7 to 12%), and
1729 BBP (4 to 12%).

1730 **4.4 Cumulative Phthalate Risk Based on NHANES Urinary Biomonitoring**

1731 To calculate cumulative risk based on phthalate exposure for the U.S. civilian population from
1732 NHANES, cumulative margins of exposure (MOEs) were calculated for each population by dividing the
1733 index chemical POD (*i.e.*, $2,100 \mu\text{g}/\text{kg}\text{-day}$ for DBP) by the cumulative daily intake estimate (in DBP
1734 equivalents) for each population. As can be seen from Table 4-2 and Table 4-3, for women of

1735 reproductive age, cumulative MOEs ranged from 407 for black non-Hispanic women of reproductive
1736 age at the 95th percentile to 3,151 for black non-Hispanic women of reproductive age at the 50th
1737 percentile. These MOEs are above the benchmark of 30, therefore representing less risk than the
1738 benchmark. Specifically, in terms of a risk cup, these MOEs indicate that the risk cup is 1.0 to 7.4
1739 percent full at a benchmark MOE of 30. Of note, the 95th percentile for black non-Hispanic women
1740 represents a value at which approximately one million individuals would be expected to have higher
1741 exposures, assuming a subpopulation size near 20 million. **These results indicate that cumulative**
1742 **exposure to DEHP, DBP, DIBP, BBP, and DINP, based on the most recent NHANES survey data**
1743 **(2017 to 2018), does not currently pose a risk to most women of reproductive age within the U.S.**
1744 **civilian population.**
1745

1746 As can be seen from Table 4-2, cumulative MOEs ranged from 194 for male children 3 to 5 years of age
1747 at the 95th percentile to 1,758 for male children 12 to 15 years of age at the 50th percentile. These
1748 MOEs indicate that the risk cup is 1.7 to 15.5 percent full at a benchmark MOE of 30. **These results**
1749 **indicate that cumulative exposure to DEHP, DBP, DIBP, BBP, and DINP, based on the most**
1750 **recent NHANES survey data (2017 to 2018), does not currently pose a risk to most male children**
1751 **within the U.S. civilian population.**

1752 **4.5 Conclusions from NHANES Analysis**

1753 Herein, EPA used NHANES urinary biomonitoring data for DEHP, BBP, DBP, DIBP, and DINP to
1754 evaluate temporal trends in phthalate exposure for the U.S. population, to estimate aggregate and
1755 cumulative phthalate exposure via reverse dosimetry, and to estimate cumulative risk exposure to
1756 DEHP, BBP, DBP, DIBP, and DINP for all populations, including women of reproductive age and male
1757 children. Based on this analysis, EPA preliminarily concludes the following:

- 1758 • Temporal trends analysis of NHANES urinary biomonitoring data from 1999 to 2018 indicates
1759 declining exposure to DEHP, DBP, and BBP for the U.S. population. In contrast, exposure to
1760 DIBP for the U.S. population has increased from 1999 to 2018, while exposure to DINP has
1761 fluctuated (*i.e.*, increased from 2005 to 2014, then declined back to approximately 2005 levels in
1762 2018) (Section 4.1).
- 1763 • Aggregate phthalate exposure for all subpopulations in the U.S. was highest for DEHP and DINP
1764 based on the most recent NHANES survey data (2017 to 2018) (Section 4.2).
- 1765 • DEHP was the largest contributor to cumulative phthalate exposure for all subpopulations in the
1766 U.S., followed by DINP or DBP, and then BBP and DIBP (Section 4.3).
- 1767 • Based on the most recent NHANES survey data (2017 to 2018), cumulative exposure to non-
1768 attributable sources of DEHP, DBP, DIBP, BBP, and DINP does not currently pose a risk to
1769 most of the U.S. population, including most women of reproductive age or male children within
1770 the U.S. population (Section 4.4). Cumulative MOEs for all populations were above the
1771 benchmark of 30 and ranged from 194 to 636 based on 95th percentile exposure estimates.
1772 However, these data do not account for acute or low-frequency exposures assessed in the
1773 individual chemical risk evaluations, such as those that may occur as a result of use of certain
1774 consumer products or occupational exposures.

1775 Ultimately the NHANES reverse dosimetry combined with the relative potency factors provides a
1776 common understanding of regular exposures and risks to the U.S. population, including the susceptible
1777 subpopulations of women of reproductive age or male children. However, as national biomonitoring
1778 data does not oversample highly exposed subpopulations, this conclusion cannot be extrapolated to

1779
1780
1781

low-frequency, high-exposure scenarios. Therefore, NHANES reverse dosimetry provides a basis for estimating total exposure that can augment specific acute scenarios in individual risk evaluations, as described further in Section 5.

1782
1783**Table 4-2. Cumulative Phthalate Daily Intake ($\mu\text{g}/\text{kg}\text{-day}$) Estimates for Women of Reproductive Age and Male Children from the 2017–2018 NHANES Cycle**

Population	Percentile	Phthalate	Aggregate Daily Intake ($\mu\text{g}/\text{kg}\text{-day}$)	RPF	Aggregate Daily Intake in DBP Equivalents ($\mu\text{g}/\text{kg}\text{-day}$)	% Contribution to Cumulative Exposure	Cumulative Daily Intake (DBP Equivalents, $\mu\text{g}/\text{kg}\text{-day}$)	Cumulative MOE (POD = 2,100 $\mu\text{g}/\text{kg}\text{-day}$)	% Contribution to Risk Cup (Benchmark = 30) ^a
Females (16–49 years old; n = 1,620)	50	DBP	0.21	1	0.210	22.1	0.950	2,211	1.4%
		DEHP	0.53	0.84	0.445	46.9			
		BBP	0.08	0.52	0.042	4.38			
		DIBP	0.2	0.53	0.106	11.2			
		DINP	0.7	0.21	0.147	15.5			
	95	DBP	0.61	1	0.610	17.2	3.55	592	5.1%
		DEHP	1.48	0.84	1.24	35.0			
		BBP	0.42	0.52	0.218	6.15			
		DIBP	0.57	0.53	0.302	8.51			
		DINP	5.6	0.21	1.18	33.1			
Males (3–5 years old; n = 267)	50	DBP	0.56	1	0.560	18.4	3.04	690	4.3%
		DEHP	2.11	0.84	1.77	58.2			
		BBP	0.22	0.52	0.114	3.76			
		DIBP	0.57	0.53	0.302	9.93			
		DINP	1.4	0.21	0.294	9.66			
	95	DBP	2.02	1	2.02	18.6	10.8	194	15.5%
		DEHP	6.44	0.84	5.41	49.9			
		BBP	2.46	0.52	1.28	11.8			
		DIBP	2.12	0.53	1.12	10.4			
		DINP	4.8	0.21	1.01	9.30			
Males (6–11 years old; n = 553)	50	DBP	0.38	1	0.380	20.1	1.89	1,111	2.7%
		DEHP	1.24	0.84	1.04	55.1			
		BBP	0.16	0.52	0.083	4.40			
		DIBP	0.33	0.53	0.175	9.26			

PUBLIC RELEASE DRAFT

May 2025

Population	Percentile	Phthalate	Aggregate Daily Intake (µg/kg-day)	RPF	Aggregate Daily Intake in DBP Equivalents (µg/kg-day)	% Contribution to Cumulative Exposure	Cumulative Daily Intake (DBP Equivalents, µg/kg-day)	Cumulative MOE (POD = 2,100 µg/kg-day)	% Contribution to Risk Cup (Benchmark = 30) ^a
	95	DINP	1	0.21	0.210	11.1	7.35	286	10.5%
		DBP	1.41	1	1.41	19.2			
		DEHP	4.68	0.84	3.93	53.5			
		BBP	0.84	0.52	0.437	5.94			
		DIBP	1.62	0.53	0.859	11.7			
		DINP	3.4	0.21	0.714	9.71			
Males (12–15 years old; n =308)	50	DBP	0.33	1	0.330	27.6	1.19	1,758	1.7%
		DEHP	0.66	0.84	0.554	46.4			
		BBP	0.14	0.52	0.073	6.09			
		DIBP	0.21	0.53	0.111	9.32			
		DINP	0.6	0.21	0.126	10.5			
	95	DBP	0.62	1	0.620	14.2	4.36	482	6.2%
		DEHP	2.51	0.84	2.11	48.3			
		BBP	0.64	0.52	0.333	7.63			
		DIBP	0.59	0.53	0.313	7.17			
		DINP	4.7	0.21	0.987	22.6			

^a A cumulative exposure of 70 µg DBP equivalents/kg-day would result in a cumulative MOE of 30 (*i.e.*, 2,100 µg DBP-equivalents/kd-day ÷ 70 µg DBP equivalents/kg-day = 30), which is equivalent to the benchmark of 30, indicating that the exposure is at the threshold for risk. Therefore, to estimate the percent contribution to the risk cup, the cumulative exposure expressed in DBP equivalents is divided by 70 µg DBP equivalents/kg-day to estimate percent contribution to the risk cup.

1784

1785
1786

Table 4-3. Cumulative Phthalate Daily Intake (µg/kg-day) Estimates for Women of Reproductive Age (16 to 49 years old) by Race and Socioeconomic Status from the 2017–2018 NHANES Cycle

Race/ Socioeconomic Status (SES)	Percentile	Phthalate	Aggregate Daily Intake (µg/kg-day)	RPF	Aggregate Daily Intake in DBP Equivalents (µg/kg-day)	% Contribution to Cumulative Exposure	Cumulative Daily Intake (DBP Equivalents, µg/kg-day)	Cumulative MOE (POD = 2,100 µg/kg- day)	% Contribution to Risk Cup (Benchmark = 30) ^a
Race: White Non-Hispanic (n = 494)	50	DBP	0.22	1	0.22	21.6	1.02	2,058	1.5%
		DEHP	0.59	0.84	0.50	48.6			
		BBP	0.10	0.52	0.05	5.1			
		DIBP	0.20	0.53	0.11	10.4			
		DINP	0.70	0.21	0.15	14.4			
	95	DBP	0.58	1	0.58	17.6	3.30	636	4.7%
		DEHP	1.44	0.84	1.21	36.6			
		BBP	0.29	0.52	0.15	4.6			
		DIBP	0.55	0.53	0.29	8.8			
		DINP	5.10	0.21	1.07	32.4			
Race: Black Non-Hispanic (n = 371)	50	DBP	0.10	1	0.10	15.0	0.667	3,151	1.0%
		DEHP	0.38	0.84	0.32	47.9			
		BBP	0.04	0.52	0.02	3.1			
		DIBP	0.15	0.53	0.08	11.9			
		DINP	0.70	0.21	0.15	22.1			
	95	DBP	0.48	1	0.48	9.3	5.16	407	7.4%
		DEHP	4.28	0.84	3.60	69.7			
		BBP	0.30	0.52	0.16	3.0			
		DIBP	0.40	0.53	0.21	4.1			
		DINP	3.40	0.21	0.71	13.8			
Race: Mexican American (n = 259)	50	DBP	0.19	1	0.19	22.4	0.849	2,474	1.2%
		DEHP	0.49	0.84	0.41	48.5			
		BBP	0.06	0.52	0.03	3.7			
		DIBP	0.17	0.53	0.09	10.6			

PUBLIC RELEASE DRAFT

May 2025

Race/ Socioeconomic Status (SES)	Percentile	Phthalate	Aggregate Daily Intake (µg/kg-day)	RPF	Aggregate Daily Intake in DBP Equivalents (µg/kg-day)	% Contribution to Cumulative Exposure	Cumulative Daily Intake (DBP Equivalents, µg/kg-day)	Cumulative MOE (POD = 2,100 µg/kg- day)	% Contribution to Risk Cup (Benchmark = 30) ^a
	95	DINP	0.60	0.21	0.13	14.8	3.61	582	5.2%
		DBP	0.42	1	0.42	11.6			
		DEHP	1.24	0.84	1.04	28.9			
		BBP	0.39	0.52	0.20	5.6			
		DIBP	0.46	0.53	0.24	6.8			
		DINP	8.10	0.21	1.70	47.1			
Race: Other (n = 496)	50	DBP	0.26	1	0.26	25.3	1.03	2041	1.5%
		DEHP	0.64	0.84	0.54	52.2			
		BBP	0.07	0.52	0.04	3.5			
		DIBP	0.15	0.46	0.07	6.7			
		DINP	0.60	0.21	0.13	12.2			
	95	DBP	0.84	1	0.84	20.7	4.06	517	5.8%
		DEHP	1.37	0.84	1.15	28.3			
		BBP	0.41	0.52	0.21	5.2			
		DIBP	0.46	0.53	0.24	6.0			
		DINP	7.70	0.21	1.62	39.8			
SES: Below Poverty Level (n = 1,056)	50	DBP	0.21	1	0.21	22.0	0.955	2,199	1.4%
		DEHP	0.53	0.84	0.45	46.6			
		BBP	0.09	0.52	0.05	4.9			
		DIBP	0.20	0.53	0.11	11.1			
		DINP	0.70	0.21	0.15	15.4			
	95	DBP	0.82	1	0.82	18.2	4.50	467	6.4%
		DEHP	1.75	0.84	1.47	32.7			
		BBP	0.34	0.52	0.18	3.9			
		DIBP	0.51	0.53	0.27	6.0			
		DINP	8.40	0.21	1.76	39.2			

PUBLIC RELEASE DRAFT

May 2025

Race/ Socioeconomic Status (SES)	Percentile	Phthalate	Aggregate Daily Intake (µg/kg-day)	RPF	Aggregate Daily Intake in DBP Equivalents (µg/kg-day)	% Contribution to Cumulative Exposure	Cumulative Daily Intake (DBP Equivalents, µg/kg-day)	Cumulative MOE (POD = 2,100 µg/kg- day)	% Contribution to Risk Cup (Benchmark = 30) ^a
SES: At or Above Poverty Level (n = 354)	50	DBP	0.20	1.00	0.20	27.9	0.718	2,924	1.0%
		DEHP	0.31	0.84	0.26	36.3			
		BBP	0.06	0.52	0.03	4.3			
		DIBP	0.15	0.53	0.08	11.1			
		DINP	0.70	0.21	0.15	20.5			
	95	DBP	0.48	1.00	0.48	16.3	2.94	713	4.2%
		DEHP	1.07	0.84	0.90	30.5			
		BBP	0.45	0.52	0.23	7.9			
		DIBP	0.65	0.53	0.34	11.7			
		DINP	4.70	0.21	0.99	33.5			
SES: Unknown (n =210)	50	DBP	0.26	1.00	0.26	23.2	1.12	1,870	1.6%
		DEHP	0.67	0.84	0.56	50.1			
		BBP	0.06	0.52	0.03	2.8			
		DIBP	0.23	0.53	0.12	10.9			
		DINP	0.70	0.21	0.15	13.1			
	95	DBP	0.60	1.00	0.60	25.5	2.35	893	3.4%
		DEHP	0.86	0.84	0.72	30.7			
		BBP	0.21	0.52	0.11	4.6			
		DIBP	0.35	0.53	0.19	7.9			
		DINP	3.50	0.21	0.74	31.2			

^a A cumulative exposure of 70 µg DBP equivalents/kg-day would result in a cumulative MOE of 30 (i.e., 2,100 µg DBP-equivalents/kd-day ÷ 70 µg DBP equivalents/kg-day = 30), which is equivalent to the benchmark of 30, indicating that the exposure is at the threshold for risk. Therefore, to estimate the percent contribution to the risk cup, the cumulative exposure expressed in DBP equivalents is divided by 70 µg DBP equivalents/kg-day to estimate percent contribution to the risk cup.

PUBLIC RELEASE DRAFT
May 2025






Figure 4-2. Percent Contribution to Cumulative Exposure for DEHP, DBP, BBP, DIBP, and DINP for Women of Reproductive Age (16 to 49 years) in 2017–2018 NHANES, Stratified by Race

1788
1789
1790



1791
1792 **Figure 4-3. Percent Contribution to Cumulative Exposure for DEHP, DBP, BBP, DIBP, and DINP for Women of Reproductive Age**
1793 **(16 to 49 years) in 2017–2018 NHANES, Stratified by Socioeconomic Status**



1794
1795
1796

Figure 4-4. Percent Contribution to Cumulative Exposure for DEHP, DBP, BBP, DIBP, and DINP for Male Children Ages 3 to 5, 6 to 11, and 12 to 15 years in 2017–2018 NHANES

5 CONCLUSION AND NEXT STEPS

EPA's draft 2023 approach ([U.S. EPA, 2023b](#)) laid out a multi-step method and conceptual model for assessing cumulative risk, with the final two steps in EPA's draft conceptual model as follows:

- Estimate cumulative exposure by combining exposures from TSCA COUs from individual phthalates (scaled by relative potency and expressed in index chemical (DBP) equivalents) with the relevant non-attributable cumulative exposures to estimate cumulative exposure in a reasonable manner for consumers and workers.
- Estimate cumulative risk for each specific exposure scenario by calculating a cumulative MOE that can in turn be compared to the benchmark MOE.

As described in Section 1.6, the SACC specifically expressed concern about combining estimates from individual assessments that represent a mix of deterministic and probabilistic methods as well as differing tiers of analyses (*i.e.* screening through more refined approaches) ([U.S. EPA, 2023b](#)). In Section 3.1, EPA explored the potential for co-exposures in occupational settings but concluded it would not be feasible to provide a robust multichemical quantitative assessment due to the wide range of plausible exposure scenarios and instead calculated an option for deriving an OEV based on cumulative exposure and relative potency assumptions (Appendix E). EPA calculated the anticipated contribution to the risk cup from monitored concentrations of phthalates in dust, a key pathway for consumer exposure, in Section 3.2 and found the contribution to be a fraction of total exposure.

Therefore, EPA has authored this technical support document to support a cumulative risk analysis for each chemical substance by adding non-attributable cumulative phthalate exposure (from NHANES) to the relevant exposure scenarios for individual TSCA COUs. These risk estimates are estimated using the draft RPFs for phthalate syndrome based on the shared endpoint and pooled dataset for assessing fetal testicular testosterone health endpoint, as laid out in Section 1.1.

Sections 5.1 and 5.2 describe two options for how to apply this quantitative approach for evaluating cumulative risk resulting from aggregate exposure to a single phthalate from an exposure scenario or COU plus non-attributable cumulative risk from NHANES. The first option presented in Section 5.1 estimates cumulative risk by first scaling each individual phthalate exposure for a consumer or occupational COU by relative potency before combining with non-attributable cumulative exposure estimated using NHANES. In the second option presented in Section 5.2, individual phthalate exposures for consumer and occupational COUs are not scaled by relative potency factors but use the individual phthalate hazard values and are still combined with non-attributable cumulative exposures estimated using NHANES. Empirical examples of estimating cumulative risk for DCHP and DEHP using the first and second option are presented in Sections 5.1 and 5.2. Examples for DCHP and DEHP were chosen to demonstrate the varying impact of option 1 across different phthalates. Estimating cumulative risk using option 1 will have a large impact for DCHP, but no impact for DEHP because the individual DEHP POD is so much more sensitive than the index chemical (DBP) POD. Option 2 will have the same impact on cumulative risk estimates for every phthalates, resulting in cumulative risk estimates that are approximately 1.1x more sensitive for both DCHP and DEHP as shown in Section 5.2.

This quantitative approach will be used in each of the individual relevant phthalate risk evaluations. Section 5.3 discusses the anticipated impacts that the two options for this cumulative approach will have for each of the phthalates being evaluated under TSCA. Section 5.4 provides a comparison of the two options.

5.1 Estimation of Cumulative Risk – Option 1

As described above, EPA is focusing its exposure assessment for the cumulative risk analysis on evaluation of exposures through individual TSCA consumer and occupational COUs for each phthalate and non-attributable cumulative exposure to DEHP, DBP, BBP, DIBP, and DINP using NHANES urinary biomonitoring data and reverse dosimetry. To estimate cumulative risk, EPA first scaled each individual phthalate exposure by relative potency using the RPFs presented in Table 2-4 to express phthalate exposure in terms of index chemical (DBP) equivalents. Exposures from individual consumer or worker COUs/OES (occupational exposure scenario) were then combined with non-attributable exposures estimated from NHANES biomonitoring data to estimate cumulative risk. Cumulative risk was estimated using the four-step process outlined below, along with two empirical examples of how EPA calculated cumulative risk for one occupational OES for DCHP (*i.e.*, Application of Paints and Coatings (Solids)) and one occupational OES for DEHP (*i.e.*, Recycling). Empirical Examples for DCHP and DEHP are also shown in Table 5-1 and Table 5-2, respectively, where they are compared against option 2. Figure 5-1 and Figure 5-2 provide visual representations of the risk cup associated with the example calculations.

Step 1: Convert Exposure Estimates for the Individual Phthalate from Each Individual Consumer and Occupational COU to Index Chemical Equivalents

In this step, acute duration exposure estimates for an individual phthalate from each consumer and occupational COU/OES are scaled by relative potency and expressed in terms of index chemical (DBP) equivalents using Equation 5-1. This step is repeated for all individual exposure estimates for each route of exposure being assessed for each COU (*i.e.*, inhalation, dermal, and aggregate exposures for occupational COUs; inhalation, ingestion, dermal, and aggregate exposure for consumer COUs).

Equation 5-1. Scaling Phthalate Exposures by Relative Potency

$$\text{Phthalate Exposure (in DBP equivalents)} = AD_{\text{Route } 1} \times RPF_{\text{Phthalate}}$$

Where:

- Phthalate exposure is the acute exposure for a given route of exposure for an individual phthalate from a single occupational or consumer COU expressed in terms of $\mu\text{g}/\text{kg}$ index chemical (DBP) equivalents.
- $AD_{\text{Route } 1}$ is the acute dose in $\mu\text{g}/\text{kg}$ from a given route of exposure from a single occupational or consumer COU/OES.
- $RPF_{\text{Phthalate}}$ is the relative potency factor (unitless) for each respective phthalate (Table 2-4).

Example (DCHP): 50th percentile inhalation and dermal DCHP exposures for female workers of reproductive age are 38.7 and 2.07 $\mu\text{g}/\text{kg}$ for the Application of Paints and Coatings (Solids) OES ([U.S. EPA, 2024o](#)). Using Equation 5-1, inhalation, dermal, and aggregate DCHP exposures for this OES can be scaled by relative potency to 64.24, 3.44, and 67.68 $\mu\text{g}/\text{kg}$ DBP equivalents, respectively (Table 5-1).

$$DCHP_{\text{Inhalation-COU}} = 64.24 \mu\text{g}/\text{kg DBP equivalents} = 38.7 \mu\text{g}/\text{kg DCHP} \times 1.66$$

$$DCHP_{\text{Dermal-COU}} = 3.44 \mu\text{g}/\text{kg DBP equivalents} = 2.07 \mu\text{g}/\text{kg DCHP} \times 1.66$$

$$\begin{aligned} DCHP_{\text{Aggregate-COU}} &= 67.68 \mu\text{g}/\text{kg DBP equivalents} \\ &= (2.07 \mu\text{g}/\text{kg DCHP} + 38.7 \mu\text{g}/\text{kg DCHP}) \times 1.66 \end{aligned}$$

Example (DEHP): 50th percentile inhalation and dermal DEHP exposures for female workers of reproductive age are 38.7 and 2.07 $\mu\text{g}/\text{kg}$ for the Recycling OES (U.S. EPA, 2025I). Using Equation 5-1, inhalation, dermal, and aggregate DEHP exposures for this OES can be scaled by relative potency to 39.0, 1.96, and 40.9 $\mu\text{g}/\text{kg}$ DBP equivalents, respectively (Table 5-2).

$$DEHP_{Inhalation-COU} = 39.0 \mu\text{g}/\text{kg DBP equivalents} = 46.9 \mu\text{g}/\text{kg DEHP} \times 0.83$$

$$DEHP_{Dermal-COU} = 1.96 \mu\text{g}/\text{kg DBP equivalents} = 2.36 \mu\text{g}/\text{kg DEHP} \times 0.83$$

$$DEHP_{Aggregate-COU} = 40.9 \mu\text{g}/\text{kg DBP equivalents} \\ = (46.9 \mu\text{g}/\text{kg DEHP} + 2.36 \mu\text{g}/\text{kg DEHP}) \times 0.83$$

Step 2: Estimate Non-attributable Cumulative Exposure to DEHP, DBP, BBP, DIBP, and DINP Using NHANES Urinary Biomonitoring Data and Reverse Dosimetry (see Section 4 for further details)

Non-attributable exposure for a national population to DEHP, DBP, BBP, DIBP, and DINP was estimated using Equation 5-2, where individual phthalate daily intake values estimated from NHANES biomonitoring data and reverse dosimetry were scaled by relative potency, expressed in terms of index chemical (DBP) equivalents, and summed to estimate non-attributable cumulative exposure in terms of DBP equivalents. Equation 5-2 was used to calculate the cumulative exposure estimates provided in Table 4-2 and Table 4-3.

Equation 5-2. Estimating Non-attributable Cumulative Exposure to DEHP, DBP, BBP, DIBP, and DINP

$$\begin{aligned} \text{Cumulative Exposure (Non - attributable)} \\ = (DI_{DEHP} \times RPF_{DEHP}) + (DI_{DBP} \times RPF_{DBP}) + (DI_{BBP} \times RPF_{BBP}) \\ + (DI_{DIBP} \times RPF_{DIBP}) + (DI_{DINP} \times RPF_{DINP}) \end{aligned}$$

Where:

- Cumulative exposure (non-attributable) is expressed in index chemical (DBP) equivalents ($\mu\text{g}/\text{kg}\text{-day}$).
- DI is the daily intake value ($\mu\text{g}/\text{kg}\text{-day}$) for each phthalate that was calculated using NHANES urinary biomonitoring data and reverse dosimetry (DI values for each phthalate for each assessed population are provided in Table 4-2 and Table 4-3).
- RPF is the relative potency factor (unitless) for each phthalate from Table 2-4.

Example: The 95th percentile cumulative exposure estimate of 5.16 $\mu\text{g}/\text{kg}\text{-day}$ DBP equivalents for black, non-Hispanic women of reproductive age (Table 4-3) is calculated using Equation 5-2 as follows:

$$\begin{aligned} 5.16 \mu\text{g}/\text{kg DBP equivalents} \\ = (4.28 \mu\text{g}/\text{kg DEHP} \times 0.84) + (0.48 \mu\text{g}/\text{kg DBP} \times 1) + (0.30 \mu\text{g}/\text{kg BBP} \times 0.52) \\ + (0.40 \mu\text{g}/\text{kg DIBP} \times 0.53) + (3.40 \mu\text{g}/\text{kg DINP} \times 0.21) \end{aligned}$$

Step 3: Calculate MOEs for Each Exposure to the Individual Phthalate and for the Non-attributable Cumulative Exposure

Next, MOEs are calculated for each exposure of interest that is included in the cumulative scenario using Equation 5-3. For example, this step involves calculating MOEs for inhalation and dermal phthalate exposures expressed in index chemical equivalents for each individual COU/OES in step 1 and an MOE for non-attributable cumulative phthalate exposure from step 2 above.

Equation 5-3. Calculating MOEs for Exposures of Interest for use in the RPF and Cumulative Approaches

$$MOE_1 = \frac{\text{Index Chemical (DBP) POD}}{\text{Exposure}_1 \text{ in DBP Equivalents}}$$

Where:

- MOE₁ (unitless) is the MOE calculated for each exposure of interest included in the cumulative scenario.
- Index chemical (DBP) POD is the POD selected for the index chemical, DBP. The index chemical POD is 2,100 µg/kg (Section 2.3).
- Exposure₁ is the exposure estimate in DBP equivalents for the pathway of interest (*i.e.*, from step 1 or 2 above).

Example (DCHP): Using Equation 5-3, the MOEs for inhalation and dermal DCHP exposure estimates for the Application of Paints and Coatings (Solids) OES in DBP equivalents from step 1 and the MOE for the non-attributable cumulative exposure estimate in DBP equivalents from step 2, are 33, 610, and 407, respectively (Table 5-1).

$$MOE_{\text{Cumulative Non-attributable}} = 407 = \frac{2,100 \mu\text{g/kg}}{5.16 \mu\text{g/kg}}$$

$$MOE_{\text{COU-Inhalation}} = 32.7 = \frac{2,100 \mu\text{g/kg}}{64.2 \mu\text{g/kg}}$$

$$MOE_{\text{COU-Dermal}} = 610 = \frac{2,100 \mu\text{g/kg}}{3.44 \mu\text{g/kg}}$$

Example (DEHP): Using Equation 5-3, the MOEs for inhalation and dermal DEHP exposure estimates for the Recycling OES in DBP equivalents from step 1 and the MOE for the non-attributable cumulative exposure estimate in DBP equivalents from step 2, are 54, 1,072, and 407, respectively (Table 5-2).

$$MOE_{\text{Cumulative Non-attributable}} = 407 = \frac{2,100 \mu\text{g/kg}}{5.16 \mu\text{g/kg}}$$

$$MOE_{\text{COU-Inhalation}} = 54 = \frac{2,100 \mu\text{g/kg}}{39.0 \mu\text{g/kg}}$$

$$MOE_{\text{COU-Dermal}} = 1,072 = \frac{2,100 \mu\text{g/kg}}{1.96 \mu\text{g/kg}}$$

Step 4: Calculate the Cumulative MOE

For the cumulative MOE approach, MOEs for each exposure of interest in the cumulative scenario are first calculated (Step 3). The cumulative MOE for the cumulative scenario can then be calculated using Equation 5-4. Equation 5-4 shows the addition of MOEs for the inhalation and dermal exposures routes from an individual COU, as well as the MOE for non-attributable cumulative exposure to phthalates from NHANES urinary biomonitoring and reverse dosimetry. Additional MOEs can be added to the equation as necessary (e.g., for the ingestion route for consumer scenarios).

Equation 5-4. Cumulative Margin of Exposure Calculation

$$Cumulative\ MOE = \frac{1}{\frac{1}{MOE_{COU-Inhalation}} + \frac{1}{MOE_{COU-Dermal}} + \frac{1}{MOE_{Cumulative-Non-attributable}} \dots}$$

Example (DCHP): The cumulative MOE for the Application of Paints and Coatings (Solids) OES is 28.9 and is calculated by summing the MOEs for each exposure of interest from step 3 as follows (Table 5-1):

$$Cumulative\ MOE = 28.9 = \frac{1}{\frac{1}{32.7} + \frac{1}{610} + \frac{1}{407}}$$

Example (DEHP): The cumulative MOE for the Recycling OES is 46 and is calculated by summing the MOEs for each exposure of interest from step 3 as follows (Table 5-2):

$$Cumulative\ MOE = 46 = \frac{1}{\frac{1}{54} + \frac{1}{1072} + \frac{1}{407}}$$

5.2 Estimation of Cumulative Risk – Option 2

As described above, EPA is focusing its exposure assessment for the cumulative risk analysis on evaluation of exposures through individual TSCA consumer and occupational COUs for each phthalate and non-attributable cumulative exposure to DEHP, DBP, BBP, DIBP, and DINP using NHANES urinary biomonitoring data and reverse dosimetry. In Section 5.1, EPA presented an option for estimating cumulative risk by first scaling each individual phthalate exposure by relative potency using the RPFs presented in Table 2-4 to express phthalate exposure in terms of index chemical (DBP) equivalents. Exposures from individual consumer or worker COUs/OES (occupational exposure scenario) were then combined with non-attributable cumulative exposures estimated using NHANES to estimate cumulative risk under TSCA. In this second option, individual phthalate exposures for consumer and occupational COUs are not scaled by relative potency factors but use the individual phthalate hazard values and are still combined with non-attributable cumulative exposures estimated using NHANES.

The four-step process for the Option 2 is outlined below, along with two empirical examples of how EPA calculated cumulative risk for one occupational OES for DCHP (i.e., Application of Paints and Coatings (Solids)) and one occupational OES for DEHP (i.e., Recycling). Empirical examples for DCHP and DEHP are also shown in Table 5-1 and Table 5-2, respectively, where they are compared against Option 1. Figure 5-1 and Figure 5-2 provide visual representations of the risk cup associated with the

2017 example calculations. Section 5.4 compares the differences in the risk estimates between the two
2018 options.

2019
2020
2021 **Step 1: Identify Exposure Estimates for the Individual Phthalate from Each Individual Consumer**
2022 **and Occupational COU to be used for the Cumulative Risk Estimate**

2023 In this step, acute duration exposure estimates for an individual phthalate from each consumer and
2024 occupational COU/OES are identified for use in the cumulative risk estimate, including exposure
2025 estimates for each route of exposure being assessed for each COU (*i.e.*, inhalation, dermal, and
2026 aggregate exposures for occupational COUs; inhalation, ingestion, dermal, and aggregate exposure for
2027 consumer COUs). Unlike in Option 1, however, these estimates are not scaled by relative potency and
2028 instead remain in dose units of the individual phthalate.

2029
2030 Example (DCHP): 50th percentile inhalation and dermal DCHP exposures for female workers of
2031 reproductive age are 38.7 and 2.07 $\mu\text{g}/\text{kg}$ for the Application of Paints and Coatings (Solids) OES ([U.S.](#)
2032 [EPA, 2024o](#)) and the aggregate exposure combining inhalation and dermal exposure is 40.7 $\mu\text{g}/\text{kg}$
2033 (Table 5-1).

2034
2035 Example (DEHP): 50th percentile inhalation and dermal DEHP exposures for female workers of
2036 reproductive age are 46.9 and 2.36 $\mu\text{g}/\text{kg}$ for the Recycling OES ([U.S. EPA, 2025l](#)) and the aggregate
2037 exposure combining inhalation and dermal exposure is 49.3 $\mu\text{g}/\text{kg}$ (Table 5-2).

2038
2039
2040 **Step 2: Estimate Non-attributable Cumulative Exposure to DEHP, DBP, BBP, DIBP, and DINP**
2041 **Using NHANES Urinary Biomonitoring Data and Reverse Dosimetry (see Section 4 for further**
2042 **details)**

2043 The step is identical to Step 2 shown for Option 1 in Section 5.1, where non-attributable exposure for a
2044 national population to DEHP, DBP, BBP, DIBP, and DINP was estimated using Equation 5-2, where
2045 individual phthalate daily intake values estimated from NHANES biomonitoring data and reverse
2046 dosimetry were scaled by relative potency, expressed in terms of index chemical (DBP) equivalents, and
2047 summed to estimate non-attributable cumulative exposure in terms of DBP equivalents. As shown in the
2048 example in Step 2 in Section 5.1, the 95th percentile cumulative exposure estimate of 5.16 $\mu\text{g}/\text{kg}\text{-day}$
2049 DBP equivalents for black, non-Hispanic women of reproductive age (Table 4-3) is calculated using
2050 Equation 5-2.

2051
2052
2053 **Step 3: Calculate MOEs for Each Exposure to the Individual Phthalate and for the Non-**
2054 **attributable Cumulative Exposure**

2055 Next, MOEs are calculated for each exposure of interest that is included in the cumulative scenario
2056 using Equation 5-5 and Equation 5-6. In Option 2, inhalation and dermal phthalate exposures for
2057 individual COU/OES are not scaled by the RPF so MOEs for individual phthalates are calculated using
2058 the individual phthalate PODs as shown in Equation 5-5.

2059
2060 For example, this step involves calculating MOEs for inhalation and dermal phthalate exposures for
2061 each individual COU/OES in step 1 using PODs for the given phthalates and an MOE for non-
2062 attributable cumulative phthalate exposure expressed in DBP equivalents from step 2 above using the
2063 DBP POD.

2065 **Equation 5-5. Calculating MOEs for Exposures of Interest for Option 2**
2066

$$2067 \quad MOE_1 = \frac{\text{Individual Chemical POD}}{\text{Individual Chemical Exposure}}$$

2068 Where:

- 2069 • MOE_1 (unitless) is the MOE calculated for each exposure of interest included in the cumulative
2070 scenario.
- 2071 • Individual chemical POD is the POD selected for the individual phthalate. The POD for DCHP is
2072 2,400 $\mu\text{g}/\text{kg}$ (Section 2.3).
- 2073 • Individual chemical exposure is the exposure estimate from the COU/OES in units $\mu\text{g}/\text{kg}$ for the
2074 individual chemical (not converted to index chemical equivalents).

2075
2076 **Equation 5-6. Calculating MOE for Non-Attributable Exposure from NHANES**
2077

$$2078 \quad MOE_{NHANES} = \frac{\text{Index Chemical (DBP) POD}}{\text{Exposures}_{NHANES} \text{ in DBP Equivalents}}$$

2079 Where:

- 2080 • MOE_{NHANES} (unitless) is the MOE calculated for the exposure estimate in DBP equivalents for
2081 the non-attributable exposure estimated from NHANES.
- 2082 • Index chemical (DBP) POD is the POD selected for the index chemical, DBP. The index
2083 chemical POD is 2,100 $\mu\text{g}/\text{kg}$ (Section 2.3).
- 2084 • $\text{Exposures}_{NHANES}$ is the exposure estimate in DBP equivalents for the non-attributable exposure
2085 estimated from NHANES (*i.e.*, from step 2 above).

2086
2087 Example (DCHP): Using Equation 5-5, the 50th percentile MOEs for inhalation, dermal, and aggregate
2088 DCHP exposure estimates for the Application of Paints and Coatings (Solids) OES are 62, 1157, and 59,
2089 respectively Table 5-1.

2090
2091 Using Equation 5-6, the MOE for the non-attributable cumulative exposure estimate in DBP equivalents
2092 is 407.

$$2093 \quad MOE_{\text{Cumulative Non-attributable}} = 407 = \frac{2,100 \mu\text{g}/\text{kg}}{5.16 \mu\text{g}/\text{kg}}$$

$$2094 \quad MOE_{\text{COU-Inhalation}} = 62 = \frac{2,400 \mu\text{g}/\text{kg}}{38.7 \mu\text{g}/\text{kg}}$$

$$2095 \quad MOE_{\text{COU-Dermal}} = 1,157 = \frac{2,400 \mu\text{g}/\text{kg}}{2.07 \mu\text{g}/\text{kg}}$$

$$2096 \quad MOE_{\text{COU-Aggregate}} = 59 = \frac{2,400 \mu\text{g}/\text{kg}}{40.7 \mu\text{g}/\text{kg}}$$

2100
2101 Example (DEHP): Using Equation 5-5, the 50th percentile MOEs for inhalation, dermal, and aggregate
2102 DCHP exposure estimates for the Recycling OES are 23, 466, and 22, respectively Table 5-2.
2103

2104 Using Equation 5-6, the MOE for the non-attributable cumulative exposure estimate in DBP equivalents
2105 is 407.

$$2106 \quad MOE_{Cumulative\ Non-attributable} = 407 = \frac{2,100\ \mu g/kg}{5.16\ \mu g/kg}$$

$$2107 \quad$$
$$2108 \quad MOE_{COU-Inhalation} = 23 = \frac{1,100\ \mu g/kg}{46.9\ \mu g/kg}$$

$$2109 \quad$$
$$2110 \quad MOE_{COU-Dermal} = 466 = \frac{1,100\ \mu g/kg}{2.36\ \mu g/kg}$$

$$2111 \quad$$
$$2112 \quad MOE_{COU-Aggregate} = 22 = \frac{1,100\ \mu g/kg}{49.3\ \mu g/kg}$$

2113
2114

2115 **Step 4: Calculate the Cumulative MOE**

2116 For the cumulative MOE approach, MOEs for each exposure of interest in the cumulative scenario are
2117 first calculated (Step 3). The cumulative MOE for the cumulative scenario can then be calculated using
2118 Equation 5-7. Equation 5-7 shows the addition of MOEs for the inhalation and dermal exposures routes
2119 from an individual COU, as well as the MOE for non-attributable cumulative exposure to phthalates
2120 from NHANES urinary biomonitoring and reverse dosimetry. Additional MOEs can be added to the
2121 equation as necessary (e.g., for the ingestion route for consumer scenarios).

2122 **Equation 5-7. Cumulative Margin of Exposure Calculation**

$$2123 \quad$$
$$2124 \quad Cumulative\ MOE = \frac{1}{\frac{1}{MOE_{COU-Inhalation}} + \frac{1}{MOE_{COU-Dermal}} + \frac{1}{MOE_{Cumulative-Non-attributable}} \dots}$$

2125

2126 Example (DCHP): The cumulative MOE for the Application of Paints and Coatings (Solids) OES is 51
2127 and is calculated by summing the MOEs for each exposure of interest from step 3 as follows (Table
2128 5-1):

2129

$$2130 \quad Cumulative\ MOE = 51 = \frac{1}{\frac{1}{62} + \frac{1}{1157} + \frac{1}{407}}$$

2131

2132 Example (DEHP): The cumulative MOE for the Recycling OES is 21 and is calculated by summing the
2133 MOEs for each exposure of interest from step 3 as follows (Table 5-2):

2134

$$2135 \quad Cumulative\ MOE = 21 = \frac{1}{\frac{1}{23} + \frac{1}{466} + \frac{1}{407}}$$

2136

5.3 Anticipated Impact of the Cumulative Analysis on Phthalates being Evaluated Under TSCA Under Option 1 and Option 2

5.3.1 Anticipated Impact of the Cumulative Analysis on Phthalates being Evaluated Under TSCA Using Option 1

The cumulative analysis approach outlined in Section 5.1 is being used by EPA to supplement the individual phthalate risk evaluations. The cumulative analysis approach will have varying impacts on each of the individual phthalate risk evaluations and will be influenced by three key factors. This includes: (1) scaling individual phthalate acute exposure estimates for each COU/OES by relative potency; (2) calculation of the cumulative MOE using the index chemical POD; and (3) addition of non-attributable cumulative exposure from NHANES. The overall effect of these three factors for each phthalate being evaluated under TSCA is summarized in Table 5-3 and is discussed further in Section 5.3.1.1 through Section 5.3.1.6.

5.3.1.1 Dibutyl Phthalate (DBP)

Application of the cumulative analysis outlined in Section 5.1 will have a small overall effect for DBP. Cumulative risk estimates will be approximately 1.1x more sensitive than in the individual DBP risk evaluation (Table 5-3). This preliminary conclusion is based on the following considerations:


- **Scaling by Relative Potency.** DBP is the index chemical and the RPF for DBP is 1 (Table 2-4). Scaling by relative potency will have no effect on scaled exposure estimates.
- **Index Chemical POD.** EPA selected the same POD of 2.1 mg/kg-day based on the BMDL₅ for reduced fetal testicular testosterone as the acute POD for the individual DBP risk evaluation ([U.S. EPA, 2024e](#)) and as the index chemical POD for use in the CRA (Section 2.3), so this also will have no effect.
- **Addition of Non-Attributable Cumulative Exposure.** This will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4). This is the only factor that will contribute to the slightly more sensitive cumulative risk estimates for DBP.



5.3.1.2 Dicyclohexyl Phthalate (DCHP)

Application of the cumulative analysis outlined in Section 5.1 will lead to risk estimates that are approximately 2x to 2.2x more sensitive (Table 5-3). This preliminary conclusion is based on the following considerations:

- **Scaling by Relative Potency.** The RPF for DCHP is 1.66 (Table 2-4). This means acute DCHP exposures when multiplied by the RPF and expressed in terms of index chemical (DBP) equivalents will increase by 66 percent, which will be the primary factor contributing to the more sensitive risk estimates.



- **Index Chemical POD.** The POD for the index chemical (DBP) used to calculate cumulative risk is 2.1 mg/kg (Section 2.3), while the acute POD for DCHP used to calculate MOEs in the individual DCHP risk evaluation is 2.4 mg/kg ([U.S. EPA, 2024g](#)). The index chemical (DBP) POD is 12.5 percent lower (*i.e.*, more sensitive) than the individual DCHP POD, which will contribute to the more sensitive risk estimates.




- **Addition of Non-Attributable Cumulative Exposure.** This will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4) and will contribute to the more sensitive risk estimates.



5.3.1.3 Diisobutyl Phthalate (DIBP)

Application of the cumulative analysis outlined in Section 5.1 will lead to risk estimates that are approximately 1.5x to 1.7x more sensitive (Table 5-3). This preliminary conclusion is based on the following considerations:


- **Scaling by Relative Potency.** The RPF for DIBP is 0.53 (Table 2-4). This means acute DIBP exposures when multiplied by the RPF and expressed in terms of index chemical (DBP) equivalents will decrease by a factor of approximately 2.



- **Index Chemical POD.** The POD for the index chemical (DBP) used to calculate cumulative risk is 2.1 mg/kg (Section 2.3), while the acute POD for DIBP used to calculate MOEs in the individual DIBP risk evaluation is 5.7 mg/kg ([U.S. EPA, 2024i](#)). The index chemical (DBP) POD is 2.7 times lower (*i.e.*, more sensitive) than the DIBP POD, which will contribute to lower cumulative MOEs.

POD ↓ MOE ↓

- **Addition of Non-Attributable Cumulative Exposure.** This will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4) and will contribute to the more sensitive risk estimates.



5.3.1.4 Butyl Benzyl Phthalate (BBP)

Application of the cumulative analysis outlined in Section 5.1 will lead to risk estimates that are approximately 3.2x to 3.5x more sensitive (Table 5-3). This preliminary conclusion is based on the following considerations:

- **Scaling by Relative Potency.** The RPF for BBP is 0.52 (Table 2-4). This means acute BBP exposures when multiplied by the RPF and expressed in terms of index chemical (DBP) equivalents will decrease by a factor of approximately 2.



- **Index Chemical POD.** The POD for the index chemical (DBP) used to calculate cumulative risk is 2.1 mg/kg (Section 2.3), while the acute POD for BBP used to calculate MOEs in the individual BBP risk evaluation is 12 mg/kg. The index chemical (DBP) POD is 5.7 times lower (*i.e.*, more sensitive) than the BBP POD, which will contribute to lower cumulative MOEs.

POD ↓ MOE ↓


- **Addition of Non-Attributable Cumulative Exposure.** This will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4) and will contribute to the more sensitive risk estimates.



5.3.1.5 Diisononyl Phthalate (DINP)

Application of the cumulative analysis outlined in Section 5.1 will lead to risk estimates that are approximately 1.3x to 1.4x more sensitive (Table 5-3). This preliminary conclusion is based on the following considerations:

- **Scaling by Relative Potency.** The RPF for DINP is 0.21 (Table 2-4). This means acute DINP exposures when multiplied by the RPF and expressed in terms of index chemical (DBP) equivalents will decrease by a factor of approximately 5.



- **Index Chemical POD.** The POD for the index chemical (DBP) used to calculate cumulative risk is 2.1 mg/kg (Section 2.3), while the acute POD for DINP used to calculate MOEs in the individual DINP risk evaluation is 12 mg/kg. The index chemical (DBP) POD is 5.7 times lower (*i.e.*, more sensitive) than the DINP POD, which will contribute to lower cumulative MOEs.




- **Addition of Non-Attributable Cumulative Exposure.** This will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4) and will contribute to the more sensitive risk estimates.



5.3.1.6 Diethylhexyl Phthalate (DEHP)

Application of the cumulative analysis outlined in Section 5.1 will lead to risk estimates that are less sensitive than in the individual DEHP risk evaluation (Table 5-1). This is because DEHP is data-rich and the POD used for the individual chemical assessment based on male reproductive tract malformations is more sensitive than the index chemical POD, which washes out the addition of the non-attributable cumulative exposure. This preliminary conclusion is based on the following considerations:

- **Scaling by Relative Potency.** The RPF for DEHP is 0.84 (Table 2-4). This means acute DEHP exposures when multiplied by the RPF and expressed in terms of index chemical (DBP) equivalents will decrease by 16 percent.



- **Index Chemical POD.** The POD for the index chemical (DBP) used to calculate cumulative risk is 2.1 mg/kg (Section 2.3), while the acute POD for DEHP used to calculate MOEs in the individual DEHP risk evaluation is 1.1 mg/kg. The index chemical (DBP) POD is 1.9 times higher (*i.e.*, less sensitive) than the DEHP POD, which will contribute to less sensitive cumulative MOEs.



- **Addition of Non-Attributable Cumulative Exposure.** This will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4) and will contribute to the more sensitive risk estimates.



5.3.2 Anticipated Impact of the Cumulative Analysis on Phthalates being Evaluated Under TSCA Under Option 2

The cumulative analysis approach outlined in Section 5.2 is another possible option for EPA to supplement the individual phthalate risk evaluations. Unlike the first option outlined in Section 5.1, which has varying impacts on the cumulative risk estimates for each of the individual phthalate risk evaluations as described in Section 5.3.1 based on the relative potency factors, the second option has the same impact on cumulative risk estimates for every phthalate being evaluated under TSCA. The only impact of option 2 is the addition of non-attributable cumulative exposure from NHANES to individual phthalate exposures, which will add 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4). Option 2 will have a small overall effect for DBP, DCHP, DIBP, BBP, DINP, and DEHP. Cumulative risk estimates for all phthalates will be approximately 1.1x more sensitive than in the individual phthalate risk evaluations (Table 5-3).

5.4 Comparison of Two Options for Estimating Cumulative Risk

There are several notable similarities and differences between the two options for estimating cumulative risk outlined above. First, both options utilize NHANES urinary biomonitoring data and reverse dosimetry to estimate non-attributable cumulative phthalate exposure expressed in index chemical (DBP) equivalents which will contribute 6.2 to 15.5 percent to the risk cup, depending on the population and lifestage being assessed (Table 5-4).

2295 A key difference between options 1 and 2 is how individual phthalate exposures from TSCA COUs are
2296 handled. For option 1, individual phthalate exposures from TSCA COUs are scaled by relative potency
2297 and expressed in terms of index chemical equivalents, which are then used to calculate an MOE using
2298 the index chemical POD. As discussed above in Section 5.3.1, scaling by relative potency and using the
2299 index chemical POD to calculate MOEs for individual phthalate exposures from TSCA COUs will have
2300 varying impacts on cumulative risk estimates across phthalates, with the largest impact for DCHP and
2301 BBP, and no impact for DEHP because the individual DEHP POD is so much more sensitive than the
2302 index chemical (DBP) POD. Comparatively, for option 2, individual phthalate exposures from TSCA
2303 COUs are not scaled by relative potency. Instead, individual phthalate exposures from TSCA COUs are
2304 used to calculate MOEs using the individual phthalate POD (not the index chemical POD), and these
2305 MOEs are combined with the non-attributable cumulative exposure MOE estimated using NHANES. A
2306 benefit of option 2 is that it will have the same impact on cumulative risk estimates for every phthalate
2307 being evaluated under TSCA (Section 5.3.2). That is, option 2 will result in cumulative risk estimates
2308 that are approximately 1.1x more sensitive than the risk estimates in the individual phthalate risk
2309 evaluations, including for DEHP, which is notable as option 1 will have no impact on risk
2310 characterization for DEHP. However, one source of uncertainty associated with option 2 is that it
2311 involves combining MOEs calculated using exposures expressed in different units, as non-attributable
2312 cumulative phthalate exposure is expressed in units of index chemical (DBP) equivalents, while
2313 exposures for individual phthalate exposures from TSCA COUs are not scaled by relative potency.


2314

Table 5-1. DCHP Risk Calculation Example for Female Workers of Reproductive Age

OES	Exposure Level	Acute MOEs From Individual DCHP Risk Evaluation (MOEs calculated by dividing the DCHP POD in µg/kg by DCHP exposure in µg/kg) ^a (Benchmark = 30)			Acute MOEs From Individual DCHP Risk Evaluation Scaled by Relative Potency (MOEs calculated by dividing the index chemical (DBP) POD in µg/kg by the DCHP exposure scaled by relative potency (RPF = 1.66) and expressed in µg/kg index chemical equivalents) ^a (Benchmark = 30)			Cumulative Non-Attributable MOE (NHANES) (MOEs calculated by dividing the index chemical (DBP) POD in µg/kg by the non-attributable cumulative exposure expressed in µg/kg index chemical equivalents) (Benchmark = 30)	Option 1: Cumulative MOE (Aggregate MOE + Cumulative Non-attributable MOE) (Benchmark = 30)	Option 2: Cumulative MOE (Aggregate MOE + Cumulative Non-attributable MOE) (Benchmark = 30)
		Inhalation MOE	Dermal MOE	Aggregate MOE	Inhalation MOE (DCHP COU)	Dermal MOE (DCHP COU)	Aggregate MOE (DCHP COU)			
Application of Paints and Coatings (Solids)	CT	62 (2,400/38.7)	1,157 (2,400/2.07)	59 (2,400/40.7)	33 (2,100/64.2)	610 (2,100/3.44)	31 (2,100/67.6)	407 (2,100/5.16)	29	51
	HE	3.5 (2,400/677)	579 (2,400/4.15)	3.5 (2,400/681)	1.9 (2,100/1,120)	305 (2,100/6.89)	1.9 (2,100/1,130)	407 (2,100/5.16)	1.8	3.5

^a Doses shown to three significant figures.

2315



2316
2317


Figure 5-1. DCHP Risk Calculation Generic Example (Not to Scale) for Female Workers of Reproductive Age

2318 **Table 5-2. DEHP Risk Calculation Example for Female Workers of Reproductive Age**

OES	Exposure Level	Acute MOEs From Individual DEHP Risk Evaluation (MOEs calculated by dividing the DEHP POD in µg/kg by DEHP exposure in µg/kg) ^a (Benchmark = 30)			Acute MOEs From Individual DEHP Risk Evaluation Scaled by Relative Potency (MOEs calculated by dividing the index chemical (DBP) POD in µg/kg by the DEHP exposure scaled by relative potency (RPF = 0.83) and expressed in µg/kg index chemical equivalents) ^a (Benchmark = 30)			Cumulative Non-Attributable MOE (NHANES) (MOEs calculated by dividing the index chemical (DBP) POD in µg/kg by the non-attributable cumulative exposure expressed in µg/kg index chemical equivalents) (Benchmark = 30)	Option 1: Cumulative MOE (Aggregate MOE + Cumulative Non-attributable MOE) (Benchmark = 30)	Option 2: Cumulative MOE (Aggregate MOE + Cumulative Non-attributable MOE) (Benchmark = 30)
		Inhalation MOE	Dermal MOE	Aggregate MOE	Inhalation MOE (DCHP COU)	Dermal MOE (DCHP COU)	Aggregate MOE (DCHP COU)			
Recycling	CT	23 (1,100/46.9)	466 (1,100/2.36)	22 (1,100/49.3)	54 (2,100/39.0)	1,072 (2,100/1.96)	51 (2,100/40.9)	407 (2,100/5.16)	46	21
	HE	15 (1,100/73.2)	233 (1,100/4.72)	14 (1,100/77.9)	35 (2,100/60.7)	536 (2,100/3.92)	32 (2,100/64.7)	407 (2,100/5.16)	30	14

^a Doses shown to three significant figures.

2319



2320
2321

Figure 5-2. DEHP Risk Calculation Generic Example (Not to Scale) for Female Workers of Reproductive Age

2322

Table 5-3. Summary of Impact of Cumulative Assessment on Phthalates Being Evaluated Under TSCA

Phthalate	Individual Phthalate Assessment			Cumulative Analysis			Option 1: Conclusions	Option 2: Conclusions
	Acute POD (mg/kg-day)	POD Type and Effect	Benchmark MOE	RPF	Index Chemical POD (mg/kg-day)	Cumulative Benchmark MOE		
DBP (index chemical)	2.1	BMDL ₅ (↓ fetal testicular testosterone)	30	1	2.1	30	Risk estimates will be ~1.1x more sensitive	Risk estimates will be ~1.1x more sensitive
DEHP	1.1	NOAEL (Phthalate syndrome-related effects)	30	0.84			Individual chemical assessment will be more sensitive based on slightly different endpoint	
BBP	12	NOAEL (Phthalate syndrome-related effects)	30	0.52			Risk estimates will be ~3.2x to 3.5x more sensitive	
DIBP	5.7	BMDL ₅ (↓ fetal testicular testosterone)	30	0.53			Risk estimates will be ~1.5x to 1.7x more sensitive	
DCHP	2.4	NOAEL (Phthalate syndrome-related effects)	30	1.66			Risk estimates will be ~2x to 2.2x more sensitive	
DINP	12	BMDL ₅ (↓ fetal testicular testosterone)	30	0.21			Risk estimates will be ~1.3x to 1.4x more sensitive	

2323

2324
2325

Table 5-4. Summary of Non-Attributable Cumulative Exposure From NHANES Being Combined for Each Assessed Population

Population	Lifestage	Non-Attributable Cumulative Exposure from NHANES (DBP Equivalents, µg/kg-day)	NHANES Population	% Contribution to Risk Cup
Worker	Women of reproductive age (16-49 years)	5.16	Black, non-Hispanic women of reproductive age (16-49 years)	7.4%
Consumer	Adult (≥21 years)			
	Teenager (16-20 years)			
	Young Teen (11-15 years)	4.36	Males (12-15 years)	6.2%
	Child (6-10 years)	7.35	Males (6-11 years)	10.5%
	Preschooler (3-5 years)	10.8	Males (3-5 years)	15.5%
	Toddler (1-2 years)			
Infant (<1 year)				

2326

REFERENCES

- 2327
- 2328 [Adham, IM; Emmen, JM; Engel, W. \(2000\)](#). The role of the testicular factor INSL3 in establishing the
2329 gonadal position [Review]. *Mol Cell Endocrinol* 160: 11-16.
2330 https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/10328887
- 2331 [Allen, BC; Kavlock, RJ; Kimmel, CA; Faustman, EM. \(1994a\)](#). Dose-response assessment for
2332 developmental toxicity II: Comparison of generic benchmark dose estimates with no observed
2333 adverse effect levels. *Fundam Appl Toxicol* 23: 487-495.
2334 <http://dx.doi.org/10.1006/faat.1994.1133>
- 2335 [Allen, BC; Kavlock, RJ; Kimmel, CA; Faustman, EM. \(1994b\)](#). Dose-response assessment for
2336 developmental toxicity III: statistical models. *Fundam Appl Toxicol* 23: 496-509.
2337 <http://dx.doi.org/10.1006/faat.1994.1134>
- 2338 [Anderson, WA; Castle, L; Hird, S; Jeffery, J; Scotter, MJ. \(2011\)](#). A twenty-volunteer study using
2339 deuterium labelling to determine the kinetics and fractional excretion of primary and secondary
2340 urinary metabolites of di-2-ethylhexylphthalate and di-iso-nonylphthalate. *Food Chem Toxicol*
2341 49: 2022-2029. <http://dx.doi.org/10.1016/j.fct.2011.05.013>
- 2342 [Anderson, WAC; Castle, L; Scotter, MJ; Massey, RC; Springall, C. \(2001\)](#). A biomarker approach to
2343 measuring human dietary exposure to certain phthalate diesters. *Food Addit Contam* 18: 1068-
2344 1074. <http://dx.doi.org/10.1080/02652030110050113>
- 2345 [Arzuaga, X; Walker, T; Yost, EE; Radke, EG; Hotchkiss, AK. \(2020\)](#). Use of the Adverse Outcome
2346 Pathway (AOP) framework to evaluate species concordance and human relevance of Dibutyl
2347 phthalate (DBP)-induced male reproductive toxicity. *Reprod Toxicol* 96: 445-458.
- 2348 [ATSDR. \(2022\)](#). Toxicological profile for di(2-ethylhexyl)phthalate (DEHP) [ATSDR Tox Profile].
2349 (CS274127-A). Atlanta, GA. <https://www.atsdr.cdc.gov/ToxProfiles/tp9.pdf>
- 2350 [Aylward, LL; Hays, SM; Zidek, A. \(2016\)](#). Variation in urinary spot sample, 24 h samples, and longer-
2351 term average urinary concentrations of short-lived environmental chemicals: implications for
2352 exposure assessment and reverse dosimetry. *J Expo Sci Environ Epidemiol* 27: 582-590.
2353 <http://dx.doi.org/10.1038/jes.2016.54>
- 2354 [Bi, C; Maestre, JP; Li, H; Zhang, G; Givehchi, R; Mahdavi, A; Kinney, KA; Siegel, J; Horner, SD; Xu,
2355 Y. \(2018\)](#). Phthalates and organophosphates in settled dust and HVAC filter dust of U.S. low-
2356 income homes: Association with season, building characteristics, and childhood asthma. *Environ*
2357 *Int* 121: 916-930. <http://dx.doi.org/10.1016/j.envint.2018.09.013>
- 2358 [Bi, X; Yuan, S; Pan, X; Winstead, C; Wang, Q. \(2015\)](#). Comparison, association, and risk assessment of
2359 phthalates in floor dust at different indoor environments in Delaware, USA. *J Environ Sci Health*
2360 *A Tox Hazard Subst Environ Eng* 50: 1428-1439.
2361 <http://dx.doi.org/10.1080/10934529.2015.1074482>
- 2362 [Biesterbos, JW; Dudzina, T; Delmaar, CJ; Bakker, MI; Russel, FG; von Goetz, N; Scheepers, PT;
2363 Roeleveld, N. \(2013\)](#). Usage patterns of personal care products: important factors for exposure
2364 assessment. *Food Chem Toxicol* 55: 8-17. <http://dx.doi.org/10.1016/j.fct.2012.11.014>
- 2365 [Boberg, J; Christiansen, S; Axelstad, M; Kledal, TS; Vinggaard, AM; Dalgaard, M; Nellesmann, C; Hass,
2366 U. \(2011\)](#). Reproductive and behavioral effects of diisononyl phthalate (DINP) in perinatally
2367 exposed rats. *Reprod Toxicol* 31: 200-209. <http://dx.doi.org/10.1016/j.reprotox.2010.11.001>
- 2368 [Boekelheide, K; Kleymenova, E; Liu, K; Swanson, C; Gaido, KW. \(2009\)](#). Dose-dependent effects on
2369 cell proliferation, seminiferous tubules, and male germ cells in the fetal rat testis following
2370 exposure to di(n-butyl) phthalate. *Microsc Res Tech* 72: 629-638.
2371 <http://dx.doi.org/10.1002/jemt.20684>
- 2372 [Bradley, EL; Burden, RA; Bentayeb, K; Driffield, M; Harmer, N; Mortimer, DN; Speck, DR; Ticha, J;
2373 Castle, L. \(2013\)](#). Exposure to phthalic acid, phthalate diesters and phthalate monoesters from

- 2374 foodstuffs: UK total diet study results. Food Addit Contam Part A Chem Anal Control Expo Risk
2375 Assess 30: 735-742. <http://dx.doi.org/10.1080/19440049.2013.781684>
- 2376 [Carruthers, CM; Foster, PMD. \(2005\)](#). Critical window of male reproductive tract development in rats
2377 following gestational exposure to di-n-butyl phthalate. Birth Defects Res B Dev Reprod Toxicol
2378 74: 277-285. <http://dx.doi.org/10.1002/bdrb.20050>
- 2379 [CDC. \(2013a\)](#). Fourth national report on human exposure to environmental chemicals, updated tables,
2380 September 2013. (CS244702-A). Atlanta, GA.
2381 http://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Sep2013.pdf
- 2382 [CDC. \(2013b\)](#). National Health and Nutrition Examination Survey: Sample design, 2007-2010. In Vital
2383 and Health Statistics: Series 2, Number 160. Atlanta, GA: U.S. Department of Health and
2384 Human Services.
- 2385 [Chi, C; Xia, M; Zhou, C; Wang, X; Weng, M; Shen, X. \(2017\)](#). Determination of 15 phthalate esters in
2386 air by gas-phase and particle-phase simultaneous sampling. J Environ Sci 55: 137-145.
2387 <http://dx.doi.org/10.1016/j.jes.2016.01.036>
- 2388 [Clark, KE; David, RM; Guinn, R; Kramarz, KW; Lampi, MA; Staples, CA. \(2011\)](#). Modeling human
2389 exposure to phthalate esters: A comparison of indirect and biomonitoring estimation methods.
2390 Hum Ecol Risk Assess 17: 923-965. <http://dx.doi.org/10.1080/10807039.2011.588157>
- 2391 [Clewell, RA; Campbell, JL; Ross, SM; Gaido, KW; Clewell HJ, III; Andersen, ME. \(2010\)](#). Assessing
2392 the relevance of in vitro measures of phthalate inhibition of steroidogenesis for in vivo response.
2393 Toxicol In Vitro 24: 327-334. <http://dx.doi.org/10.1016/j.tiv.2009.08.003>
- 2394 [Clewell, RA; Sochaski, M; Edwards, K; Creasy, DM; Willson, G; Andersen, ME. \(2013\)](#). Disposition of
2395 diisononyl phthalate and its effects on sexual development of the male fetus following repeated
2396 dosing in pregnant rats. Reprod Toxicol 35: 56-69.
2397 <http://dx.doi.org/10.1016/j.reprotox.2012.07.001>
- 2398 [Conley, JM; Lambright, CS; Evans, N; Cardon, M; Medlock-Kakaley, E; Wilson, VS; Gray, LE. \(2021\)](#).
2399 A mixture of 15 phthalates and pesticides below individual chemical no observed adverse effect
2400 levels (NOAELs) produces reproductive tract malformations in the male rat. Environ Int 156:
2401 106615. <http://dx.doi.org/10.1016/j.envint.2021.106615>
- 2402 [Culty, M; Thuillier, R; Li, W; Wang, Y; Martinez-Arguelles, D; Benjamin, C; Triantafilou, K; Zirkin, B;
2403 Papadopoulos, V. \(2008\)](#). In utero exposure to di-(2-ethylhexyl) phthalate exerts both short-term
2404 and long-lasting suppressive effects on testosterone production in the rat. Biol Reprod 78: 1018-
2405 1028. <http://dx.doi.org/10.1095/biolreprod.107.065649>
- 2406 [David, RM. \(2000\)](#). Exposure to phthalate esters [Letter]. Environ Health Perspect 108: A440.
2407 <http://dx.doi.org/10.1289/ehp.108-a440a>
- 2408 [Dodson, RE; Camann, DE; Morello-Frosch, R; Brody, JG; Rudel, RA. \(2015\)](#). Semivolatile organic
2409 compounds in homes: strategies for efficient and systematic exposure measurement based on
2410 empirical and theoretical factors. Environ Sci Technol 49: 113-122.
2411 <http://dx.doi.org/10.1021/es502988r>
- 2412 [EC/HC. \(2015\)](#). State of the science report: Phthalate substance grouping: Medium-chain phthalate
2413 esters: Chemical Abstracts Service Registry Numbers: 84-61-7; 84-64-0; 84-69-5; 523-31-9;
2414 5334-09-8;16883-83-3; 27215-22-1; 27987-25-3; 68515-40-2; 71888-89-6. Gatineau, Quebec:
2415 Environment Canada, Health Canada. [https://www.ec.gc.ca/ese-ees/4D845198-761D-428B-
2416 A519-75481B25B3E5/SoS_Phthalates%20%28Medium-chain%29_EN.pdf](https://www.ec.gc.ca/ese-ees/4D845198-761D-428B-A519-75481B25B3E5/SoS_Phthalates%20%28Medium-chain%29_EN.pdf)
- 2417 [ECCC/HC. \(2020\)](#). Screening assessment - Phthalate substance grouping. (En14-393/2019E-PDF).
2418 Environment and Climate Change Canada, Health Canada.
2419 [https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-
2420 substances/screening-assessment-phthalate-substance-grouping.html](https://www.canada.ca/en/environment-climate-change/services/evaluating-existing-substances/screening-assessment-phthalate-substance-grouping.html)
- 2421 [ExxonMobil. \(2022\)](#). EM BRCP DINP/DIDP facility – virtual tour (sanitized). Houston, TX.

- 2422 [Faustman, EM; Allen, BC; Kavlock, RJ; Kimmel, CA.](#) (1994). Dose-response assessment for
2423 developmental toxicity: I characterization of data base and determination of no observed adverse
2424 effect levels. *Fundam Appl Toxicol* 23: 478-486. <http://dx.doi.org/10.1006/faat.1994.1132>
- 2425 [Furr, JR; Lambright, CS; Wilson, VS; Foster, PM; Gray, LE, Jr.](#) (2014). A short-term in vivo screen
2426 using fetal testosterone production, a key event in the phthalate adverse outcome pathway, to
2427 predict disruption of sexual differentiation. *Toxicol Sci* 140: 403-424.
2428 <http://dx.doi.org/10.1093/toxsci/kfu081>
- 2429 [Gray, LE; Furr, J; Tatum-Gibbs, KR; Lambright, C; Sampson, H; Hannas, BR; Wilson, VS; Hotchkiss,](#)
2430 [A; Foster, PM.](#) (2016). Establishing the Biological Relevance of Dipentyl Phthalate Reductions
2431 in Fetal Rat Testosterone Production and Plasma and Testis Testosterone Levels. *Toxicol Sci*
2432 149: 178-191. <http://dx.doi.org/10.1093/toxsci/kfv224>
- 2433 [Gray, LE; Lambright, CS; Conley, JM; Evans, N; Furr, JR; Hannas, BR; Wilson, VS; Sampson, H;](#)
2434 [Foster, PMD.](#) (2021). Genomic and Hormonal Biomarkers of Phthalate-Induced Male Rat
2435 Reproductive Developmental Toxicity Part II: A Targeted RT-qPCR Array Approach That
2436 Defines a Unique Adverse Outcome Pathway. *Toxicol Sci* 182: 195-214.
2437 <http://dx.doi.org/10.1093/toxsci/kfab053>
- 2438 [Gray, LE; Lambright, CS; Evans, N; Ford, J; Conley, JM.](#) (2024). Using targeted fetal rat testis genomic
2439 and endocrine alterations to predict the effects of a phthalate mixture on the male reproductive
2440 tract. *Curr Res Toxicol* 7: 100180. <http://dx.doi.org/10.1016/j.crttox.2024.100180>
- 2441 [Guo, Y; Kannan, K.](#) (2011). Comparative assessment of human exposure to phthalate esters from house
2442 dust in China and the United States. *Environ Sci Technol* 45: 3788-3794.
2443 <http://dx.doi.org/10.1021/es2002106>
- 2444 [Hallmark, N; Walker, M; McKinnell, C; Mahood, IK; Scott, H; Bayne, R; Coutts, S; Anderson, RA;](#)
2445 [Greig, I; Morris, K; Sharpe, RM.](#) (2007). Effects of monobutyl and di(n-butyl) phthalate in vitro
2446 on steroidogenesis and Leydig cell aggregation in fetal testis explants from the rat: Comparison
2447 with effects in vivo in the fetal rat and neonatal marmoset and in vitro in the human. *Environ*
2448 *Health Perspect* 115: 390-396. <http://dx.doi.org/10.1289/ehp.9490>
- 2449 [Hammel, SC; Levasseur, JL; Hoffman, K; Phillips, AL; Lorenzo, AM; Calafat, AM; Webster, TF;](#)
2450 [Stapleton, HM.](#) (2019). Children's exposure to phthalates and non-phthalate plasticizers in the
2451 home: The TESIIE study. *Environ Int* 132: 105061.
2452 <http://dx.doi.org/10.1016/j.envint.2019.105061>
- 2453 [Han, Eu; Choi, K; Sim, S; Choi, J; Uhm, Y; Kim, S; Lim, E; Lee, Y.](#) (2020). Patterns of household and
2454 personal care product use by the Korean population: implications for aggregate human exposure
2455 and health risk. *Environ Sci Eur.* <http://dx.doi.org/10.1186/s12302-020-00417-3>
- 2456 [Hannas, BR; Lambright, CS; Furr, J; Evans, N; Foster, PMD; Gray, EL; Wilson, VS.](#) (2012). Genomic
2457 biomarkers of phthalate-induced male reproductive developmental toxicity: A targeted RT-PCR
2458 array approach for defining relative potency. *Toxicol Sci* 125: 544-557.
2459 <http://dx.doi.org/10.1093/toxsci/kfr315>
- 2460 [Hannas, BR; Lambright, CS; Furr, J; Howdeshell, KL; Wilson, VS; Gray, LE.](#) (2011). Dose-response
2461 assessment of fetal testosterone production and gene expression levels in rat testes following in
2462 utero exposure to diethylhexyl phthalate, diisobutyl phthalate, diisooheptyl phthalate, and
2463 diisononyl phthalate. *Toxicol Sci* 123: 206-216. <http://dx.doi.org/10.1093/toxsci/kfr146>
- 2464 [Heger, NE; Hall, SJ; Sandrof, MA; McDonnell, EV; Hensley, JB; McDowell, EN; Martin, KA; Gaido,](#)
2465 [KW; Johnson, KJ; Boekelheide, K.](#) (2012). Human fetal testis xenografts are resistant to
2466 phthalate-induced endocrine disruption. *Environ Health Perspect* 120: 1137-1143.
2467 <http://dx.doi.org/10.1289/ehp.1104711>

- 2468 [Hines, C; Hopf, N; Deddens, J; Silva, M; Calafat, A.](#) (2011). Estimated daily intake of phthalates in
2469 occupationally exposed groups. *J Expo Sci Environ Epidemiol* 21: 133-141.
2470 <http://dx.doi.org/10.1038/jes.2009.62>
- 2471 [Howdeshell, KL; Hotchkiss, AK; Gray, LE.](#) (2017). Cumulative effects of antiandrogenic chemical
2472 mixtures and their relevance to human health risk assessment [Review]. *Int J Hyg Environ*
2473 *Health* 220: 179-188. <http://dx.doi.org/10.1016/j.ijheh.2016.11.007>
- 2474 [Howdeshell, KL; Rider, CV; Wilson, VS; Furr, JR; Lambright, CR; Gray, LE.](#) (2015). Dose addition
2475 models based on biologically relevant reductions in fetal testosterone accurately predict postnatal
2476 reproductive tract alterations by a phthalate mixture in rats. *Toxicol Sci* 148: 488-502.
2477 <http://dx.doi.org/10.1093/toxsci/kfv196>
- 2478 [Howdeshell, KL; Wilson, VS; Furr, J; Lambright, CR; Rider, CV; Blystone, CR; Hotchkiss, AK; Gray,](#)
2479 [LE, Jr.](#) (2008). A mixture of five phthalate esters inhibits fetal testicular testosterone production
2480 in the Sprague-Dawley rat in a cumulative, dose-additive manner. *Toxicol Sci* 105: 153-165.
2481 <http://dx.doi.org/10.1093/toxsci/kfn077>
- 2482 [IPCS.](#) (2007). Harmonization project document no. 4: Part 1: IPCS framework for analysing the
2483 relevance of a cancer mode of action for humans and case-studies: Part 2: IPCS framework for
2484 analysing the relevance of a non-cancer mode of action for humans. Geneva, Switzerland: World
2485 Health Organization.
2486 http://www.who.int/ipcs/methods/harmonization/areas/cancer_mode.pdf?ua=1
- 2487 [Johnson, KJ; Hensley, JB; Kelso, MD; Wallace, DG; Gaido, KW.](#) (2007). Mapping gene expression
2488 changes in the fetal rat testis following acute dibutyl phthalate exposure defines a complex
2489 temporal cascade of responding cell types. *Biol Reprod* 77: 978-989.
2490 <http://dx.doi.org/10.1095/biolreprod.107.062950>
- 2491 [Johnson, KJ; McDowell, EN; Viereck, MP; Xia, JQ.](#) (2011). Species-specific dibutyl phthalate fetal
2492 testis endocrine disruption correlates with inhibition of SREBP2-dependent gene expression
2493 pathways. *Toxicol Sci* 120: 460-474. <http://dx.doi.org/10.1093/toxsci/kfr020>
- 2494 [Koch, HM; Becker, K; Wittassek, M; Seiwert, M; Angerer, J; Kolossa-Gehring, M.](#) (2007). Di-n-
2495 butylphthalate and butylbenzylphthalate - urinary metabolite levels and estimated daily intakes:
2496 Pilot study for the German Environmental Survey on children. *J Expo Sci Environ Epidemiol* 17:
2497 378-387. <http://dx.doi.org/10.1038/sj.jes.7500526>
- 2498 [Koch, HM; Drexler, H; Angerer, J.](#) (2003). An estimation of the daily intake of di(2-
2499 ethylhexyl)phthalate (DEHP) and other phthalates in the general population. *Int J Hyg Environ*
2500 *Health* 206: 77-83. <http://dx.doi.org/10.1078/1438-4639-00205>
- 2501 [Kuhl, AJ; Ross, SM; Gaido, KW.](#) (2007). CCAAT/enhancer binding protein beta, but not steroidogenic
2502 factor-1, modulates the phthalate-induced dysregulation of rat fetal testicular steroidogenesis.
2503 *Endocrinology* 148: 5851-5864. <http://dx.doi.org/10.1210/en.2007-0930>
- 2504 [Lambrot, R; Muczynski, V; Lecureuil, C; Angenard, G; Coffigny, H; Pairault, C; Moison, D; Frydman,](#)
2505 [R; Habert, R; Rouiller-Fabre, V.](#) (2009). Phthalates impair germ cell development in the human
2506 fetal testis in vitro without change in testosterone production. *Environ Health Perspect* 117: 32-
2507 37. <http://dx.doi.org/10.1289/ehp.11146>
- 2508 [Lin, H; Ge, R; Chen, G; Hu, G; Dong, L; Lian, Q; Hardy, D; Sottas, C; Li, X; Hardy, M.](#) (2008).
2509 Involvement of testicular growth factors in fetal Leydig cell aggregation after exposure to
2510 phthalate in utero. *Proc Natl Acad Sci USA* 105: 7218-7222.
2511 <http://dx.doi.org/10.1073/pnas.0709260105>
- 2512 [Lucas-Herald, AK; Mitchell, RT.](#) (2022). Testicular Sertoli cell hormones in differences in sex
2513 development [Review]. *Front Endocrinol (Lausanne)* 13: 919670.
2514 https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/10706127

- 2515 [MacLeod, DJ; Sharpe, RM; Welsh, M; Fiskens, M; Scott, HM; Hutchison, GR; Drake, AJ; van Den](#)
2516 [Driesche, S.](#) (2010). Androgen action in the masculinization programming window and
2517 development of male reproductive organs. *Int J Androl* 33: 279-287.
2518 <http://dx.doi.org/10.1111/j.1365-2605.2009.01005.x>
- 2519 [Mage, DT; Allen, RH; Kodali, A.](#) (2008). Creatinine corrections for estimating children's and adult's
2520 pesticide intake doses in equilibrium with urinary pesticide and creatinine concentrations. *J Expo*
2521 *Sci Environ Epidemiol* 18: 360-368. <http://dx.doi.org/10.1038/sj.jes.7500614>
- 2522 [Martino-Andrade, AJ; Morais, RN; Botelho, GG; Muller, G; Grande, SW; Carpentieri, GB; Leao, GM;](#)
2523 [Dalsenter, PR.](#) (2008). Coadministration of active phthalates results in disruption of foetal
2524 testicular function in rats. *Int J Androl* 32: 704-712. <http://dx.doi.org/10.1111/j.1365->
2525 [2605.2008.00939.x](http://dx.doi.org/10.1111/j.1365-2605.2008.00939.x)
- 2526 [Mitchell, RT; Childs, AJ; Anderson, RA; van Den Driesche, S; Saunders, PTK; McKinnell, C; Wallace,](#)
2527 [WHB; Kelnar, CJH; Sharpe, RM.](#) (2012). Do phthalates affect steroidogenesis by the human
2528 fetal testis? Exposure of human fetal testis xenografts to di-n-butyl phthalate. *J Clin Endocrinol*
2529 *Metab* 97: E341-E348. <http://dx.doi.org/10.1210/jc.2011-2411>
- 2530 [NASEM.](#) (2017). Application of systematic review methods in an overall strategy for evaluating low-
2531 dose toxicity from endocrine active chemicals. In Consensus Study Report. Washington, D.C.:
2532 The National Academies Press. <http://dx.doi.org/10.17226/24758>
- 2533 [NCHS.](#) (2012). The National Health and Nutrition Examination Survey: Sample design, 1999-2006.
2534 (Vital and Health Statistics: Series 2, No. 155). Hyattsville, MD: National Center for Health
2535 Statistics. http://www.cdc.gov/nchs/data/series/sr_02/sr02_155.pdf
- 2536 [NCHS.](#) (2021). National Health and Nutrition Examination Survey - 2017-2018 Data Documentation,
2537 Codebook, and Frequencies: Phthalates and Plasticizers Metabolites - Urine (PHTHTE_J)
2538 [Website]. https://wwwn.cdc.gov/Nchs/Nhanes/2017-2018/PHTHTE_J.htm
- 2539 [NRC.](#) (2008). Phthalates and cumulative risk assessment: The task ahead. Washington, DC: National
2540 Academies Press. <http://dx.doi.org/10.17226/12528>
- 2541 [OECD.](#) (2013). Guidance document supporting OECD test guideline 443 on the extended one
2542 generation reproductive toxicity test. In Series on Testing and Assessment. (No. 151 /
2543 ENV/JM/MONO(2013)10). Paris, France: OECD Environment, Health and Safety Publications.
2544 https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/3449546
- 2545 [Page, BD; Lacroix, GM.](#) (1995). The occurrence of phthalate ester and di-2-ethylhexyl adipate
2546 plasticizers in Canadian packaging and food sampled in 1985-1989: A survey. *Food Addit*
2547 *Contam* 12: 129-151. <http://dx.doi.org/10.1080/02652039509374287>
- 2548 [Rudel, RA; Brody, JG; Spengler, JD; Vallarino, J; Geno, PW; Sun, G; Yau, A.](#) (2001). Identification of
2549 selected hormonally active agents and animal mammary carcinogens in commercial and
2550 residential air and dust samples. *J Air Waste Manag Assoc* 51: 499-513.
2551 <http://dx.doi.org/10.1080/10473289.2001.10464292>
- 2552 [Safford, B; Api, AM; Barratt, C; Comiskey, D; Daly, EJ; Ellis, G; McNamara, C; O'Mahony, C;](#)
2553 [Robison, S; Smith, B; Thomas, R; Tozer, S.](#) (2015). Use of an aggregate exposure model to
2554 estimate consumer exposure to fragrance ingredients in personal care and cosmetic products.
2555 *Regul Toxicol Pharmacol* 72: 673-682. <http://dx.doi.org/10.1016/j.yrtph.2015.05.017>
- 2556 [Saillenfait, AM; Sabaté, JP; Robert, A; Rouiller-Fabre, V; Roudot, AC; Moison, D; Denis, F.](#) (2013).
2557 Dose-dependent alterations in gene expression and testosterone production in fetal rat testis after
2558 exposure to di-n-hexyl phthalate. *J Appl Toxicol* 33: 1027-1035.
2559 <http://dx.doi.org/10.1002/jat.2896>
- 2560 [Schechter, A; Lorber, M; Guo, Y; Wu, Q; Yun, SH; Kannan, K; Hommel, M; Imran, N; Hynan, LS;](#)
2561 [Cheng, D; Colacino, JA; Birnbaum, LS.](#) (2013). Phthalate concentrations and dietary exposure

2562 from food purchased in New York State. Environ Health Perspect 121: 473-494.

2563 <http://dx.doi.org/10.1289/ehp.1206367>

2564 [Schwartz, CL; Christiansen, S; Hass, U; Ramhøj, L; Axelstad, M; Löbl, NM; Svingen, T.](#) (2021). On the
2565 use and interpretation of areola/nipple retention as a biomarker for anti-androgenic effects in rat
2566 toxicity studies [Review]. Front Toxicol 3: 730752.

2567 https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/10492323

2568 [Scott, HM; Mason, JI; Sharpe, RM.](#) (2009). Steroidogenesis in the fetal testis and its susceptibility to
2569 disruption by exogenous compounds [Review]. Endocr Rev 30: 883-925.

2570 <http://dx.doi.org/10.1210/er.2009-0016>

2571 [Shin, HM; Bennett, DH; Barkoski, J; Ye, X; Calafat, AM; Tancredi, D; Hertz-Picciotto, I.](#) (2019).

2572 Variability of urinary concentrations of phthalate metabolites during pregnancy in first morning
2573 voids and pooled samples. Environ Int 122: 222-230.

2574 <http://dx.doi.org/10.1016/j.envint.2018.11.012>

2575 [Shin, HM; McKone, TE; Nishioka, MG; Fallin, MD; Croen, LA; Hertz-Picciotto, I; Newschaffer, CJ;
2576 Bennett, DH.](#) (2014). Determining source strength of semivolatile organic compounds using
2577 measured concentrations in indoor dust. Indoor Air 24: 260-271.

2578 <http://dx.doi.org/10.1111/ina.12070>

2579 [Spade, DJ; Hall, SJ; Saffarini, C; Huse, SM; McDonnell, EV; Boekelheide, K.](#) (2014). Differential
2580 response to abiraterone acetate and di-n-butyl phthalate in an androgen-sensitive human fetal
2581 testis xenograft bioassay. Toxicol Sci 138: 148-160. <http://dx.doi.org/10.1093/toxsci/kft266>

2582 [Stanfield, Z; Addington, CK; Dionisio, KL; Lyons, D; Tornero-Velez, R; Phillips, KA; Buckley, TJ;
2583 Isaacs, KK.](#) (2021). Mining of Consumer Product Ingredient and Purchasing Data to Identify
2584 Potential Chemical Coexposures. Environ Health Perspect 129: 67006.

2585 <http://dx.doi.org/10.1289/EHP8610>

2586 [Stanfield, Z; Setzer, RW; Hull, V; Sayre, RR; Isaacs, KK; Wambaugh, JF.](#) (2024). Characterizing
2587 chemical exposure trends from NHANES urinary biomonitoring data. Environ Health Perspect
2588 132: 17009. <http://dx.doi.org/10.1289/EHP12188>

2589 [Statistics Canada.](#) (2004). Canadian Community Health Survey – Nutrition (CCHS). Detailed
2590 information for 2004 (cycle 2.2) [Website].

2591 https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/7273228

2592 [Struve, MF; Gaido, KW; Hensley, JB; Lehmann, KP; Ross, SM; Sochaski, MA; Willson, GA; Dorman,
2593 DC.](#) (2009). Reproductive toxicity and pharmacokinetics of di-n-butyl phthalate (DBP) following
2594 dietary exposure of pregnant rats. Birth Defects Res B Dev Reprod Toxicol 86: 345-354.

2595 <http://dx.doi.org/10.1002/bdrb.20199>

2596 [Tornero-Velez, R; Isaacs, K; Dionisio, K; Prince, S; Laws, H; Nye, M; Price, PS; Buckley, TJ.](#) (2021).
2597 Data Mining Approaches for Assessing Chemical Coexposures Using Consumer Product
2598 Purchase Data. Risk Anal 41: 1716-1735. <http://dx.doi.org/10.1111/risa.13650>

2599 [U.S. CPSC.](#) (2014). Chronic Hazard Advisory Panel on Phthalates and Phthalate Alternatives (with
2600 appendices). Bethesda, MD: U.S. Consumer Product Safety Commission, Directorate for Health
2601 Sciences. <https://www.cpsc.gov/s3fs-public/CHAP-REPORT-With-Appendices.pdf>

2602 [U.S. CPSC.](#) (2015). Estimated phthalate exposure and risk to pregnant women and women of
2603 reproductive age as assessed using four NHANES biomonitoring data sets (2005/2006,
2604 2007/2008, 2009/2010, 2011/2012). Rockville, Maryland: U.S. Consumer Product Safety
2605 Commission, Directorate for Hazard Identification and Reduction.

2606 [https://web.archive.org/web/20190321120312/https://www.cpsc.gov/s3fs-public/NHANES-
2607 Biomonitoring-analysis-for-Commission.pdf](https://web.archive.org/web/20190321120312/https://www.cpsc.gov/s3fs-public/NHANES-Biomonitoring-analysis-for-Commission.pdf)

2608 [U.S. EPA.](#) (1986). Guidelines for the health risk assessment of chemical mixtures. Fed Reg 51: 34014-
2609 34025.

PUBLIC RELEASE DRAFT
May 2025

- 2610 [U.S. EPA. \(2000\)](#). Supplementary guidance for conducting health risk assessment of chemical mixtures
2611 (pp. 1-209). (EPA/630/R-00/002). Washington, DC: U.S. Environmental Protection Agency,
2612 Risk Assessment Forum. <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=20533>
- 2613 [U.S. EPA. \(2002a\)](#). Guidance on cumulative risk assessment of pesticide chemicals that have a common
2614 mechanism of toxicity [EPA Report]. Washington, D.C.
- 2615 [U.S. EPA. \(2002b\)](#). A review of the reference dose and reference concentration processes.
2616 (EPA630P02002F). Washington, DC. <https://www.epa.gov/sites/production/files/2014-12/documents/rfd-final.pdf>
- 2617
- 2618 [U.S. EPA. \(2005\)](#). Guidelines for carcinogen risk assessment [EPA Report]. (EPA630P03001F).
2619 Washington, DC. https://www.epa.gov/sites/production/files/2013-09/documents/cancer_guidelines_final_3-25-05.pdf
- 2620
- 2621 [U.S. EPA. \(2007\)](#). Analysis of total food intake and composition of individual's diet based on the
2622 USDA's 1994-1996, 1998 continuing survey of food intakes by individuals (CSFII) [EPA
2623 Report]. (EPA/600/R-05/062F). Washington, DC.
2624 https://heronet.epa.gov/heronet/index.cfm/reference/download/reference_id/1065008
- 2625 [U.S. EPA. \(2011a\)](#). Exposure factors handbook: 2011 edition [EPA Report]. (EPA/600/R-090/052F).
2626 Washington, DC: U.S. Environmental Protection Agency, Office of Research and Development,
2627 National Center for Environmental Assessment.
2628 <https://nepis.epa.gov/Exe/ZyPURL.cgi?Dockey=P100F2OS.txt>
- 2629 [U.S. EPA. \(2011b\)](#). Recommended use of body weight 3/4 as the default method in derivation of the
2630 oral reference dose. (EPA100R110001). Washington, DC.
2631 <https://www.epa.gov/sites/production/files/2013-09/documents/recommended-use-of-bw34.pdf>
- 2632 [U.S. EPA. \(2012\)](#). Benchmark dose technical guidance [EPA Report]. (EPA100R12001). Washington,
2633 DC: U.S. Environmental Protection Agency, Risk Assessment Forum.
2634 <https://www.epa.gov/risk/benchmark-dose-technical-guidance>
- 2635 [U.S. EPA. \(2016\)](#). Pesticide cumulative risk assessment: Framework for screening analysis.
2636 Washington, DC: Office of Pesticide Programs. <https://www.epa.gov/pesticide-science-and-assessing-pesticide-risks/pesticide-cumulative-risk-assessment-framework>
- 2637
- 2638 [U.S. EPA. \(2017\)](#). Estimation Programs Interface Suite™ v.4.11. Washington, DC: U.S. Environmental
2639 Protection Agency, Office of Pollution Prevention Toxics. Retrieved from
2640 <https://www.epa.gov/tsca-screening-tools/download-epi-suitetm-estimation-program-interface-v411>
- 2641
- 2642 [U.S. EPA. \(2020a\)](#). Use report for butyl benzyl phthalate (BBP) - 1,2-Benzenedicarboxylic acid, 1- butyl
2643 2(phenylmethyl) ester (CAS RN 85-68-7). (EPA-HQ-OPPT-2018-0501-0035). Washington, DC:
2644 U.S. Environmental Protection Agency. <https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0501-0035>
- 2645
- 2646 [U.S. EPA. \(2020b\)](#). Use report for di-ethylhexyl phthalate (CAS RN 117-81-7). (EPA-HQ-OPPT-2018-
2647 0433-0024). Washington, DC: U.S. Environmental Protection Agency.
2648 <https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0433-0024>
- 2649 [U.S. EPA. \(2020c\)](#). Use report for di-isobutyl phthalate (CAS RN 84-69-5). (EPA-HQ-OPPT-2018-
2650 0434-0029). Washington, DC: U.S. Environmental Protection Agency.
2651 <https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0434-0029>
- 2652 [U.S. EPA. \(2020d\)](#). Use report for dibutyl phthalate (DBP) - (1,2-Benzenedicarboxylic acid, 1,2- dibutyl
2653 ester) (CAS RN 84-74-2). (EPA-HQ-OPPT-2018-0503-0023). Washington, DC: U.S.
2654 Environmental Protection Agency. <https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0503-0023>
- 2655

PUBLIC RELEASE DRAFT
May 2025

- 2656 [U.S. EPA. \(2020e\)](#). Use report for dicyclohexyl phthalate (CAS RN 84-61-7). (EPA-HQ-OPPT-2018-
2657 0504-0030). Washington, DC: U.S. Environmental Protection Agency.
2658 <https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0504-0030>
- 2659 [U.S. EPA. \(2021\)](#). Final use report for di-isononyl phthalate (DINP) - (1,2-benzene-dicarboxylic acid,
2660 1,2-diisononyl ester, and 1,2-benzenedicarboxylic acid, di-C8-10-branched alkyl esters, C9-rich)
2661 (CASRN 28553-12-0 and 68515-48-0). (EPA-HQ-OPPT-2018-0436-0035). Washington, DC:
2662 U.S. Environmental Protection Agency. [https://www.regulations.gov/document/EPA-HQ-OPPT-
2663 2018-0436-0035](https://www.regulations.gov/document/EPA-HQ-OPPT-2018-0436-0035)
- 2664 [U.S. EPA. \(2022\)](#). ORD staff handbook for developing IRIS assessments [EPA Report]. (EPA 600/R-
2665 22/268). Washington, DC: U.S. Environmental Protection Agency, Office of Research and
2666 Development, Center for Public Health and Environmental Assessment.
2667 https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=356370
- 2668 [U.S. EPA. \(2023a\)](#). Advances in dose addition for chemical mixtures: A white paper. (EPA/100/R-
2669 23/001). Washington, DC. <https://assessments.epa.gov/risk/document/&deid=359745>
- 2670 [U.S. EPA. \(2023b\)](#). Draft Proposed Approach for Cumulative Risk Assessment of High-Priority
2671 Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act.
2672 (EPA-740-P-23-002). Washington, DC: U.S. Environmental Protection Agency, Office of
2673 Chemical Safety and Pollution Prevention. [https://www.regulations.gov/document/EPA-HQ-
2674 OPPT-2022-0918-0009](https://www.regulations.gov/document/EPA-HQ-OPPT-2022-0918-0009)
- 2675 [U.S. EPA. \(2023c\)](#). Science Advisory Committee on Chemicals meeting minutes and final report, No.
2676 2023-01 - A set of scientific issues being considered by the Environmental Protection Agency
2677 regarding: Draft Proposed Principles of Cumulative Risk Assessment (CRA) under the Toxic
2678 Substances Control Act and a Draft Proposed Approach for CRA of High-Priority Phthalates and
2679 a Manufacturer-Requested Phthalate. (EPA-HQ-OPPT-2022-0918). Washington, DC: U.S.
2680 Environmental Protection Agency, Office of Chemical Safety and Pollution Prevention.
2681 <https://www.regulations.gov/document/EPA-HQ-OPPT-2022-0918-0067>
- 2682 [U.S. EPA. \(2024a\)](#). Draft Consumer and Indoor Dust Exposure Assessment for Dicyclohexyl Phthalate
2683 (DCHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2684 [U.S. EPA. \(2024b\)](#). Draft Environmental Media and General Population and Environmental Exposure
2685 for Dicyclohexyl Phthalate (DCHP). Washington, DC: Office of Pollution Prevention and
2686 Toxics.
- 2687 [U.S. EPA. \(2024c\)](#). Draft Environmental Release and Occupational Exposure Assessment for
2688 Dicyclohexyl Phthalate (DCHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2689 [U.S. EPA. \(2024d\)](#). Draft Meta-Analysis and Benchmark Dose Modeling of Fetal Testicular
2690 Testosterone for Di(2-ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), Butyl Benzyl
2691 Phthalate (BBP), Diisobutyl Phthalate (DIBP), and Dicyclohexyl Phthalate (DCHP).
2692 Washington, DC: Office of Pollution Prevention and Toxics.
- 2693 [U.S. EPA. \(2024e\)](#). Draft Non-cancer Human Health Hazard Assessment for Butyl benzyl phthalate
2694 (BBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2695 [U.S. EPA. \(2024f\)](#). Draft Non-cancer Human Health Hazard Assessment for Dibutyl Phthalate (DBP).
2696 Washington, DC: Office of Pollution Prevention and Toxics.
- 2697 [U.S. EPA. \(2024g\)](#). Draft Non-Cancer Human Health Hazard Assessment for Dicyclohexyl Phthalate
2698 (DCHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2699 [U.S. EPA. \(2024h\)](#). Draft Non-cancer Human Health Hazard Assessment for Diethylhexyl Phthalate
2700 (DEHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2701 [U.S. EPA. \(2024i\)](#). Draft Non-cancer Human Health Hazard Assessment for Diisobutyl phthalate
2702 (DIBP). Washington, DC: Office of Pollution Prevention and Toxics.

PUBLIC RELEASE DRAFT
May 2025

- 2703 [U.S. EPA. \(2024j\)](#). Draft Physical Chemistry Assessment for Butyl benzyl phthalate (BBP).
2704 Washington, DC: Office of Pollution Prevention and Toxics.
- 2705 [U.S. EPA. \(2024k\)](#). Draft Physical Chemistry Assessment for Dibutyl Phthalate (DBP). Washington,
2706 DC: Office of Pollution Prevention and Toxics.
- 2707 [U.S. EPA. \(2024l\)](#). Draft Physical Chemistry Assessment for Dicyclohexyl Phthalate (DCHP).
2708 Washington, DC: Office of Pollution Prevention and Toxics.
- 2709 [U.S. EPA. \(2024m\)](#). Draft Physical Chemistry Assessment for Diethylhexyl Phthalate (DEHP).
2710 Washington, DC: Office of Pollution Prevention and Toxics.
- 2711 [U.S. EPA. \(2024n\)](#). Draft Physical Chemistry Assessment for Diisobutyl phthalate (DIBP). Washington,
2712 DC: Office of Pollution Prevention and Toxics.
- 2713 [U.S. EPA. \(2024o\)](#). Draft Risk Calculator for Occupational Exposures for Dicyclohexyl Phthalate
2714 (DCHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2715 [U.S. EPA. \(2024p\)](#). Draft Summary of Facility Release Data for Di(2-ethylhexyl) Phthalate (DEHP),
2716 Dibutyl Phthalate (DBP), and Butyl Benzyl Phthalate (BBP). Washington, DC: Office of
2717 Pollution Prevention and Toxics.
- 2718 [U.S. EPA. \(2024q\)](#). Draft Technical Support Document for the Cumulative Risk Analysis of Di(2-
2719 ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), Butyl Benzyl Phthalate (BBP),
2720 Diisobutyl Phthalate (DIBP), Dicyclohexyl Phthalate (DCHP), and Diisononyl Phthalate (DINP)
2721 Under the Toxic Substances Control Act (TSCA). Washington, DC: Office of Chemical Safety
2722 and Pollution Prevention.
- 2723 [U.S. EPA. \(2024r\)](#). Science Advisory Committee on Chemicals Meeting Minutes and Final Report No.
2724 2024-2, Docket ID: EPA-HQ-OPPT-2024-0073: For the Draft Risk Evaluation for Di-isodecyl
2725 Phthalate (DIDP) and Draft Hazard Assessments for Di-isononyl Phthalate (DINP). Washington,
2726 DC: U.S. Environmental Protection Agency, Science Advisory Committee on Chemicals.
- 2727 [U.S. EPA. \(2025a\)](#). Consumer and Indoor Exposure Assessment for Diisononyl Phthalate (DINP).
2728 Washington, DC: Office of Pollution Prevention and Toxics.
- 2729 [U.S. EPA. \(2025b\)](#). Draft Consumer and Indoor Dust Exposure Assessment for Butyl benzyl phthalate
2730 (BBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2731 [U.S. EPA. \(2025c\)](#). Draft Consumer and Indoor Dust Exposure Assessment for Dibutyl Phthalate
2732 (DBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2733 [U.S. EPA. \(2025d\)](#). Draft Consumer and Indoor Dust Exposure Assessment for Diisobutyl phthalate
2734 (DIBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2735 [U.S. EPA. \(2025e\)](#). Draft Consumer and Indoor Exposure Assessment for Diethylhexyl Phthalate
2736 (DEHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2737 [U.S. EPA. \(2025f\)](#). Draft Environmental Media and General Population and Environment Exposure for
2738 Butyl benzyl phthalate (BBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2739 [U.S. EPA. \(2025g\)](#). Draft Environmental Media and General Population and Environmental Exposure
2740 for Dibutyl Phthalate (DBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2741 [U.S. EPA. \(2025h\)](#). Draft Environmental Media and General Population and Environmental Exposure
2742 for Diethylhexyl Phthalate (DEHP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2743 [U.S. EPA. \(2025i\)](#). Draft Environmental Media and General Population and Environmental Exposure for
2744 Diisobutyl phthalate (DIBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2745 [U.S. EPA. \(2025j\)](#). Draft Environmental Release and Occupational Exposure Assessment for Butyl
2746 benzyl phthalate (BBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2747 [U.S. EPA. \(2025k\)](#). Draft Environmental Release and Occupational Exposure Assessment for Dibutyl
2748 Phthalate (DBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2749 [U.S. EPA. \(2025l\)](#). Draft Environmental Release and Occupational Exposure Assessment for
2750 Diethylhexyl Phthalate (DEHP). Washington, DC: Office of Pollution Prevention and Toxics.

PUBLIC RELEASE DRAFT
May 2025

- 2751 [U.S. EPA. \(2025m\)](#). Draft Environmental Release and Occupational Exposure Assessment for
2752 Diisobutyl phthalate (DIBP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2753 [U.S. EPA. \(2025n\)](#). Environmental Media and General Population Screening for Diisononyl Phthalate
2754 (DINP). Washington, DC: Office of Pollution Prevention and Toxics.
- 2755 [U.S. EPA. \(2025o\)](#). Environmental Release and Occupational Exposure Assessment for Diisononyl
2756 Phthalate (DINP) Washington, DC: Office of Pollution Prevention and Toxics.
- 2757 [U.S. EPA. \(2025p\)](#). Non-Cancer Human Health Hazard Assessment for Diisononyl Phthalate (DINP)
2758 Washington, DC: Office of Pollution Prevention and Toxics.
- 2759 [U.S. EPA. \(2025q\)](#). Physical Chemistry Assessment for Diisononyl Phthalate (DINP). Washington, DC:
2760 Office of Pollution Prevention and Toxics.
- 2761 [van Den Driesche, S; McKinnell, C; Calarã, A; Kennedy, L; Hutchison, GR; Hrabalkova, L; Jobling,
2762 MS; Macpherson, S; Anderson, RA; Sharpe, RM; Mitchell, RT](#). (2015). Comparative effects of
2763 di(n-butyl) phthalate exposure on fetal germ cell development in the rat and in human fetal testis
2764 xenografts. Environ Health Perspect 123: 223-230. <http://dx.doi.org/10.1289/ehp.1408248>
- 2765 [Welsh, M; Saunders, PTK; Fiskens, M; Scott, HM; Hutchison, GR; Smith, LB; Sharpe, RM](#). (2008).
2766 Identification in rats of a programming window for reproductive tract masculinization, disruption
2767 of which leads to hypospadias and cryptorchidism. J Clin Invest 118: 1479-1490.
2768 <http://dx.doi.org/10.1172/jci34241>
- 2769 [Wilson, NK; Chuang, JC; Lyu, C](#). (2001). Levels of persistent organic pollutants in several child day
2770 care centers. J Expo Anal Environ Epidemiol 11: 449-458.
2771 <http://dx.doi.org/10.1038/sj.jea.7500190>
- 2772 [Wilson, NK; Chuang, JC; Lyu, C; Menton, R; Morgan, MK](#). (2003). Aggregate exposures of nine
2773 preschool children to persistent organic pollutants at day care and at home. J Expo Anal Environ
2774 Epidemiol 13: 187-202. <http://dx.doi.org/10.1038/sj.jea.7500270>
- 2775 [Wormuth, M; Scheringer, M; Vollenweider, M; Hungerbuhler, K](#). (2006). What are the sources of
2776 exposure to eight frequently used phthalic acid esters in Europeans? Risk Anal 26: 803-824.
2777 <http://dx.doi.org/10.1111/j.1539-6924.2006.00770.x>
- 2778

2779
2780
2781
2782
2783

APPENDICES

Appendix A FETAL TESTICULAR TESTOSTERONE DATA FOR DEHP AND DBP

Table_Apx A-1. Summary of Fetal Testicular Testosterone Data for DEHP^a

Brief Study Description, Measured Outcome (Reference)	Dose (mg/kg-day)															
	0	10	50	100	117	150	234	300	469	500	600	625	750	875	900	938
Long-Evans rats gavaged with 0, 10, 100, 750 mg/kg-day DEHP on GD 2-20. Fetal testis testosterone content on GD 21 (Lin et al., 2008)	100% (n=6)	157%* (n=6)	-	78% (n=6)	-	-	-	-	-	-	-	-	33%* (n=9)	-	-	-
Pregnant Wistar rats gavaged with 0, 150 mg/kg-day DEHP on GD 13-21. Fetal testis testosterone content on GD 21 (Martino-Andrade et al., 2008)	100% (n=7)	-	-	-	-	71%* (n=7)	-	-	-	-	-	-	-	-	-	-
Pregnant Wistar rats (3-6 dams/group) gavaged with 0, 100, 300, 500, 625, 750, 875 mg/kg-day DEHP on GD 14-18. <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Hannas et al., 2011)	100% (n=6)	-	-	100% (n=3)	-	-	-	50%* (n=3)	-	36%* (n=6)	-	24%* (n=4)	14%* (n=4)	18%* (n=3)	-	-
Pregnant SD rats (3-6 dams/group) gavaged with 0, 100, 300, 500, 625, 750, 875 mg/kg-day DEHP on GD 14-18. <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Hannas et al., 2011)	100% (n=6)	-	-	107% (n=3)	-	-	-	61%* (n=3)	-	40%* (n=6)	-	21%* (n=4)	29%* (n=4)	48%* (n=4)	-	-
Pregnant SD rats (3 dams/group) gavaged with 0, 117, 234, 469, 938 mg/kg-day DEHP on GD 14-20. <i>Ex vivo</i> fetal testicular testosterone production (24-hour incubation) on GD 21 (Culty et al., 2008)	100% (n=3)	-	-	-	41%* (n=3)	-	37%* (n=3)	-	23%* (n=3)	-	-	-	-	-	-	8.5% (n=3)
Pregnant SD rats (2-3 dams/group) gavaged with 0, 100, 300, 600, 900 mg/kg-day DEHP on GD 14-18 (Block 31). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Furr et al., 2014)	100% (n=3)	-	-	37%* (n=2)	-	-	-	18%* (n=3)	-	-	7.1%* (n=3)	-	-	-	6.0%* (n=2)	-
Pregnant SD rats (2-3 dams/group) gavaged with 0, 100, 300, 600, 900 mg/kg-day DEHP on GD 14-18 (Block 32). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Furr et al., 2014)	100% (n=2)	-	-	79%* (n=3)	-	-	-	35%* (n=3)	-	-	15%* (n=3)	-	-	-	12%* (n=2)	-

PUBLIC RELEASE DRAFT

May 2025

Brief Study Description, Measured Outcome (Reference)	Dose (mg/kg-day)															
	0	10	50	100	117	150	234	300	469	500	600	625	750	875	900	938
Pregnant SD rats (4 dams/group) gavaged with 0, 100, 300, 600, 900 mg/kg-day DEHP on GD 14-18. <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Howdeshell et al., 2008)	100% (n=4)	-	-	82% (n=4)	-	-	-	58%* (n=4)	-	-	41%* (n=4)	-	-	-	22%* (n=4)	-
Pregnant SD rats (8-16 dams/group) gavaged with 0, 50, 625 mg/kg-day DEHP on GD 12-19. <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 19 (Saillenfait et al., 2013)	100% (n=16)	-	72%* (n=8)	-	-	-	-	-	-	-	-	16%* (n=8)	-	-	-	-
Pregnant SD rats (2-3 dams/group) gavaged with 0, 100, 300, 600, 900 mg/kg-day DEHP on GD 14-18 (Block 76). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Gray et al., 2021)	100% (n=3)	-	-	104% (n=3)	-	-	-	75% (n=2)	-	-	30% (n=3)	-	-	-	20% (n=3)	-
Pregnant SD rats (3 dams/group) gavaged with 0, 100, 300, 600, 900 mg/kg-day DEHP on GD 14-18 (Block 77). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Gray et al., 2021)	100% (n=3)	-	-	99% (n=3)	-	-	-	67% (n=3)	-	-	25% (n=3)	-	-	-	25% (n=3)	-

^a Asterisk (*) indicates a statistically significant effect compared to the concurrent control as calculated by original study authors. Percent testosterone values indicate the percent testosterone or testosterone production compared to the concurrent control as calculated by EPA.

2784

2785 Table_Apx A-2. Summary of Fetal Testicular Testosterone Data for DBP

Brief Study Description, Measured Outcome (Reference)	Dose (mg/kg-day)											
	0	1	10	33	50	100	112	300	500	581	600	900
Pregnant Wistar rats gavaged with 0, 100, 500 mg/kg-day DBP on GD 13-21. Fetal testis testosterone content on GD 21 (Martino-Andrade et al., 2008)	100% (n=7)	-	-	-	-	71% (n=8)	-	-	37%* (n=7)	-	-	-
Pregnant SD rats (2-3 dams/group) gavaged with 0, 33, 50, 100, 300 mg/kg-day DBP on GD 14-18 (Block 18). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Furr et al., 2014)	100% (n=3)	-	-	32% (n=3)	86% (n=2)	65%* (n=3)	-	23%* (n=3)	-	-	-	-
Pregnant SD rats (3-4 dams/group) gavaged with 0, 1, 10, 100 mg/kg-day DBP on GD 14-18 (Block 22). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Furr et al., 2014)	100% (n=3)	88% (n=3)	80% (n=4)	-	-	64%* (n=4)	-	-	-	-	-	-
Pregnant SD rats (3-4 dams/group) gavaged with 0, 1, 10, 100 mg/kg-day DBP on GD 14-18 (Block 26). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Furr et al., 2014)	100% (n=3)	160% (n=4)	119% (n=4)	-	-	75% (n=3)	-	-	-	-	-	-
Pregnant SD rats (3-4 dams/group) gavaged with 0, 33, 50, 100, 300, 600 mg/kg-day DBP on GD 8-18. <i>Ex vivo</i> fetal testicular testosterone production (2-hour incubation) on GD 18 (Howdeshell et al., 2008)	100% (n=3)	-	-	94% (n=4)	78% (n=4)	84% (n=4)	-	66%* (n=4)	-	-	33%* (n=4)	-
Pregnant SD rats (3-4 dams/group) gavaged with 0, 100, 500 mg/kg-day DBP on GD 18. Fetal testis testosterone content on GD 19. (Kuhl et al., 2007)	100% (n=10)	-	-	-	-	71% (n=10)	-	-	33%* (n=10)	-	-	-
Pregnant SD rats (7-9 dams/group) gavaged with 0, 112, 581 mg/kg-day DBP on GD 12-19. Fetal testis testosterone content on GD 19 (4 hour post-exposure) (Struve et al., 2009)	100% (n=9)	-	-	-	-	-	56% (n=7)	-	-	3.7%* (n=7)	-	-
Pregnant SD rats (7-9 dams/group) gavaged with 0, 112, 581 mg/kg-day DBP on GD 12-19. Fetal testis testosterone content on GD 19 (24 hour post-exposure) (Struve et al., 2009)	100% (n=9)	-	-	-	-	-	29%* (n=7)	-	-	7.1%* (n=7)	-	-
Pregnant SD rats (5-6 dams/group) gavaged with 0, 100 mg/kg-day DBP on GD 12-20. Fetal testis testosterone content on GD 20 (Johnson et al., 2011)	100% (n=5)	-	-	-	-	77% (n=6)	-	-	-	-	-	-
Pregnant SD rats (5-6 dams/group) gavaged with 0, 500 mg/kg-day DBP on GD 12-20. Fetal testis testosterone content on GD 20 (Johnson et al., 2011)	100% (n=6)	-	-	-	-	-	-	-	15%* (n=5)	-	-	-
Pregnant SD rats (5 dams/group) gavaged with 0, 1, 10, 100 mg/kg-day DBP on GD 19. Fetal testis testosterone content on GD 19 (Johnson et al., 2007)	100% (n=5)	109% (n=5)	67% (n=5)	-	-	84% (n=5)	-	-	-	-	-	-

PUBLIC RELEASE DRAFT
May 2025

Brief Study Description, Measured Outcome (Reference)	Dose (mg/kg-day)											
	0	1	10	33	50	100	112	300	500	581	600	900
Pregnant SD rats (3–4 dams/group) gavaged with 0, 300, 600, 900 mg/kg-day DBP on GD 14-18 (Block 70). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Gray et al., 2021)	100% (n=3)	-	-	-	-	-	-	62% (n=4)	-	-	25% (n=4)	16% (n=4)
Pregnant SD rats (3–4 dams/group) gavaged with 0, 300, 600, 900 mg/kg-day DBP on GD 14-18 (Block 71). <i>Ex vivo</i> fetal testicular testosterone production (3-hour incubation) on GD 18 (Gray et al., 2021)	100% (n=4)	-	-	-	-	-	-	47% (n=3)	-	-	22% (n=4)	13% (n=4)
^a Asterisk (*) indicates a statistically significant effect compared to the concurrent control as calculated by original study authors. Percent testosterone values indicate the percent testosterone or testosterone production compared to the concurrent control as calculated by EPA.												

2786

Appendix B CONSIDERATIONS FOR BENCHMARK RESPONSE (BMR) SELECTION FOR REDUCED FETAL TESTICULAR TESTOSTERONE

B.1 Purpose

EPA has conducted an updated meta-analysis and benchmark dose modeling (BMD) analysis of decreased fetal rat testicular testosterone ([U.S. EPA, 2024d](#)). During the July 2024 Science Advisory Committee on Chemicals (SACC) peer-review meeting of the draft risk evaluation of diisodecyl phthalate (DIDP) and draft human health hazard assessments for diisononyl phthalate (DINP), the SACC recommended that EPA should clearly state its rationale for selection of benchmark response (BMR) levels evaluated for decreases in fetal testicular testosterone ([U.S. EPA, 2024r](#)). This appendix describes EPA's rationale for evaluating BMRs of 5, 10, and 40 percent for decreases in fetal testicular testosterone.

B.2 Methods

As described in EPA's *Benchmark Dose Technical Guidance* ([U.S. EPA, 2012](#)), "Selecting a BMR(s) involves making judgments about the statistical and biological characteristics of the dataset and about the applications for which the resulting BMDs/BMDLs will be used." For the updated meta-analysis and BMD modeling analysis of fetal rat testicular testosterone, EPA evaluated BMR values of 5, 10, and 40 percent based on both statistical and biological considerations ([U.S. EPA, 2024d](#)).

In 2017, NASEM ([2017](#)) modeled BMRs of 5 and 40 percent for decreases in fetal testicular testosterone. NASEM did not provide explicit justification for selection of a BMR of 5 percent. However, justification for the BMR of 5 can be found elsewhere. As discussed in EPA's *Benchmark Dose Technical Guidance* ([U.S. EPA, 2012](#)), a BMR of 5 percent is supported in most developmental and reproductive studies. Comparative analyses of a large database of developmental toxicity studies demonstrated that developmental NOAELs are approximately equal to the BMDL₅ ([Allen et al., 1994a, b](#); [Faustman et al., 1994](#)).

EPA also evaluated a BMR of 10 percent as part of the updated BMD analysis. BMD modeling of fetal testosterone conducted by NASEM ([2017](#)) indicated that BMD₅ estimates are below the lowest dose with empirical testosterone data for several of the phthalates (*e.g.*, DIBP, BBP). As discussed in EPA's *Benchmark Dose Technical Guidance* ([U.S. EPA, 2012](#)) "For some datasets the observations may correspond to response levels far in excess of a selected BMR and extrapolation sufficiently below the observable range may be too uncertain to reliably estimate BMDs/BMDLs for the selected BMR." Therefore, EPA modeled a BMR of 10 percent because datasets for some of the phthalates may not include sufficiently low doses to support modeling of a 5 percent response level.

NASEM ([2017](#)) also modeled a BMR of 40 percent using the following justification: "previous studies have shown that reproductive-tract malformations were seen in male rats when fetal testosterone production was reduced by about 40% ([Gray et al., 2016](#); [Howdeshell et al., 2015](#))."

Further description of methods and results for the updated meta-analysis and BMD modeling analysis that evaluated BMRs of 5, 10, and 40 percent for decreased fetal testicular testosterone are provided in EPA's *Draft Meta-Analysis and Benchmark Dose Modeling of Fetal Testicular Testosterone for Di(2-*

2830 ethylhexyl) Phthalate (DEHP), Dibutyl Phthalate (DBP), Butyl Benzyl Phthalate (BBP), Diisobutyl
2831 Phthalate (DIBP), and Dicyclohexyl Phthalate (DCHP) ([U.S. EPA, 2024d](#)).

2832 **B.3 Results**

2833 BMD estimates, as well as 95 percent upper and lower confidence limits, for decreased fetal testicular
2834 testosterone for the evaluated BMRs of 5, 10, and 40 percent are shown in Table_Apx B-1. BMD₅
2835 estimates ranged from 8.4 to 74 mg/kg-day for DEHP, DBP, DCHP, and DINP; however, a BMD₅
2836 estimate could not be derived for BBP or DIBP. Similarly, BMD₁₀ estimates ranged from 17 to 152 for
2837 DEHP, DBP, DCHP, DIBP and DINP; however, a BMD₁₀ estimate could not be derived for BBP.
2838 BMD₄₀ estimates were derived for all phthalates (*i.e.*, DEHP, DBP, DCHP, DIBP, BBP, DINP) and
2839 ranged from 90 to 699 mg/kg-day.

2840
2841 In the mode of action (MOA) for phthalate syndrome, which is described elsewhere ([U.S. EPA, 2023b](#))
2842 and in Section 1.1 of this document, decreased fetal testicular testosterone is an early, upstream event in
2843 the MOA that precedes downstream apical outcomes such as male nipple retention, decreased anogenital
2844 distance, and reproductive tract malformations. Decreased fetal testicular testosterone should occur at
2845 lower or equal doses than downstream apical outcomes associated with a disruption of androgen action.
2846 Because the lower 95 percent confidence limit on the BMD, or BMDL, is used for deriving a point of
2847 departure (POD), EPA compared BMDL estimates at the 5, 10, and 40 percent response levels for each
2848 phthalate (DEHP, DBP, DCHP, DIBP, BBP, DINP) to the lowest identified apical outcomes associated
2849 with phthalate syndrome to determine which response level is protective of downstream apical
2850 outcomes.

2851
2852 Table_Apx B-1 provides a comparison of BMD and BMDL estimates for decreased fetal testicular
2853 testosterone at BMRs of 5, 10, and 40 percent, the lowest LOAEL(s) for apical outcomes associated
2854 with phthalate syndrome, and the POD selected for each phthalate for use in risk characterization. As
2855 can be seen from Table_Apx B-1, BMDL₄₀ values for DEHP, DBP, DIBP, BBP, DCHP, and DINP are
2856 all well above the PODs selected for use in risk characterization for each phthalate by 3x (for BBP) to
2857 25.4x (for DEHP). Further, BMDL₄₀ values for DEHP, DBP, DIBP, BBP, and DCHP, but not DINP, are
2858 above the lowest LOAELs identified for apical outcomes on the developing male reproductive system.
2859 These results clearly demonstrate that a BMR of 40 percent is not appropriate for use in human health
2860 risk assessment.

2861
2862 As can be seen from Table_Apx B-1, BMDL₁₀ values for DBP (BMDL₁₀, POD, LOAEL = 20, 9, 30
2863 mg/kg-day, respectively) and DCHP (BMDL₁₀, POD, LOAEL = 12, 10, 20 mg/kg-day, respectively) are
2864 slightly higher than the PODs selected for use in risk characterization and slightly less than the lowest
2865 LOAELs identified based on apical outcomes associated with the developing male reproductive system.
2866 This indicates that a BMR of 10% may be protective of apical outcomes evaluated in available studies
2867 for both DBP and DCHP. BMDL₁₀ values could not be derived for DIBP or BBP (Table_Apx B-1).
2868 Therefore, no comparisons to the POD or lowest LOAEL for apical outcomes could be made for either
2869 of these phthalates at the 10 percent response level.

2870
2871 For DEHP, the BMDL₁₀ is greater than the POD selected for use in risk characterization by 5x (BMDL₁₀
2872 and POD = 24 and 24.8 mg/kg-day, respectively) and is greater than the lowest LOAEL identified for
2873 apical outcomes on the developing male reproductive system by 2.4x (BMDL₁₀ and LOAEL = 24 and 10
2874 mg/kg-day, respectively). This indicates that a BMR of 10 percent for decreased fetal testicular
2875 testosterone is not health protective for DEHP. For DEHP, the BMDL₅ (11 mg/kg-day) is similar to the

2876 selected POD (NOAEL of 4.8 mg/kg-day) and the lowest LOAEL identified for apical outcomes on the
2877 developing male reproductive system (10 mg/kg-day).

2878 **B.4 Weight of Scientific Evidence Conclusion**

2879 As discussed elsewhere ([U.S. EPA, 2023b](#)), DEHP, DBP, BBP, DIBP, DCHP, and DINP are
2880 toxicologically similar and induce effects on the developing male reproductive system consistent with a
2881 disruption of androgen action. Because these phthalates are toxicologically similar, it is more
2882 appropriate to select a single BMR for decreased fetal testicular testosterone to provide a consistent
2883 basis for dose response analysis and for deriving PODs relevant to the single chemical assessments and
2884 CRA. EPA has reached the preliminary conclusion that a BMR of 5 percent is the most appropriate and
2885 health protective response level for evaluating decreased fetal testicular testosterone when sufficient
2886 dose-response data are available to support modeling of fetal testicular testosterone in the low-end range
2887 of the dose-response curve. This conclusion is supported by the following weight of scientific evidence
2888 considerations.

- 2889 • For DEHP, the BMDL₁₀ estimate is greater than the POD selected for use in risk characterization
2890 by 5x and is greater than the lowest LOAEL identified for apical outcomes on the developing
2891 male reproductive system by 2.4x. This indicates that a BMR of 10 percent is not protective for
2892 DEHP.
- 2893 • The BMDL₅ estimate for DEHP is similar to the selected POD and lowest LOAEL for apical
2894 outcomes on the developing male reproductive system.
- 2895 • BMDL₁₀ estimates for DBP (BMDL₁₀, POD, LOAEL = 20, 9, 30 mg/kg-day, respectively) and
2896 DCHP (BMDL₁₀, POD, LOAEL = 12, 10, 20 mg/kg-day, respectively) are slightly higher than
2897 the PODs selected for use in risk characterization and slightly less than the lowest LOAELs
2898 identified based on apical outcomes associated with the developing male reproductive system.
2899 This indicates that a BMR of 10 percent may be protective of apical outcomes evaluated in
2900 available studies for both DBP and DCHP. However, this may be a reflection of the larger
2901 database of studies and wider range of endpoints evaluated for DEHP, compared to DBP and
2902 DCHP.
- 2903 • NASEM ([2017](#)) modeled a BMR of 40 percent using the following justification: “*previous*
2904 *studies have shown that reproductive-tract malformations were seen in male rats when fetal*
2905 *testosterone production was reduced by about 40% ([Gray et al., 2016](#); [Howdeshell et al., 2015](#)).”
2906 However, publications supporting a 40 percent response level are relatively narrow in scope and
2907 assessed the link between reduced fetal testicular testosterone in SD rats on GD 18 and later life
2908 reproductive tract malformations in F1 males. More specifically, Howdeshell et al. ([2015](#)) found
2909 reproductive tract malformations in 17 to 100 percent of F1 males when fetal testosterone on GD
2910 18 was reduced by approximately 25 to 72 percent, while Gray et al. ([2016](#)) found dose-related
2911 reproductive alterations in F1 males treated with dipentyl phthalate (a phthalate not currently
2912 being evaluated under TSCA) when fetal testosterone was reduced by about 45 percent on GD
2913 18. Although NASEM modeled a BMR of 40 percent based on biological considerations, there is
2914 no scientific consensus on the biologically significant response level and no other authoritative
2915 or regulatory agencies have endorsed the 40 percent response level as biologically significant for
2916 reductions in fetal testosterone.*
- 2917 • BMDL₄₀ values for DEHP, DBP, DIBP, BBP, DCHP, and DINP are above the PODs selected for
2918 use in risk characterization for each phthalate by 3x to 25.4x (Table_Apx B-1). BMDL₄₀ values
2919 for DEHP, DBP, DIBP, BBP, and DCHP, but not DINP, are above the lowest LOAELs

2920
2921

identified for apical outcomes on the developing male reproductive system. These results clearly demonstrate that a BMR of 40 percent is not health protective.

2922
2923

Table_Apx B-1. Comparison of BMD/BMDL Values Across BMRs of 5%, 10%, and 40% with PODs and LOAELs for Apical Outcomes for DEHP, DBP, DIBP, BBP, DCHP, and DINP

Phthalate	POD (mg/kg-day) Selected for use in Risk Characterization (Effect)	Lowest LOAEL(s) (mg/kg-day) for Apical Effects on the Male Reproductive System	BMD ₅ Estimate ^a (mg/kg-day) [95% CI]	BMD ₁₀ Estimate ^a (mg/kg-day) [95% CI]	BMD ₄₀ Estimate ^a (mg/kg-day) [95% CI]	Reference For Further Details on the Selected POD and Lowest Identified LOAEL,
DEHP	NOAEL = 4.8 (↑ male RTM in F1 and F2 males)	10 to 15 (NR, ↓ AGD, RTMs)	17 [11, 31]	35 [24, 63]	178 [122, 284]	(U.S. EPA, 2024h)
DBP	BMDL ₅ = 9 (↓ fetal testicular testosterone)	30 (↑ Testicular Pathology)	14 [9, 27]	29 [20, 54]	149 [101, 247]	(U.S. EPA, 2024f)
DIBP	BMDL ₅ = 24 (↓ fetal testicular testosterone)	125 (↑ Testicular Pathology)	_b	55 [NA, 266] ^b	279 [136, 517]	(U.S. EPA, 2024i)
BBP	NOAEL = 50 (phthalate syndrome-related effects)	100 (↓ AGD)	_b	_b	284 [150, 481]	(U.S. EPA, 2024e)
DCHP	NOAEL = 10 (phthalate syndrome-related effects)	20 (↑ Testicular Pathology)	8.4 [6.0, 14]	17 [12, 29]	90 [63, 151]	(U.S. EPA, 2024g)
DINP	BMDL ₅ = 49 (↓ fetal testicular testosterone)	600 (↓ sperm motility)	74 [47, 158]	152 [97, 278]	699 [539, 858]	(U.S. EPA, 2025p)
<p>Abbreviations: AGD = anogenital distance; BMD = benchmark dose; BMDL = lower 95% confidence limit on BMD; CI = 95% confidence interval; LOAEL = lowest observable-adverse-effect level; NOAEL = no observable-adverse-effect level; POD = point of departure; RTM = reproductive tract malformations</p> <p>^a The linear-quadratic model provided the best fit (based on lowest AIC) for DEHP, DBP, DIBP, BBP, DCHP, and DINP.</p> <p>^b BMD and/or BMDL estimate could not be derived.</p>						

2924

2925 Appendix C NHANES URINARY BIOMONITORING

2926 C.1 Urinary Biomonitoring: Methods and Results

2927 EPA analyzed urinary biomonitoring data from the U.S. Centers for Disease Control and Prevention
2928 (CDC) National Health and Nutrition Evaluation Surveys (NHANES), which reports urinary
2929 concentrations for 15 phthalate metabolites specific to individual phthalate diesters.

2930
2931 **DEHP.** Four urinary metabolites of DEHP, mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHP), mono(2-
2932 ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), and
2933 mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) have been reported in the NHANES data. MEHP has
2934 been reported in NHANES beginning with the 1999 cycle and measured in 26,740 members of the
2935 general public, including 7,331 children under age 16 and 19,409 adults aged 16 and over. MEHHP was
2936 added starting in the 2001 to 2002 NHANES cycle and has been measured in 24,199 participants,
2937 including 6,617 children and 17,852 adults. MEOHP was added starting in the 2001 to 2002 NHANES
2938 cycle and has been measured in 24,199 participants, including 6,617 children and 17,582 adults. MECPP
2939 was added starting in the 2003 to 2004 NHANES cycles and has been measured in 21,417 participants,
2940 including 5,839 children and 15,578 adults. Metabolites of DEHP were quantified in urinary samples
2941 from a one-third subsample of all participants aged 6 and older. Beginning with the 2005–2006 cycle of
2942 NHANES, all participants between 3–5 years were eligible for DEHP metabolite urinary analysis.
2943 Urinary DEHP metabolite concentrations were quantified using high performance liquid
2944 chromatography-electrospray ionization-tandem mass spectrometry. Limits of detection (LOD) for each
2945 cycle on NHANES are provided in Table_Apx C-1. Values below the LOD were replaced by the lower
2946 limit of detection divided by the square root of two ([NCHS, 2021](#)). As can be seen from Table_Apx C-2,
2947 MEHHP, MEOHP, and MECPP were above the LOD in the urine of more than 99 percent of all
2948 NHANES participants (n=2,762) in the most recent survey (2017 to 2018), while MEHP was above the
2949 LOD in approximately 46 percent of samples.
2950

2951
2952 **DBP.** Two urinary metabolites of DBP, mono-n-butyl phthalate (MnBP) and mono-3-hydroxybutyl
2953 phthalate (MHBP), have been reported in the NHANES data. MnBP has been reported in NHANES
2954 beginning with the 1999 cycle and was measured in 26,740 members of the general public, including
2955 7,331 children under age 16 and 19,409 adults aged 16 and over. Although MHBP was measured in the
2956 2013 to 2018 NHANES cycles, the data for the 2013 to 2014 NHANES cycle was determined to be
2957 inaccurate due to procedural error and only released as surplus data, which is not readily publicly
2958 available (https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/SSPHTE_H.htm). As a result, the present
2959 analysis only includes urinary MHBP data from the 2015 to 2018 NHANES cycles. The present analysis
2960 of MHBP includes data from the 2015 to 2018 NHANES cycles and has been measured in 5,737
2961 participants, including 1,961 children under age 16 and 3,776 adults aged 16 and older. Urinary MnBP
2962 and MHBP concentrations were quantified using high performance liquid chromatography-electrospray
2963 ionization-tandem mass spectrometry. Limits of detection (LOD) for each cycle on NHANES are
2964 provided in Table_Apx C-1. Values below the LOD were replaced by the lower limit of detection
2965 divided by the square root of two ([NCHS, 2021](#)). As can be seen from Table_Apx C-2, MnBP was
2966 above the LOD in the urine of more than 99 percent of all NHANES participants (n=2,762) in the most
2967 recent survey (2017 to 2018), while MHBP was above the LOD in approximately 75 percent of samples.
2968
2969
2970

2971 **BBP.** One urinary metabolite of BBP, mono-benzyl phthalate (MBzP), has been reported in the
2972 NHANES dataset. MBzP has been reported in NHANES beginning with the 1999 cycle and measured in
2973 26,740 members of the general public, including 7,331 children aged 15 and under and 19,409 adults
2974 aged 16 and over. Urinary MBzP concentrations were quantified using high performance liquid
2975 chromatography-electrospray ionization-tandem mass spectrometry. Limits of detection (LOD) for each
2976 cycle on NHANES are provided in Table_Apx C-1. Values below the LOD were replaced by the lower
2977 limit of detection divided by the square root of two ([NCHS, 2021](#)). As can be seen from Table_Apx C-2,
2978 MBzP was above the LOD in the urine of 96.2 percent of all NHANES participants (n=2,762) in the
2979 most recent survey (2017 to 2018).

2980
2981
2982 **DIBP.** Two urinary metabolites of DIBP, mono-2-methyl-2-hydroxypropyl phthalate (MHiBP) and
2983 mono-isobutyl phthalate (MIBP), have been reported in the NHANES dataset. MIBP has been reported
2984 starting in the 2001 to 2002 NHANES cycle and has been measured in 24,199 participants, including
2985 6,617 children and 17,582 adults. Although MHiBP was measured in the 2013 to 2018 NHANES cycles,
2986 the data for the 2013 to 2014 NHANES cycle was determined to be inaccurate due to procedural error
2987 and only released as surplus data, which is not readily publicly available
2988 (https://wwwn.cdc.gov/Nchs/Nhanes/2013-2014/SSPHTE_H.htm). As a result, the present analysis only
2989 includes urinary MHiBP data from the 2015 to 2018 NHANES cycles. From 2015 to 2018, MHiBP and
2990 has been measured in 5,737 members of the general public, including 1,961 children aged 15 and under
2991 and 3,776 adults aged 16 and over. Urinary MIBP and MHiBP concentrations were quantified using
2992 high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Limits of
2993 detection (LOD) for each cycle of NHANES are provided in Table_Apx C-1. Values below the LOD
2994 were replaced by the lower limit of detection divided by the square root of two ([NCHS, 2021](#)). As can
2995 be seen from Table_Apx C-2, MHiBP was above the LOD in the urine of approximately 98 percent of
2996 all NHANES participants (n=2,762) in the most recent survey (2017 to 2018), while MIBP was above
2997 the LOD in approximately 95 percent of samples.

2998
2999
3000 **DINP.** Three metabolites of DINP, mono-isononyl phthalate (MINP), mono-oxoisononyl phthalate
3001 (MONP), and mono-(carboxyoctyl) phthalate (MCOP) have been reported in the NHANES dataset.
3002 MINP has been reported in NHANES beginning with the 1999 cycle and measured in 26,740 members
3003 of the general public, including 7,331 children aged 15 and under and 19,409 adults aged 16 and over.
3004 MCOP was added starting in the 2005 to 2006 NHANES cycle and has been measured in 18,812
3005 participants, including 5,123 children and 13,689 adults. Most recently (in 2017 to 2018), NHANES
3006 began reporting concentrations of MONP, which has been measured in 2,762 participants, including 866
3007 children and 1,896 adults. Urinary MINP, MONP, and MCOP concentrations were quantified using high
3008 performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Limits of
3009 detection (LOD) for each cycle on NHANES are provided in Table_Apx C-1. Values below the LOD
3010 were replaced by the lower limit of detection divided by the square root of two ([NCHS, 2021](#)). As can
3011 be seen from Table_Apx C-2, MCOP was above the LOD in the urine of greater than 99 percent of all
3012 NHANES participants (n=2,762) in the most recent survey (2017 to 2018), while MINP and MONP
3013 were above the LOD in approximately 87 percent of samples.

3014
3015
3016 **DCHP.** One metabolite of DCHP, mono-cyclohexyl phthalate (MCHP), has been reported in the
3017 NHANES dataset. MCHP has been reported in NHANES beginning with the 1999 cycle and measured
3018 in 15,829 members of the general public, including 4,130 children age 15 and under and 11,699 adults

age 16 and over. However, MCHP was excluded from the NHANES survey due to low detection levels and a low frequency of detection in human urine after the 2009 to 2010 survey cycle (CDC, 2013a). Urinary MCHP concentrations were quantified using high performance liquid chromatography-electrospray ionization-tandem mass spectrometry. Limits of detection (LOD) for each cycle on NHANES are provided in Table_Apx C-1. Values below the LOD were replaced by the lower limit of detection divided by the square root of two (NCHS, 2021). In the 1999 to 2000 NHANES survey, MCHP was above the LOD in 100 percent of urine samples; however, the percent of samples with levels of MCHP above the LOD dropped precipitously in subsequent survey years. In the 2009 to 2010 survey year (last survey in which MCHP was monitored), MCHP was above the LOD in 4.3 percent of samples for all adults aged 16 years and older, and 7.9 percent of samples for all children 3 to less than 16 years of age (see Appendix B of the *Draft Environmental Media, General Population, and Environmental Exposure for Dicyclohexyl Phthalate (DCHP)* (U.S. EPA, 2024b)).

Table_Apx C-1. Limit of Detection (ng/mL) of Urinary Phthalate Metabolites by NHANES Survey Year

Phthalate	Urinary Metabolite	NHANES Survey Year									
		1999–2000	2001–2002	2003–2004	2005–2006	2007–2008	2009–2010	2011–2012	2013–2014	2015–2016	2017–2018
DEHP	MEHP	0.86	0.86	0.9	1.2	1.2	0.5	0.5	0.8	0.8	0.8
	MEHHP	-	-	0.32	0.7	0.7	0.2	0.2	0.4	0.4	0.4
	MECPP	-	-	0.25	0.6	0.6	0.2	0.2	0.4	0.4	0.4
	MEOHP	-	-	0.45	0.7	0.7	0.2	0.2	0.2	0.2	0.2
DBP	MnBP	0.94	0.94	0.4	0.6	0.6	0.4	0.2	0.4	0.4	0.4
	MHBP	-	-	-	-	-	-	-	-	0.4	0.4
BBP	MBzP	0.47	0.47	0.11	0.3	0.3	0.216	0.3	0.3	0.3	0.3
DIBP	MiBP	-	0.94	0.26	0.3	0.3	0.2	0.2	0.8	0.8	0.8
	MHiBP	-	-	-	-	-	-	-	-	0.4	0.4
DCHP	MCHP	0.93	0.93	0.2	0.3	0.3	0.402	-	-	-	-
DINP	MiNP	0.79	0.79	1.54	1.23	1.23	0.77	0.5	0.9	0.9	0.9
	MCOP	-	-	-	0.7	0.7	0.2	0.2	0.3	0.3	0.3
	MONP	-	-	-	-	-	-	-	-	-	0.4

Table_Apx C-2. Summary of Phthalate Metabolite Detection Frequencies in NHANES^a

Parent Phthalate	Urinary Metabolite	Percentage Below the Limit of Detection		
		2017–2018 NHANES (All Participants; N=2762)	2017–2018 NHANES (Women Aged 16–49; N=470)	2017–2018 NHANES (Children Aged 6–17; N=866)
BBP	Mono-benzyl phthalate (MBzP)	3.8%	6.25%	0.81%
DBP	Mono-n-butyl phthalate (MnBP)	0.69%	0.81%	0.58%

Parent Phthalate	Urinary Metabolite	Percentage Below the Limit of Detection		
		2017–2018 NHANES (All Participants; N=2762)	2017–2018 NHANES (Women Aged 16–49; N=470)	2017–2018 NHANES (Children Aged 6–17; N=866)
	Mono-3-hydroxybutyl phthalate (MHBP)	24.91%	27.82%	15.82%
DEHP	Mono-2-ethylhexyl phthalate (MEHP)	43.77%	41.13%	36.84%
	Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP)	0.98%	1.21%	0.12%
	Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP)	0.83%	1.21%	0.12%
	Mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP)	0.18%	–	–
DIBP	Mono-isobutyl phthalate (MiBP)	4.89%	7.46%	1.5%
	Mono-2-methyl-2-hydroxypropyl Phthalate (MHiBP)	2.17%	2.34%	1.03%
DINP	Mono-isononyl phthalate (MiNP)	12.57%	14.37%	18.01%
	Mono-(carboxyoctyl) phthalate (MCOP)	0.51%	0.40%	0.11%
	Mono-oxoisononyl phthalate (MONP)	12.85%	11.06%	7.62%

– Indicates that the metabolite was not included as part of the analysis.
^a Collection of DCHP was discontinued after the 2009–2010 NHANES cycle and is not included in this table.

C.2 Urinary Biomonitoring: Temporal Trends Analysis

C.2.1 DEHP

Temporal trends in urinary MEHP, MEHHP, MEOHP, and MEOCP, which are metabolites of DEHP, are summarized below and discussed in detail in Section 10.2 of EPA’s *Draft Environmental Media and General Population and Environmental Exposure for Diethylhexyl Phthalate (DEHP)* ([U.S. EPA, 2025h](#)). **Overall, 50th and 95th percentile urinary MEHP, MEHPP, MEOHP and MEOCP concentrations have significantly decreased over time (1999–2018) for all lifestages.**

For MEHP (NHANES reporting years: 1999–2018), the following trends were observed:

- Overall, median and 95th percentile MEHP urinary concentrations have decreased over time (1999–2018) for all lifestages.
- Median and 95th percentile urinary MEHP concentrations decreased significantly among all children under age 16, as well as among children aged 3 to less than 6 years, 6 to less than 11 years, and 11 to less than 16 years from 1999 to 2018. There were also significant decreases in median and 95th percentile urinary MEHP concentrations for all male children and all female children under age 16 from 1999 to 2018.
- Median and 95th percentile urinary MEHP concentrations decreased significantly among all adults, female adults, and male adults 16 years and older from 1999 to 2018. Among women of reproductive age, there were statistically significant decreases in 50th and 95th percentile MEHP urinary concentrations from 1999 to 2018.

3058
3059 For MEHHP and MEOHP (NHANES reporting years for both metabolites: 2001–2018), the following
3060 trends were observed:

- 3061 • Overall, median and 95th percentile MEHHP and MEOHP concentrations have decreased over
3062 time (2001–2018) for all lifestages.
- 3063 • Statistically significant decreases in 50th and 95th percentile urinary MEHHP and MEOHP
3064 concentrations were observed among all children under age 16, as well as among children aged 3
3065 to less than 6 years, 6 to less than 11 years, and 11 to less than 16 years from 1999 to 2018.
3066 Median and 95th percentile urinary MEHHP and MEOHP concentrations also decreased
3067 significantly for all male and all female children, and female children under age 16, from 1999 to
3068 2018.
- 3069 • Median and 95th percentile MEHHP and MEOHP urinary concentrations decreased significantly
3070 among all adults, as well as among adult males, and among adult females 16 years and older
3071 from 2001 to 2018. Among women of reproductive age, there were statistically significant
3072 decreases in 50th and 95th percentile MEHHP and MEOHP urinary concentrations from 2001 to
3073 2018.

3074
3075 For MECPP (NHANES reporting years: 2003–2018), the following trends were observed:

- 3076 • Overall, median and 95th percentile MECPP concentrations have decreased over time (2003–
3077 2018) for all lifestages.
- 3078 • Statistically significant decreases in 50th and 95th percentile urinary MECPP concentrations
3079 were observed among all children under age 16, as well as among children aged 3 to less than 6
3080 years, 6 to less than 11 years, and 11 to less than 16 years from 2003 to 2018. Median and 95th
3081 percentile urinary MECPP concentrations also decreased significantly for all male and all female
3082 children and female children under age 16 from 1999 to 2018.
- 3083 • Median and 95th percentile MECPP urinary concentrations decreased significantly among all
3084 adults, as well as among adult males, and among adult females 16 years and older from 2003 to
3085 2018. Among women of reproductive age, there were statistically significant decreases in 50th
3086 and 95th percentile MECPP urinary concentrations from 2003 to 2018.

3088 C.2.2 DBP

3089 Temporal trends in urinary MnBP and MHBP, which are metabolites of DBP, are summarized below
3090 and discussed in detail in Section 10.2 of EPA’s *Draft Environmental Media and General Population*
3091 *and Environmental Exposure for Dibutyl Phthalate (DBP)* ([U.S. EPA, 2025g](#)). **Overall, 50th and 95th**
3092 **percentile urinary MnBP concentrations have decreased over time (1999–2018) for all life stages.**
3093 For urinary MHBP, consistent temporal trends across populations are less apparent; however, MHBP
3094 has only been measured in NHANES from 2015 to 2018. This shorter sampling period may account for
3095 some of the observed variability and inconsistency.

3096
3097 For MnBP (NHANES reporting years: 1999–2018), the following trends were observed:

- 3098 • Overall, 50th and 95th MnBP urinary concentrations have decreased over time (1999–2018) for
3099 all life stages.

- From 1999 to 2018, 50th and 95th percentile urinary MnBP concentrations significantly decreased over time for all children under 16 years of age, as well as for children aged 3 to less than 6 years, 6 to less than 11 years, and 11 to less than 16 years; all adults, all female adults, and all male adults 16 years and older; and women of reproductive age (16 to 49 years of age).

For MHPBP (NHANES reporting years: 2015–2018), the following trends were observed:

- While 95th percentile MHPBP concentrations tended to decrease over time for children and adults, they increased over time among women of reproductive age. Meanwhile, 50th percentile MHPBP concentrations tended to increase over time among children under 16, decrease for adults, and have no significant changes for women of reproductive age.
- From 2015 to 2018, 50th percentile MHPBP concentrations increased over time among all children under 16, and among adolescents aged 11 to less than 16 years old. However, 95th percentile MHPBP concentrations decreased over time among all children under 16, male children under 16, children aged 6 to less than 11 years, and adolescents aged 11 to less than 16 years.
- Additionally, 50th percentile MHPBP concentrations decreased over time among all adults and for adult females. During this period, 95th percentile MHPBP concentrations also decreased among all adults, adult males, and adult females. Among women of reproductive age, 95th percentile MHPBP concentrations increased significantly, though no significant changes were observed at the 50th percentile.

C.2.3 BBP

Temporal trends in urinary MBzP, a metabolite of BBP, are summarized below and discussed in detail in Section 10.2 of EPA’s *Draft Environmental Media and General Population and Environment Exposure for Butyl benzyl phthalate (BBP)* ([U.S. EPA, 2025f](#)). **Overall, 50th and 95th percentile urinary MBzP concentrations significantly decreased over time (1999–2018) for all lifestages.**

For MBzP (NHANES reporting years: 1999–2018), the following trends were observed:

- Overall, MBzP urinary concentrations have decreased over time across all life stages between 1999 and 2018.
- From 1999 to 2018, 50th and 95th percentile MBzP concentrations decreased significantly for all children under 16 over time, as well as for male children and female children. This significant trend held for all age groups: 3 to less than 6 years, 6 to less than 11, and 11 to less than 16 years. The 50th and 95th percentile MBzP urinary concentrations also decreased significantly amongst all adults, adult males, and adult females ages 16 years and older.
- From 1999 to 2018, both 50th and 95th percentile MBzP urinary concentrations decreased amongst women of reproductive age (16 to 49 years of age) over time.

C.2.4 DIBP

Temporal trends in urinary MIBP and MHiBP, which are metabolites of DIBP, are summarized below and in more detail in Section 10.2 of EPA’s *Draft Environmental Media and General Population and Environment Exposure for Diisobutyl phthalate (DIBP)* ([U.S. EPA, 2025i](#)). **Overall, 50th and 95th**

percentile urinary MIBP concentrations significantly increased over time (1999–2018) for all lifestages, while 50th and 95th percentile MHiBP urinary concentrations decreased over time (2015–2018) for most life stages.

For MIBP (NHANES reporting years: 2001–2018), the following trends were observed:

- Overall, median and 95th percentile MIBP urinary concentrations significantly increased over time for all life stages from 2001 to 2018.
- From 2001 to 2018, median and 95th percentile urinary MIBP concentrations significantly increased among all children 3 to less than 16 years, as well as for children 6 to less than 11 years and children 11 to less than 16 years. MIBP concentrations also significantly increased among toddlers 3 to less than 6 years at the 95th percentile. Similarly, median and 95th percentile MIBP concentrations significantly increased among all adults, adult males, and adult females, females ages 16 years and older, as well as for women of reproductive age (16 to 49 years).

For MHiBP (NHANES reporting years: 2015–2018), the following trends were observed:

- Overall, median and 95th percentile MHiBP urinary concentrations decreased over time for most life stages.
- From 2015 to 2018, median MHiBP urinary concentrations decreased among all children 3 to less than 16 years, as well as for the children 6 to less than 11 years. However, median MHiBP urinary concentrations increased among adolescents 11 to less than 16 years. During this time, 95th percentile MHiBP urinary concentrations decreased significantly over time among all children 3 to less than 16 years, male children, female children, and among the following age groups: toddlers 3 to less than 6 years, children 6 to less than 11 years, and adolescents 11 to less than 16 years.
- Significant decreases in median MHiBP urinary concentrations were observed among all adults aged 16 and older, adult females, adult males, and women of reproductive age (16 to 49 years). Additionally, 95th percentile MHiBP urinary concentrations decreased significantly among all adults aged 16 and older, as well as for male adults, and women of reproductive age (16 to 49 years).

C.2.5 DINP

Temporal trends in urinary MINP and MCOP, which are metabolites of DINP, are summarized below and in more detail in Section 10.2 of EPA's *Draft Environmental Media and General Population Screening for Diisononyl Phthalate (DINP)* ([U.S. EPA, 2025n](#)). For MONP, no temporal trends analysis was conducted because MONP has only been measured in the most recent NHANES survey (2017 to 2018).

For MINP (NHANES reporting years: 1999–2018), the following trends were observed:

- Among all NHANES participants, the direction of the trend of MiNP concentrations changed over time. MiNP significantly increased ($p < 0.001$ for both 50th and 95th percentile exposures) between 1999 and 2014, but decreased between 2015 and 2018; the decrease was statistically significant at the 95th percentile ($p = 0.007$), but not at the 50th percentile.
- Overall, urinary concentrations of MINP have generally decreased over time for most lifestages.

- Among all children under 16, significant changes were observed in 50th and 95th percentile MINP concentrations (50th percentile, $p < 0.001$; 95th percentile, $p < 0.001$), as well as a significant increase in 95th percentile concentrations among male children under 16 ($p < 0.001$), and a significant decrease among female children under 16 ($p < 0.001$). Within age groups, MINP concentrations significantly decreased among children aged 3 to less than 6 years of age (95th percentile, $p < 0.001$) and significantly increased among adolescents 11 to less than 16 years of age (50th percentile, $p < 0.001$; 95th percentile, $p < 0.001$); no significant changes in 50th or 95th percentile MINP concentrations over time were observed among children aged 6 to less than 11.
- MINP concentrations significantly decreased among all adults (50th percentile, $p < 0.001$; 95th percentile, $p < 0.001$), adult males (95th percentile, $p < 0.001$), and adult females (50th percentile, $p < 0.001$). A significant increase in MINP concentrations were observed among adult females (50th percentile, $p < 0.001$; 95th percentile, $p < 0.001$) and in 50th percentile concentrations among women of reproductive age ($p = 0.03$).

For MCOP (NHANES reporting years: 2005–2018), the following trends were observed:

- Among all NHANES participants, the direction of the trend of MiNP concentrations changed over time. Between 2005 and 2014, MCOP concentrations significantly increased among all NHANES participants (50th percentile, $p < 0.001$). After 2014, MCOP concentrations significantly decreased at both the 50th and 95th percentile for all participants ($p < 0.001$ for both analyses).
- Overall, median MCOP concentrations have decreased over time for all lifestages, while 95th percentile concentrations increased over time for all lifestages.
- There was a significant decrease in 50th percentile urinary MCOP concentrations among all children under 16 ($p < 0.001$), as well as among children aged 6 to less than 11 years ($p < 0.001$). Increases in 95th percentile urinary MCOP concentrations were observed among all children under 16 ($p < 0.001$), all male children under 16 ($p < 0.001$), and all female children under 16 ($p < 0.001$). Additionally, a significant increase in 95th percentile concentrations over time was observed among toddlers aged 3 to less than 6, and a significant decrease in MCOP concentrations was observed among children aged 6 to less than 11 years old ($p < 0.001$). At both the 50th and 95th percentile, significant differences in urinary MCOP concentrations were observed between male and female children under 16 over time (50th percentile, $p < 0.001$; 95th percentile, $p < 0.001$).
- Among adults, 50th percentile MCOP concentrations significantly decreased over time for all adults, but significantly increased over time for adults at the 95th percentile of exposure. Significant decreases in MCOP were also observed among adult males (50th percentile, $p < 0.001$) and adult females (50th percentile, $p < 0.001$; 95th percentile, $p = 0.005$) but not for women of reproductive age. Additionally, a significant difference in 95th percentile MCOP concentrations were observed between adult men and women ($p < 0.001$), but no difference was observed for 50th percentile MCOP concentrations.

C.3 Reverse Dosimetry: Methods and Results

Using urinary metabolite concentrations for DEHP, DBP, BBP, DIBP, and DINP measured in the most recently available NHANES sampling cycle (2017 to 2018), EPA estimated phthalate daily intake

through reverse dosimetry. Reverse dosimetry approaches that incorporate basic pharmacokinetic information are available for phthalates (Koch et al., 2007; Koch et al., 2003; David, 2000) and have been used in previous phthalate risk assessments conducted by U.S. CPSC (2014) and Health Canada (ECCC/HC, 2020) to estimate daily intake values for exposure assessment. For phthalates, reverse dosimetry can be used to estimate a daily intake (DI) value for a parent phthalate diester based on phthalate monoester metabolites measured in human urine using Equation_Apx C-1 (Koch et al., 2007).

Equation_Apx C-1. Calculating the Daily Intake Value from Urinary Biomonitoring Data

$$Phthalate\ DI = \frac{(UE_{sum} \times CE)}{Fue_{sum}} \times MW_{Parent}$$

Where:

- Phthalate DI = Daily intake (µg/kg_{bw}/day) value for the parent phthalate diester
- UE_{sum} = The sum molar concentration of urinary metabolites associated with the parent phthalate diester (in units of µmole per gram creatinine).
- CE = The creatinine excretion rate normalized by body weight (in units of mg creatinine per kg bodyweight per day). CE can be estimated from the urinary creatinine values reported in biomonitoring studies (*i.e.*, NHANES) using the equations of Mage et al. (2008) based on age, gender, height, and race, as was done by Health Canada (ECCC/HC, 2020) and U.S. CPSC (2014).
- Fue_{sum} = The summed molar fraction of urinary metabolites. The molar fraction describes the molar ratio between the amount of metabolite excreted in urine and the amount of parent compound taken up. Fue values used for daily intake value calculations are shown in Table_Apx C-3.
- MW_{parent} = The molecular weight of the parent phthalate diester (in units of g/mole).

Daily intake values were calculated for each participant from NHANES. A creatinine excretion rate for each participant was calculated using equations provided by Mage et al. (2008). The applied equation is dependent on the participant’s age, height, race, and sex to accommodate variances in urinary excretion rates. Creatinine excretion rate equations were only reported for people who are non-Hispanic Black and non-Hispanic White, so the creatinine excretion rate for participants of other races were calculated using the equation for non-Hispanic White adults or children, in accordance with the approach used by U.S. CPSC (2015).

Table_Apx C-3. Fue Values Used for the Calculation of Daily Intake Values of DEHP, BBP, DBP, DIBP, and DINP

Parent Phthalate	Study Population	Metabolite(s)	Fue ^a	Fue Sum	Reference
DEHP	N = 10 men (20–42 years of age) and 10 women (18–77 years of age)	MEHP	0.062	0.452	(Anderson et al., 2011)
		MEHHP	0.149		
		MEOHP	0.109		
		MECPP	0.132		
BBP	N = 14 volunteers (gender and age not provided)	MBzP	0.73	0.73	(Anderson et al., 2001)

PUBLIC RELEASE DRAFT
May 2025

Parent Phthalate	Study Population	Metabolite(s)	Fue ^a	Fue Sum	Reference
DBP	N = 13 volunteers (gender and age not provided)	MBP	0.69	0.69	(Anderson et al., 2001)
DIBP	N = 13 volunteers (gender and age not provided)	MiBP	0.69	0.69	(Anderson et al., 2001)
DINP	N = 10 men (20–42 years of age) and 10 women (18–77 years of age)	MINP	0.030	0.192	(Anderson et al., 2011)
		MONP	0.063		
		MCOP	0.099		
^a Fue values are presented on a molar basis and were estimated by study authors based on metabolite excretion over a 24-hour period (DINP, DBP, DIBP). ^b Fue value of 0.69 based on excretion of DBP urinary metabolite MnBP.					

C.4 Statistical Analysis of Cumulative Phthalate Exposure

Table_Apx C-4. Statistical Analysis (t-test) of Cumulative Phthalate Exposure for Women of Reproductive Age by Race^a

Variable	Method	Variances	tValue	DF	Probt	Race 1 ^b	Race 2 ^b
50th Percentile	Pooled	Equal	-0.7049	8	0.5009	white	black
50th percentile	Pooled	Equal	-0.2509	8	0.8082	white	mexic
50th percentile	Pooled	Equal	0.5053	8	0.6270	white	other
50th percentile	Pooled	Equal	-0.4905	8	0.6369	black	mexic
50th percentile	Pooled	Equal	-1.0495	8	0.3246	black	other
50th percentile	Pooled	Equal	-0.7143	8	0.4954	mexic	other
50th percentile	Pooled	Equal	0.5780	8	0.5792	white	black
50th percentile	Pooled	Equal	-0.4230	8	0.6834	white	mexic
50th percentile	Pooled	Equal	1.0271	8	0.3344	white	other
50th percentile	Pooled	Equal	0.8771	8	0.4060	black	mexic
50th percentile	Pooled	Equal	-0.6560	8	0.5302	black	other
50th percentile	Pooled	Equal	-1.1843	8	0.2703	mexic	other
50th percentile	Pooled	Equal	-0.7049	8	0.5009	white	black
50th percentile	Pooled	Equal	-0.2509	8	0.8082	white	mexic
50th percentile	Pooled	Equal	0.5053	8	0.6270	white	other
50th percentile	Pooled	Equal	-0.4905	8	0.6369	black	mexic
50th percentile	Pooled	Equal	-1.0495	8	0.3246	black	other
50th percentile	Pooled	Equal	-0.7143	8	0.4954	mexic	other
95th percentile	Pooled	Equal	0.5780	8	0.5792	white	black
95th percentile	Pooled	Equal	-0.4230	8	0.6834	white	mexic
95th percentile	Pooled	Equal	1.0271	8	0.3344	white	other
95th percentile	Pooled	Equal	0.8771	8	0.4060	black	mexic
95th percentile	Pooled	Equal	-0.6560	8	0.5302	black	other
95th percentile	Pooled	Equal	-1.1843	8	0.2703	mexic	other
95th percentile	Pooled	Equal	-0.7049	8	0.5009	white	black
95th percentile	Pooled	Equal	-0.2509	8	0.8082	white	mexic
95th percentile	Pooled	Equal	0.5053	8	0.6270	white	other
95th percentile	Pooled	Equal	-0.4905	8	0.6369	black	mexic
95th percentile	Pooled	Equal	-1.0495	8	0.3246	black	other
95th percentile	Pooled	Equal	-0.7143	8	0.4954	mexic	other
95th percentile	Pooled	Equal	0.5780	8	0.5792	white	black
95th percentile	Pooled	Equal	-0.4230	8	0.6834	white	mexic
95th percentile	Pooled	Equal	1.0271	8	0.3344	white	other
95th percentile	Pooled	Equal	0.8771	8	0.4060	black	mexic
95th percentile	Pooled	Equal	-0.6560	8	0.5302	black	other
95th percentile	Pooled	Equal	-1.1843	8	0.2703	mexic	other

^a Independent t-test with pooled variance (assuming equal variance in exposures among both racial groups) to assess differences in mean phthalate exposure between different racial groups.

^b Racial groups include White non-Hispanic, Black non-Hispanic, Mexican American, and Other.

3265
3266
3267

Table_Apx C-5. Statistical Analysis (ANOVA with Tukey Post-Hoc Test) of Cumulative Phthalate Exposure for Women of Reproductive Age by Race^a

Dependent	Source	DF	SS	MS	F Value	ProbF
50th percentile	Model	3	0.053263348	0.017754449	0.491687573	0.693011899
	Error	16	0.577747344	0.036109209		
	Corrected Total	19	0.631010692			
95th percentile	Model	3	7.932713778	2.644237926	0.850142129	0.486666284
	Error	16	49.76556906	3.110348067		
	Corrected Total	19	57.69828284			

Abbreviations: DF = Degrees of freedom; MS = mean squares; SS = sum-of-squares;
^a ANOVA to determine whether there are significant differences in phthalate exposure among racial groups among women of reproductive age. Post-hoc tests were performed to examine differences in exposure between races. No differences were observed and output was not generated.

3268
3269
3270
3271

Table_Apx C-6. Statistical Analysis (ANOVA with Tukey Post-Hoc Test) of Cumulative Phthalate Exposure for Women of Reproductive Age by Socioeconomic Status^a

Dependent	Source	DF	SS	MS	F Value	ProbF
50th percentile	Model	2	0.058905	0.029453	0.299768	0.74638
	Error	12	1.179014	0.098251		
	Corrected Total	14	1.237919			
95th percentile	Model	2	6.019748	3.009874	0.085482	0.918624
	Error	12	422.5295	35.21079		
	Corrected Total	14	428.5493			

Abbreviations: DF = Degrees of freedom; MS = mean squares; SS = sum-of-squares;
^a ANOVA to determine whether there are significant differences in phthalate exposure among socioeconomic status groups among women of reproductive age. Post-hoc tests were performed to examine differences in exposure between socioeconomic status. No differences were observed and output was not generated.

3272
3273
3274
3275

Table_Apx C-7. Statistical Analysis (ANOVA with Tukey Post-Hoc Test) of Cumulative Phthalate Exposure for Women of Reproductive Age and Male Children by Age^a

Dependent	Source	DF	SS	MS	F Value	ProbF
50th percentile	Model	3	0.527705678	0.175901893	1.061407322	0.393002372
	Error	16	2.651602472	0.165725155		
	Corrected Total	19	3.17930815			
95th percentile	Model	3	6.568006156	2.189335385	1.403496422	0.278192271
	Error	16	24.95864302	1.559915189		

Dependent	Source	DF	SS	MS	F Value	ProbF
	Corrected Total	19	31.52664917			

Abbreviations: DF = Degrees of freedom; MS = mean squares; SS = sum-of-squares;
^a ANOVA to determine whether there are significant differences in phthalate exposure among age groups (women aged 16-49, boys age 3-5, boys age 6-11, and boys age 12-15). Post-hoc tests were performed to examine differences in exposure between races. No differences were observed and output was not generated.

C.5 Limitations and Uncertainties of Reverse Dosimetry Approach

3276
3277 Controlled human exposure studies have been conducted and provide estimates of the urinary molar
3278 excretion factor (*i.e.*, the Fue) to support use of a reverse dosimetry approach. These studies most
3279 frequently involve oral administration of an isotope-labelled (*e.g.*, deuterium or carbon-13) phthalate
3280 diester to a healthy human volunteer and then urinary excretion of monoester metabolites is monitored
3281 over 24 to 48 hours. Fue values estimated from these studies have been used by both U.S. CPSC (2014)
3282 and Health Canada (ECCC/HC, 2020) to estimate phthalate daily intake values using urinary
3283 biomonitoring data.

3284
3285 Use of reverse dosimetry and urinary biomonitoring data to estimate daily intake of phthalates is
3286 consistent with approaches employed by both U.S. CPSC (2014) and Health Canada (ECCC/HC, 2020).
3287 However, there are challenges and sources of uncertainty associated with the use of reverse dosimetry
3288 approaches. U.S. CPSC considered several sources of uncertainty associated with use of human urinary
3289 biomonitoring data to estimate daily intake values and conducted a semi-quantitative evaluation of
3290 uncertainties to determine the overall effect on daily intake estimates (see Section 4.1.3 of (U.S. CPSC,
3291 2014)). Identified sources of uncertainty include: (1) analytical variability in urinary metabolite
3292 measurements; (2) human variability in phthalate metabolism and its effect on metabolite conversion
3293 factors (*i.e.*, the Fue); (3) temporal variability in urinary phthalate metabolite levels; (4) variability in
3294 urinary phthalate metabolite levels due to fasting prior to sample collection; (5) variability due to fast
3295 elimination kinetics and spot samples; and (6) creatinine correction models for estimating daily intake
3296 values.

3297
3298 In addition to some of the limitations and uncertainties discussed above and outlined by U.S. CPSC
3299 (2014), the short half-lives of phthalates can be a challenge when using a reverse dosimetry approach.
3300 Phthalates have elimination half-lives on the order of several hours and are quickly excreted from the
3301 body in urine and to some extent feces (ATSDR, 2022; EC/HC, 2015). Therefore, spot urine samples, as
3302 collected through NHANES and many other biomonitoring studies, are representative of relatively
3303 recent exposures. Spot urine samples were used by Health Canada (ECCC/HC, 2020) and U.S. CPSC
3304 (2014) to estimate daily intake values. However, due to the short half-lives of phthalates, a single spot
3305 sample may not be representative of average urinary concentrations that are collected over a longer term
3306 or calculated using pooled samples (Shin et al., 2019; Aylward et al., 2016). Multiple spot samples
3307 provide a better characterization of exposure, with multiple 24-hour samples potentially leading to better
3308 characterization, but are less feasible to collect for large studies (Shin et al., 2019). Due to rapid
3309 elimination kinetics, U.S. CPSC concluded that spot urine samples collected at a short time (2 to 4
3310 hours) since last exposure may overestimate human exposure, while samples collected at a longer time
3311 (greater than 14 hours) since last exposure may underestimate exposure (see Section 4.1.3 of (U.S.
3312 CPSC, 2014) for further discussion).

3313 **Appendix D Supporting Analyses for Occupational Exposure to**
3314 **Phthalates**

3315 **D.1 Trends in National Aggregate Production Volume**

3316 EPA also considered whether trends in national aggregate production volume data may mirror temporal
3317 trends noted in NHANES urinary biomonitoring data. To do this, EPA extracted national aggregate
3318 production volume (PV) data for DEHP, DBP, DIBP, BBP, DCHP, and DINP from the 2016 and 2020
3319 Chemical Data Reporting (CDR), which is shown in Table_Apx D-1. In CDR, national aggregate PV
3320 data is reported as a range to protect PV data claimed as confidential business information (CBI). Given
3321 the large ranges in reported PV data for each phthalate, it is difficult to definitively conclude whether or
3322 not there are any trends in PV for any phthalate. Based on available CDR data, there is no evidence of a
3323 trend in national aggregate PV for DEHP (PV ranged from 10,000,000 lbs to less than 50,000,000 lbs in
3324 2012 through 2019), DBP (PV ranged 1,000,000 lbs to less than 10,000,000 lbs in 2012 through 2019),
3325 or DCHP (PV ranged from 500,000 lbs to less than 1,000,000 lbs in 2012 through 2019). For BBP, there
3326 is some limited evidence of a decline in PV, which was reported as 10,000,000 to less than 50,000,000
3327 lbs from 2012 to 2015 and declined to 10,000,000 to less than 20,000,000 lbs from 2016 through 2019.
3328 For DIBP, there is some limited evidence of a decline in PV, with PV reported as ranging from
3329 1,000,000 to less than 20,000,000 lbs in 2012 and declining to less than 1,000,000 lbs in 2013 through
3330 2019. For DINP (CASRN 28553-12-0), there is some limited evidence of a decline in PV with PV
3331 reported as 100,000,000 to less than 250,000,000 lbs in 2012 through 2018 and declining to 50,000,000
3332 to less than 100,000,000 lbs in 2019. In contrast, there is some limited evidence of an increase in PV for
3333 DINP (CASRN 68515-48-0), with PV reported as 100,000,000 to less than 250,000,000 lbs in 2012
3334 through 2015 and 100,000,000 to less than 1,000,000,000 lbs in 2016 through 2019.

3335
3336 Overall, given the large ranges in reported PV, it is difficult to conclude whether or not there are any
3337 trends in PV data for any phthalate.

PUBLIC RELEASE DRAFT

May 2025

3338

Table_Apx D-1. Trends in Nationally Aggregated Production Volume (lbs) Data for DEHP, DBP, BBP, DIBP, DCHP, and DINP

Phthalate	CASRN	2019	2018	2017	2016	2015	2014	2013	2012
DEHP	117-81-7	10,000,000 – <50,000,000	10,000,000 – <50,000,000	10,000,000 – <50,000,000	10,000,000 – <50,000,000	10,000,000 - <50,000,000	10,000,000 - <50,000,000	10,000,000 - <50,000,000	10,000,000 - <50,000,000
DBP	84-74-2	1,000,000 – <10,000,000	1,000,000 – <10,000,000	1,000,000 – <10,000,000	1,000,000 – <10,000,000	1,000,000 - <10,000,000	1,000,000 - <10,000,000	1,000,000 - <10,000,000	1,000,000 - <10,000,000
BBP	85-68-7	1,000,000 – <20,000,000	1,000,000 – <20,000,000	1,000,000 – <20,000,000	1,000,000 – <20,000,000	10,000,000 - <50,000,000	10,000,000 - <50,000,000	10,000,000 - <50,000,000	10,000,000 - <50,000,000
DIBP	84-69-5	407,303	403,833	384,591	440,833	<1,000,000	<1,000,000	<1,000,000	1,000,000 - <20,000,000
DCHP	84-61-7	500,000 - <1,000,000	<1,000,000	500,000 - <1,000,000	500,000 - <1,000,000	500,000 - <1,000,000	500,000 - <1,000,000	500,000 - <1,000,000	500,000 - <1,000,000
DINP	28553-12-0	50,000,000 – <100,000,000	100,000,000 – <250,000,000	100,000,000 – <250,000,000	100,000,000 – <250,000,000	100,000,000 - <250,000,000	100,000,000 - <250,000,000	100,000,000 - <250,000,000	100,000,000 - <250,000,000
	68515-48-0	100,000,000 – <1,000,000,000	100,000,000 – <1,000,000,000	100,000,000 – <1,000,000,000	100,000,000 – <1,000,000,000	100,000,000 - <250,000,000	100,000,000 - <250,000,000	100,000,000 - <250,000,000	100,000,000 - <250,000,000

3339

D.2 Industrial and Commercial Products Containing Multiple Phthalates

Table_Apx D-2. Summary of Industrial and Commercial Products that Contain Multiple Phthalates

Manufacturer	Product	Physical State	Source	Use	DEHP	DBP	BBP	DIBP	DINP	DCHP
Restek Corporation	33227 / EPA Method 8061A Phthalate Esters Mixture	No data available	Restek Corporation (2019)	Laboratory chemical	0.10%	0.10%	0.10%	0.10%		0.10%
Phenova	BN Extractables – Skinner List	Liquid	Phenova (2017a)	Laboratory chemical	0.20%	0.20%	0.20%			
Phenova	Custom 8061 Phthalates Mix	Liquid	Phenova (2017)	Laboratory chemical	0.10%	0.10%	0.10%	0.10%		
Phenova	Custom 8270 Cal Mix 1	Liquid	Phenova (2018a)	Laboratory chemical	0.10%	0.10%	0.10%			
Phenova	Custom 8270 Cal Standard	Liquid	Phenova (2017c)	Laboratory chemical	0.20%	0.20%	0.20%			
Phenova	Custom 8270 Plus Cal Mix	Liquid	Phenova (2017d)	Laboratory chemical	0.10%	0.10%	0.10%			
Phenova	Custom Low ICAL Mix	Liquid	Phenova (2017e)	Laboratory chemical	0.10%	0.10%	0.10%			
Phenova	Custom SS 8270 Cal Mix 1	Liquid	Phenova (2018b)	Laboratory chemical	0.10%	0.10%	0.10%			
Phenova	EPA 525.2 Semivolatile Mix	Liquid	Phenova (2018c)	Laboratory chemical	0.10%	0.10%	0.10%			
Lord Corporation	Fusor 108B, 109B Metal Bonding ADH PT B	Paste	LORD Corporation (2017)	Adhesive (acrylic)		1-5%				1-5%
SPEX CertiPrep LLC	Phthalate Standard	Liquid	SPEX CertiPrep LLC (2017b)	Laboratory chemical	0.10%	0.10%	0.10%		0.10%	
SPEX CertiPrep LLC	Phthalates in Poly(vinyl chloride)	Solid	SPEX CertiPrep LLC (2017c)	Laboratory chemical	0.30%	0.30%	0.30%		3.00%	
SPEX CertiPrep LLC	Phthalates in Polyethylene Standard	Solid	SPEX CertiPrep LLC (2017c)	Laboratory chemical	0.30%	0.30%	0.30%		3.00%	
SPEX CertiPrep LLC	Phthalates in Polyethylene Standard w/BPA	Solid	SPEX CertiPrep LLC (2017d)	Laboratory chemical	0.10%	0.10%	0.10%		0.10%	
Penn State Industries	PSI PolyClay Canes and PSI PolyClay Bricks	Solid	Penn State Industries (2016)	Polymer clay bricks, canes	<2.5%	<2.5%	<2.5%		<2.5%	

D.3 Parent Company Overlap in Phthalate Manufacture and Processing

3344
3345 Data from CDR provide manufacture and processing information from parent companies, including
3346 overall production volume and number of facilities, and all phthalates considered in this cumulative
3347 assessment are reported to CDR. Though these data provide a broad overview of the various businesses
3348 involved in the phthalate industry, the CDR data provide information about the parent company only and
3349 are not granular enough to determine if multiple phthalates are being processed within a singular facility.
3350 Therefore, there is uncertainty associated with assigning co-exposures based on parent company
3351 reporting data from CDR. Table_Apx D-3 characterizes the various parent companies from 2016 and
3352 2020 CDR that report use of multiple phthalates considered in this cumulative assessment, as well as
3353 parent companies reporting use of DEHP and DBP under the 2017 to 2022 TRI.

3354
3355

Table_Apx D-3. Parent Companies Reporting Use of Multiple Phthalates (DEHP, DBP, BBP, DIBP, DINP, DCHP) to 2016 and 2020 CDR and 2017 through 2022 TRI

CDR or TRI Year	Use Category	Domestic Parent Company Name	Address	City	State	Postal Code	Reported in TRI		Reported in CDR					
							DEHP	DBP	DBP	DEHP	DINP	DCHP	BBP	DBP
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	ALAC International Inc	350 Fifth Avenue	New York	NY	10118				X	X			
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Allchem Industries Holding Corp	6010 NW First Place	Gainesville	FL	32607			X	X				
2017–2022 TRI	Processing	American Polymers Corp	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	BASF Corporation	100 Park Avenue	Florham Park	MI	7932					X		X	
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^b	CBI ^b	CBI ^b	CBI ^b	CBI ^b			X		X		X	
2016 CDR	Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is Air Prod & Chem Hamilton Blvd Fac)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is Exxon Mobil BR Chemical Plant)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X			
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is Greenchem)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is M. Argueso & Co., Inc.)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X		X	
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is Mak Chemicals)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X		X	
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is Tremco Incorporated)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X		X	
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	CBI ^c (reporting site name is Tricon International, Ltd)	CBI ^c	CBI ^c	CBI ^c	CBI ^c			X	X	X			
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	ChemSpec, Ltd.	1559 Corporate Woods Parkway	Uniontown	OH	44685				X	X			
2017–2022 TRI	Waste Handling	Clean Harbors Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						

PUBLIC RELEASE DRAFT
May 2025

CDR or TRI Year	Use Category	Domestic Parent Company Name	Address	City	State	Postal Code	Reported in TRI		Reported in CDR					
							DEHP	DBP	DBP	DEHP	DINP	DCHP	BBP	DBP
2020–2022 TRI	Processing	Danfoss Power Solutions (US) Co	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2017 TRI	Processing	DOW Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X			X ^d			
2017–2019 TRI	Processing	EATON Corp	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Formosa Plastics Corporation, U.S.A.	9 Peach Tree Hill Rd.	Livingston	NJ	7039				X	X			
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	FRP Services & Co. (America) INC	25 West 45th Street	New York	NY	10036				X	X			
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	G.J. Chemical Co., Inc.	40 Veronic Ave.	Somerset	NJ	8873			X	X				
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	GEON Performance Solutions LLC	25777 Detroit Road, Suite 202	Westlake	OH	44145				X	X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Greenchem Industries LLC	222 Clematis St.	West Palm Beach	FL	33401			X		X			
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	H I G Capital LLC	7500 East Pleasant Valley Road	Independence	OH	44131			X				X	
2016 CDR; 2020 CDR; 2017–2018 TRI	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Hallstar Co	120 S. Riverside Drive	Chicago	IL	60606	X		X	X	X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Harwick Standard Distribution Corporation	60 S. Seiberling St.	Akron	OH	44305				X	X			
2017–2021 TRI	Processing	Henkel of America Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X			X ^d			
2017–2022 TRI	Waste Handling	Heritage-WTI LLC	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	ICC Industries Inc.	460 Park Ave	New York	NY	10022			X	X	X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	ICC Industries Inc.	725 Fifth Avenue	New York	NY	10022			X	X	X			
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Industrial Chemicals Inc.	2042 Montreat Dr.	Birmingham	AL	35216			X	X	X			
2016 CDR; 2020 CDR;	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Lanxess Corporation	111 RIDC Park West Dr.	Pittsburgh	PA	15275	X	X	X			X		X

PUBLIC RELEASE DRAFT

May 2025

CDR or TRI Year	Use Category	Domestic Parent Company Name	Address	City	State	Postal Code	Reported in TRI		Reported in CDR					
							DEHP	DBP	DBP	DEHP	DINP	DCHP	BBP	DBP
2017–2022 TRI														
2017–2022 TRI	Waste Handling	Lehigh Hanson	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	M.A. Global Resources Inc	1028 Branch Line Lane	Apex	NC	27502				X	X			
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	MC International, LLC	2 Ne 40th St	Miami	FL	33137			X	X	X			
2016 CDR; 2017–2022 TRI	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Mexichem SAB DE CV	170 Pioneer Drive	Leominster	MA	01453	X			X	X		X	
2017–2022 TRI	Processing	Parker Hannifin Corp	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	POLYONE CORPORATION	33587 Walker Rd	Avon Lake	OH	44012				X	X			
2017–2022 TRI	Waste Handling	RC Lonestar Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2017–2022 TRI	Waste Handling	RI Technologies Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Royce International	3400 Tamiami Trail, Suite 300	Sarasota	FL	34239			X		X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Shrieve Chemical Company	1755 Woodstead Court	The Woodlands	TX	77380			X	X				
2020 CDR; 2018–2022 TRI	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Sika Corporation	201 Polito Avenue	Lyndhurst	NJ	7071		X	X					X
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Silver Fern Chemical	2226 Queen Anne Avenue N.	Seattle	WA	98109				X	X			
2016 CDR; 2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Soyventis North America LLC	100 Town Square Pl.	Jersey City	NJ	07310			X		X			
2018–2022 TRI	Processing	Superior Industrial Solutions Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2020 CDR; 2016 CDR (under different address);	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Teknor Apex Co	505 Central Ave	Pawtucket	RI	02861	X			X	X			

PUBLIC RELEASE DRAFT

May 2025

CDR or TRI Year	Use Category	Domestic Parent Company Name	Address	City	State	Postal Code	Reported in TRI		Reported in CDR					
							DEHP	DBP	DBP	DEHP	DINP	DCHP	BBP	DBP
2017–2022 TRI														
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	The Chemical Company	44 Southwest Avenue	Jamestown	RI	2835				X	X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Tribute Energy, Inc.	2100 W. Loop South	Houston	TX	77027				X	X			
2020 CDR; 2016 CDR (under different address); 2017–2022 TRI	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Univar Solutions Inc.	3075 Highland Pkwy., Ste. 200	Downers Grove	IL	60515-5560	X	X	X	X	X			
2017–2020 TRI	Waste Handling	US Ecology Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Valtris	7500 East Pleasant Valley	Independence	OH	44131			X				X	
2017 TRI	Waste Handling	Veolia Environmental Services North America LLC	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2017–2022 TRI	Processing	W R Grace & Co	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2017–2019 TRI	Waste Handling	Waste Management Inc	n/a ^a	n/a ^a	n/a ^a	n/a ^a	X	X						
2016 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Wego Chemical Group	239 Great Neck Road	Great Neck	NY	11021			X		X			
2020 CDR	Manufacture; Industrial Processing and Use; Consumer and Commercial Use	Wilbur-Ellis Company LLC	345 California Street	San Francisco	CA	94104				X	X			

^a 'n/a' = not applicable, parent company address not provided in TRI.

^b Because all information is claimed as CBI, it is possible that this row represents multiple parent companies that reported some combination of the flagged phthalates.

^c Because parent company information is claimed as CBI, it is possible that there are fewer parent companies than rows with CBI parent companies but non-CBI reporting site names.

^d In TRI, these companies reported releases of DBP and/or DEHP and used a different parent company name than in CDR. In CDR, these sites only reported for DINP. As well, the physical reporting sites themselves have different addresses. Therefore, there is uncertainty in whether the same parent company applies to both the TRI and CDR reports.

D.4 Conditions of Use Listed in Final Scopes for Individual Phthalate Risk Evaluations

Table_Apx D-4. Categories of Conditions of Use for High-Priority Phthalates and a Manufacturer-Requested Phthalate

Use	Conditions of Use	DBP	BBP	DEHP	DCHP	DIBP	DINP
Industrial	Adhesive and sealants		X		X	X	X
	Automotive care products		X				X
	Building/construction materials not covered elsewhere		X			X	X
	Castings		X				
	Chemical intermediate		X				
	Fabric, textile, and leather products not covered elsewhere		X			X	
	Finishing agent				X		
	Floor coverings		X			X	
	Fuels and related products					X	
	Hydraulic fluid		X				
	Hydraulic fracturing			X			
	Ink, toner, and colorant products		X		X	X	
	Laboratory chemicals		X	X			
	Paints and coatings		X	X		X	
	Plastic and rubber products not covered elsewhere		X		X	X	
	Plasticizer						X
	Solvent	X					
	Transportation equipment manufacturing				X		
	Adhesives and sealants	X	X	X	X	X	X
Commercial	Air care products					X	X
	Arts, crafts and hobby materials			X			X
	Automotive care products		X	X			X
	Batteries			X			
	Building/construction materials not covered elsewhere		X	X	X		X
	Castings		X				
	Chemical intermediate		X				
	Chemiluminescent light stick	X					

PUBLIC RELEASE DRAFT
May 2025

Use	Conditions of Use	DBP	BBP	DEHP	DCHP	DIBP	DINP
Commercial	Cleaning and furnishing care products	X					X
	Dyes and pigments			X			
	Electrical and electronic products			X			X
	Explosive materials	X					
	Fabric, textile, and leather products not covered elsewhere		X	X			X
	Floor coverings	X	X			X	X
	Foam seating and bedding products						X
	Furniture and furnishings not covered elsewhere	X		X			X
	Hydraulic fluid						X
	Ink, toner, and colorant products	X	X		X	X	
	Inspection penetrant kit	X					
	Laboratory chemical	X	X		X	X	X
	Lawn and garden care products			X			
	Lubricants	X					
	Paints and coatings	X	X	X	X	X	X
	Personal care products	X					
	Pigment						X
	Plastic and rubber products						X
	Plastic and rubber products not covered elsewhere	X	X	X	X	X	X
Solvent						X	
Toys, playground, and sporting equipment			X			X	
Consumer	Adhesives and sealants	X	X	X	X	X	X
	Air care products					X	X
	Arts, crafts and hobby materials	X	X	X	X		X
	Automotive Care products		X	X			X
	Batteries			X			
	Building/construction materials not covered elsewhere		X	X			X
	Chemiluminescent light stick	X					
	Cleaning and furnishing care products	X	X				X
	Dyes and pigments			X			

PUBLIC RELEASE DRAFT
May 2025

Use	Conditions of Use	DBP	BBP	DEHP	DCHP	DIBP	DINP
	Electrical and electronic products			X			X
	Fabric, textile, and leather products not covered elsewhere	X	X	X		X	X
	Floor coverings	X	X			X	X
	Foam seating and bedding products						X
	Furniture and furnishings not covered elsewhere	X		X			X
	Ink, toner, and colorant products		X		X	X	X
	Lawn and garden care products			X			
	Paints and coatings	X	X	X	X	X	X
	Paper products						X
	Plastic and rubber products						X
	Plastic and rubber products not covered elsewhere	X	X	X	X	X	X
	Reference material and/or laboratory reagent			X			
	Toys, playground, and sporting equipment	X	X	X		X	X

^a Table taken from EPA's *Draft Proposed Approach for Cumulative Risk Assessment of High-Priority Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act* ([U.S. EPA, 2023b](#)). COU overlap based on COU tables presented in the final scoping documents for DEHP, DBP, BBP, DIBP, DCHP, and DINP.

3362

Appendix E Calculation of Occupational Exposure Values Based on Cumulative Exposures and Relative Potency Assumptions

EPA typically derives an occupational exposure value (OEV) to represent the exposure concentration below which exposed workers and occupational non-users are not expected to exhibit any appreciable risk of adverse toxicological outcomes. For exposures to individual chemicals, this can be easily calculated based on the POD for the most sensitive human health effect supported by the weight of scientific evidence, expressed relative to benchmarks and standard occupational scenario assumptions.

A singular value cannot be applied across the board for application to cumulative risk analysis of all phthalates, given that neither the identity nor relative ratio of the phthalates present in a given exposure scenario can be generalized. Therefore, EPA derived an inhalation OEV for the index chemical, which can then incorporate RPFs to determine whether cumulative exposures result in risk relative to benchmark based on measurement of phthalates in air (Appendix E.2).

Similar to OEVs for individual chemicals, the index chemical OEV may be used to support risk management efforts for phthalates under TSCA section 6(a), 15 U.S.C. 2605. TSCA requires risk evaluations to be conducted without consideration of cost and other non-risk factors, and thus this most sensitive OEV represents a risk-only number. If risk management is implemented following the final risk evaluation for any phthalates covered by the cumulative risk analysis TSD, EPA may consider cost and other non-risk factors, such as technological feasibility, the availability of alternatives, and the potential for critical or essential uses. Any existing chemical exposure limit (ECEL) used for occupational safety risk management purposes could differ from the OEVs used in these example calculations based on additional consideration of exposures and non-risk factors consistent with TSCA section 6(c).

The index chemical OEV represents the exposure concentration below which exposed workers and occupational non-users are not expected to exhibit any appreciable risk for reduced fetal testicular testosterone, the basis of RPFs across the phthalates. This OEV accounts for PESS. This value is expressed relative to benchmarks and standard occupational scenario assumptions of 8 hours per day, 5 days per week exposures for a total of 250 days exposure per year, and a 40-year working life.

E.1 Occupational Exposure Value for the Index Chemical (DBP)

This section presents the calculations used to estimate a draft OEV for the index chemical, DBP, using inputs derived in this analysis. For DBP, the index chemical HED used for cumulative risk assessment and application of RPFs is 2.1 mg/kg-day, for reduced fetal testicular testosterone (Section 2.3). Based on average adult body weight of 80 kg and default resting breathing rate of 14.7 m³/day (0.6125 m³/hour for 24 hours) ([U.S. EPA, 2011a](#)), the inhalation HEC based on route-to-route extrapolation is 11.4 mg/m³.

Draft Occupational Exposure Value for DBP

The draft OEV was calculated as the concentration at which the MOE would equal the benchmark MOE for occupational exposures using Equation_Apx E-1. The OEV was derived based on acute exposures, the most sensitive exposure scenario relevant to reduced fetal testicular testosterone.

3409 **Equation_Apx E-1.**

3410
$$OEV_{index} = \frac{HEC_{acute}}{Benchmark\ MOE_{acute}} * \frac{AT_{HECacute}}{ED} * \frac{IR_{resting}}{IR_{workers}} =$$

3411

3412
$$\frac{11.4\ mg/m^3}{30} * \frac{\frac{24h}{d}}{\frac{8h}{d}} * \frac{0.6125\ \frac{m^3}{h}}{1.25\ \frac{m^3}{h}} = 0.56\ mg/m^3$$

3413

3414
$$OEV_{index}\ (ppm) = \frac{EV\ \frac{mg}{m^3} * Molar\ Volume}{MW} = \frac{0.56\ mg/m^3 * 24.45\ \frac{L}{mol}}{278\ \frac{g}{mol}} = 0.049\ ppm$$

3415

3416 The parameters used in the above equations are described below.

3417

3418 *Where:*

- 3419 *AT_{HECacute}* = Averaging time for the POD/HEC used for evaluating non-cancer,
3420 acute occupational risk, based on study conditions and/or any HEC
3421 adjustments (24hrs/day)
- 3422 *Benchmark MOE_{acute}* = Acute non-cancer benchmark margin of exposure, based on the total
3423 uncertainty factor of 30
- 3424 *OEV_{index}* = Draft occupational exposure value based on reduced fetal testicular
3425 testosterone
- 3426 *ED* = Exposure duration (8 hrs/day)
- 3427 *HEC_{acute}* = Human equivalent concentration for acute, intermediate, or chronic
3428 occupational exposure scenarios
- 3429 *IR* = Inhalation rate (default is 1.25 m³/hr for workers and 0.6125 m³/hr for
3430 the general population at rest)
- 3431 *Molar Volume* = 24.45 L/mol, the volume of a mole of gas at 1 atm and 25 °C
- 3432 *MW* = Molecular weight of DBP (278.0 g/mole)
- 3433

3434 **E.2 Estimating Inhalation Risk to Air Mixtures using Cumulative and**

3435 **Individual OEVs**

3436 As stated above, the index chemical OEV alone cannot be used to summarize risk thresholds for
3437 cumulative exposures covering any mixture of phthalates. In EPA's proposed approach, adapted from
3438 the [OSHA Technical Manual \(OTM\) - Section II: Chapter 1 | Occupational Safety and Health](#)
3439 [Administration](#), concentrations of the individual phthalates are compared to their respective OEV, and
3440 the ratios are summed together to determine if the cumulative concentration is greater than 1 (indicating
3441 potential risk). This is presented in the equation below:

3442

$$E_m = \frac{C_1}{L_1} + \frac{C_2}{L_2} + \dots + \frac{C_n}{L_n}$$

3443 Where:

3444 E_m is the minimum equivalent exposure for the mixture (E_m should be less than or equal to 1 for
3445 compliance);
3446 C_n is the measured concentration of a particular substance;
3447 L_n is the corresponding occupational exposure value for a particular substance in the same units
3448 as the concentration.
3449

3450 The OSHA method has a few complications however when applied to the phthalates. First, the health
3451 endpoint and POD from the DBP dataset that is the basis of the RPF for comparison across phthalates is
3452 not always the most sensitive POD for each phthalate. Therefore, risks must be evaluated both for the
3453 individual phthalate OEV and also the cumulative hazard index based on RPFs. The equation above
3454 would therefore be applied to the RPF-adjusted OEVs (derived from the OEV_{index} of 0.049 ppm and
3455 represented by L_1 , L_2 etc. in the above equation). Risk for the most sensitive endpoint would then also
3456 be considered independently for each individual phthalate. Individual OEVs for each phthalate are
3457 derived based on the most sensitive human health effect relative to benchmarks from their respective
3458 risk evaluation and human health hazard assessment.
3459

3460 Another major limitation is that only two phthalates (DEHP and DBP) currently have fully validated air
3461 monitoring methods, including [OSHA Method 104 for DEHP and DBP](#) and NIOSH Method 5020,
3462 which is fully validated for [DBP](#) and partially validated for [DEHP](#). Although air monitoring methods for
3463 DIBP, BBP, and DCHP have been reported in the peer-reviewed literature ([Chi et al., 2017](#)), this
3464 approach is therefore currently limited in its application to workplaces only for DEHP and DBP, until
3465 validated methods are available for BBP, DIBP, DCHP, and DINP. Additionally, an OEV based only on
3466 workplace air concentrations will not be inclusive of non-attributable national (non-occupational)
3467 exposure. As a possible alternative approach, urinary biomonitoring of phthalate metabolites in workers
3468 is available for all phthalate species and could be inclusive of both occupational and non-workplace
3469 exposures to phthalates (depending on whether a baseline/background comparison was implemented).
3470 Urinary biomonitoring and reverse dosimetry methods have been previously applied by NIOSH for
3471 measuring phthalate intake among workers ([Hines et al., 2011](#)).
3472

3473 Urinary biomonitoring is clearly limited in that it does not allow real-time workplace monitoring and
3474 could only be implemented either based on a regular schedule or some triggering event/air concentration
3475 limit. Baseline measurements would also be required to establish internal dose based on non-attributable
3476 national exposures. Despite these limitations this approach could be valuable for being able to measure
3477 all phthalate species and being inclusive of aggregate exposures, including non-attributable, non-
3478 occupational exposures. EPA will explore the possibility of developing a method for applying the RPF
3479 approach to urinary biomonitoring in addition to other alternative approaches. Draft methods may be
3480 shared alongside future phthalate risk evaluations. EPA welcomes feedback for these and any other
3481 potential alternative approaches.

3482
3483
3484
3485

Appendix F Supporting Analyses for Consumer Exposure to Phthalates

Table_Apx F-1. Sample of Consumer Products Containing Phthalates^f

Phthalate	Product ^{a b c}	Manufacturer ^d
BBP	Sakrete Blacktop Repair Tube	Sakrete of North America
	Concrete Patching Compound	Quikrete Companies
	Mortar Repair Sealant	Quikrete Companies
	DAP Roof & Flashing Sealant, Polyurethane	DAP Products, Inc.
	Pre-Mixed Stucco Patch	Quikrete Companies
	Hercules Plumber's Caulk - White/Linen	HCC Holdings Inc.
	Wilsonart Color Matched Caulk	Wilsonart LLC
	Acrylic Caulk	Momentive Performance Materials - Daytona
	Silicone Fortified Window & Door Sealant	Henry Company
	Air Bloc 33	Henry Company
	PSI PolyClay Canes and PSI PolyClay Bricks ^e	Penn State Industries
	Double Bubble Urethane High Peel Strength D50 Part A (04022)	Royal Adhesives & Sealants
	Dymonic FC Anodized Aluminum	Tremco Canadian Sealants [Canada]
	GE7000	Momentive Performance Materials
	Hydrogel SX	Prime Resins Inc.
	Permatite Acrylic Sealant	Permatite / Division of DSI
	Protecto Sealant 25XL	Protecto Wrap Company
	Spectrem 3 Aluminum Stone - 30 CTG	Tremco Canadian Sealants [Canada]
	Spectrem 4	Tremco U.S Sealants
	STP 17925 Power Steering Fluid & Stop Leak	Armored AutoGroup Inc.
	126VR Disc Brake Quiet 0.25 Fl. Oz Pouch	ITW Permatex
	Steri-Crete SL Component A	Dudick, Inc.
	Stonclad UT Resin Polyol	Stonhard, Division of StonCor Group, Inc.
	ENSURE Sterilization Emulator	SciCan Ltd. [Canada]
	Phthalates in Poly(vinyl chloride)	SPEX CertiPrep, LLC
	Elmer's Model + Hobby Cement	Elmers Products, Inc.
	Accent MBRU 6pk Silver Metallic 2oz	Rust-Oleum Corporation
	Champion Sprayon Acrylic Matte Finish	Chase Products Co.
	6840 Ultra Black	BJB Enterprises, Inc.
	Handstamp - Blue	Identity Group
Repair and Refinishing Spray	Multi-Tech Products Corp.	
Armacell WB Finish	Mon-Eco Industries, Inc.	
Black Tire Paint Concentrate	Akron Paint and Varnish (dba APV Engineered Coatings)	

PUBLIC RELEASE DRAFT
May 2025

Phthalate	Product ^{a b c}	Manufacturer ^d
BBP	IC 1-gl 2pk Gray Shop Coat Primer	Rust-Oleum Corporation
	Klean-Strip Mask & Peel Paint Booth Coating	W. M. Barr
	Lacquer Touch-up Paint - Clear Topcoat	Ford Motor Company
	SK Clear-Seal Satin Sealer 5 Gal	Rust-Oleum Corporation
DBP	3M Bondo Glazing & Spot Putty	3M Company
	SureFlex Multi-Purpose Adhesive, SH-360	Barristo Enterprises, Inc. dba SureHold
	Lanco Seal	Lanco Mfg. Corp.
	PSI PolyClay Canes and PSI PolyClay Bricks ^e	Penn State Industries
	Hydrostop Premiumcoat Finish Coat	GAF
	Hydrostop Premiumcoat Foundation Coat	GAF
	Hydrostop Trafficcoat Deck Coating	GAF
	Pro 1-GL 2PK Flat Aluminum Primer	Rust-Oleum Corporation
	DURALAQ-WB WATERBORNE WHITE ACRYLIC FINISH DULL RUBBED	Benjamin Moore & Co.
	Hydrostop Premiumcoat Foundation Coat Summer	GAF
	Bondo Gray Filler Primer	3M Company
	Pettit XL Vivid 1861 Black	Kop-Coat, Inc. / Pettit Marine Paint
	Accurate Solo 1000, Accurate LT-30, Accurate LT-32, Accurate 2015, Accurate 2495, Accurate 4064, Accurate 4350	Western Powders, Inc.
	Cartridge 9 mm FX Marking, Toxfree primer	General Dynamics - Ordnance and Tactical Systems - Canada Inc. [Canada]
	Rimfire Blank Round - Circuit Breaker	Olin Corporation - Winchester Division, Inc.
Wizard 31 Epoxy Ball Plug Hardener	Brunswick Bowling Products, LLC	
DEHP	765-1553 BALKAMP VINYL REPAIR KIT	Permatex, Inc.
	Chocolate	Wellington Fragrance
	PSI PolyClay Canes and PSI PolyClay Bricks ^e	Penn State Industries
	DUPLI-COLOR BED ARMOR	Dupli-Color Products Company
	DUPLI-COLOR High Performance Textured Metallic Coating Charcoal	Dupli-Color Products Company
	264 BLACK TRUCK BED LNR 6UC	The Valspar Corporation
	RED GLAZING PUTTY 1# TUBE	The Valspar Corporation
	Prime WPC/Prime Essentials/Prime SPC	Carlton Hardwood Flooring
	Lenox MetalMax	Lenox Tools
	6.17 OZ 100040 FH FRESH SCENT PET TW 12PK	Fresh House

PUBLIC RELEASE DRAFT
May 2025

Phthalate	Product ^{a b c}	Manufacturer ^d
	KRYLON Fusion All-In-One Textured Galaxy	Krylon Products Group
	Self-cath pediatric 30 pack	Coloplast Corp.
	3M™ Economy Vinyl Electrical Tape 1400, 1400C	3M
	Pronto Putty	The Valspar Corporation
	Red Glazing Putty 1# Tube	Quest Automotive Products
	BD Loop Goop	Royal Adhesives and Sealants Canada Ltd.
	SCOFIELD® CureSeal 350	Sika Corporation
DCHP	Duco Cement (bottle and tube)1	ITW Consumer - Devcon/Versachem
	Fusor 108B, 109B Metal Bonding ADH PT B	LORD Corporation
DIBP	Blue Label Washable PVA Adhesive	Colorlord Ltd.
	BETAKRIL TEXTURE	Betek Boya ve Kimya Sanayi A.S [Turkey]
	Centerfire Pistol & Revolver and Rifle Cartridges	Companhia Brasileira de Cartuchos (CBC)
	Art Board	Ningbo Zhonghua Paper Co. Ltd.
	Glitter Boards	DJECO
	Painting - Oh, It's Magic	DJECO
<p>^a This table includes a sample of products listed in the Use Reports for each DBP, BBP, DIBP, DEHP, DCHP (U.S. EPA, 2021, 2020a, b, c, d, e).</p> <p>^b This table may represent updated information with products listed that are not identified in the published Use Reports.</p> <p>^c This is not a comprehensive list of products containing each phthalate nor does the presence of a product on this list indicate its availability in the United States for consumer purchase</p> <p>^d Some manufacturers may appear over-represented in this table. This may mean that they are more likely to disclose product ingredients online than other manufacturers, but this does not imply anything about use of the chemical compared to other manufacturers in this sector.</p> <p>^e The SDS for PSI PolyClay Canes and PSI PolyClay Bricks, which lists the product as containing multiple phthalates is available here: https://www.pennstateind.com/MSDS/POLYCLAY_MSDS.pdf.</p> <p>^f Table from <i>Draft Proposed Approach for Cumulative Risk Assessment of High-Priority Phthalates and a Manufacturer-Requested Phthalate under the Toxic Substances Control Act</i> (U.S. EPA, 2023b).</p>		

3486